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Abstract
Therapeutic hypothermia to reduce intracranial pressure
after traumatic brain injury: the Eurotherm3235 RCT
Peter JD Andrews,1* H Louise Sinclair,1 Aryelly Rodríguez,2
Bridget Harris,1 Jonathan Rhodes,3 Hannah Watson3
and Gordon Murray2 on behalf of the Eurotherm3235
trial collaborators
1Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
2Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK
3NHS Lothian, Edinburgh, UK
*Corresponding author p.andrews@ed.ac.uk
Background: Traumatic brain injury (TBI) is a major cause of disability and death in young adults worldwide.
It results in around 1 million hospital admissions annually in the European Union (EU), causes a majority of
the 50,000 deaths from road traffic accidents and leaves a further ≈10,000 people severely disabled.
Objective: The Eurotherm3235 Trial was a pragmatic trial examining the effectiveness of hypothermia
(32–35 °C) to reduce raised intracranial pressure (ICP) following severe TBI and reduce morbidity and
mortality 6 months after TBI.
Design: An international, multicentre, randomised controlled trial.
Setting: Specialist neurological critical care units.
Participants: We included adult participants following TBI. Eligible patients had ICP monitoring in place
with an ICP of > 20 mmHg despite first-line treatments. Participants were randomised to receive standard
care with the addition of hypothermia (32–35 °C) or standard care alone. Online randomisation and the
use of an electronic case report form (CRF) ensured concealment of random treatment allocation. It was
not possible to blind local investigators to allocation as it was obvious which participants were receiving
hypothermia. We collected information on how well the participant had recovered 6 months after injury.
This information was provided either by the participant themself (if they were able) and/or a person close to
them by completing the Glasgow Outcome Scale – Extended (GOSE) questionnaire. Telephone follow-up
was carried out by a blinded independent clinician.
Interventions: The primary intervention to reduce ICP in the hypothermia group after randomisation was
induction of hypothermia. Core temperature was initially reduced to 35 °C and decreased incrementally
to a lower limit of 32 °C if necessary to maintain ICP at < 20 mmHg. Rewarming began after 48 hours
if ICP remained controlled. Participants in the standard-care group received usual care at that centre,
but without hypothermia.
Main outcome measures: The primary outcome measure was the GOSE [range 1 (dead) to 8 (upper
good recovery)] at 6 months after the injury as assessed by an independent collaborator, blind to the
intervention. A priori subgroup analysis tested the relationship between minimisation factors including
being aged < 45 years, having a post-resuscitation Glasgow Coma Scale (GCS) motor score of < 2 on
admission, having a time from injury of < 12 hours and patient outcome.
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Results: We enrolled 387 patients from 47 centres in 18 countries. The trial was closed to recruitment
following concerns raised by the Data and Safety Monitoring Committee in October 2014. On an intention-
to-treat basis, 195 participants were randomised to hypothermia treatment and 192 to standard care.
Regarding participant outcome, there was a higher mortality rate and poorer functional recovery at 6 months
in the hypothermia group. The adjusted common odds ratio (OR) for the primary statistical analysis of the
GOSE was 1.54 [95% confidence interval (CI) 1.03 to 2.31]; when the GOSE was dichotomised the OR was
1.74 (95% CI 1.09 to 2.77). Both results favoured standard care alone. In this pragmatic study, we did not
collect data on adverse events. Data on serious adverse events (SAEs) were collected but were subject to
reporting bias, with most SAEs being reported in the hypothermia group.
Conclusions: In participants following TBI and with an ICP of > 20 mmHg, titrated therapeutic
hypothermia successfully reduced ICP but led to a higher mortality rate and worse functional outcome.
Limitations: Inability to blind treatment allocation as it was obvious which participants were randomised
to the hypothermia group; there was biased recording of SAEs in the hypothermia group. We now believe
that more adequately powered clinical trials of common therapies used to reduce ICP, such as hypertonic
therapy, barbiturates and hyperventilation, are required to assess their potential benefits and risks to
patients.
Trial registration: Current Controlled Trials ISRCTN34555414.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 22, No. 45.
See the NIHR Journals Library website for further project information. The European Society of Intensive
Care Medicine supported the pilot phase of this trial.
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Plain English summary
Following a blow to the head [traumatic brain injury (TBI)], the brain can swell like a bruise, but isenclosed within the skull. If the brain swells, it can lead to a build-up of pressure that can cause
damage to parts of the brain. Many patients who have suffered a traumatic brain injury are admitted to
an intensive care unit. This is usually because they have become unconscious as a result of the brain injury.
These patients require specialised care and often cannot breathe well enough for themselves. They are
therefore sedated and attached to a breathing machine, called a ventilator.
This study included 387 participants and looked at whether or not cooling the body down to between 32 and
35 °C within 10 days of injury to try to reduce any brain swelling affected longer-term recovery from TBI. Each
participant was randomly allocated to receive either the usual care given or the usual care with the additional
treatment of cooling the body to between 32 and 35 °C for at least 48 hours.
The study was stopped early because of concerns about safety raised by the independent Data and Safety
Monitoring Committee and agreed by the Trial Steering Committee. The results of this study showed that
more patients died after receiving hypothermia than standard care alone and that the survivors who had
received hypothermia made a less good recovery than those receiving standard care alone.
It was conclude that hypothermia should not be used to reduce pressure after a TBI.
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Scientific summary
Background
Traumatic brain injury (TBI) is damage to the brain caused by trauma from incidents such as falls, traffic
accidents and assault. It is a major cause of death and severe disability throughout the world and leads
to around 1 million hospital admissions each year throughout the European Union (EU). TBI causes the
majority of the 50,000 deaths from road traffic accidents and leaves 10,000 patients severely disabled each
year; three-quarters of these victims are young people. This has a devastating emotional and physical
impact and presents an enormous financial burden.
One of the most harmful consequences of TBI is cell injury and cell death in the brain. When this occurs,
it starts a complex sequence of harmful, and potentially irreversible, processes at the cellular level. These
processes can cause swelling (oedema) in the brain. This swelling increases the pressure inside the head
and makes the injury worse. Preventing cell injury and death is therefore an important part of treatment.
Cell death can occur from minutes to hours after injury and the harmful effects can last for 72 hours or
longer. Thus, there may be a window of opportunity of several hours, or even days, during which cell
death can be prevented by treatments such as hypothermia. Hypothermia treatment lowers the patient’s
temperature to below normal, which has a potentially beneficial effect on a number of problems caused
by injury to brain cells.
In total, 29 studies in patients have been performed to assess the effects of hypothermia after TBI. These
were of varying size and quality, but all observed reduced brain swelling and pressure levels inside the skull
during hypothermia treatment. Thirteen of these studies reported significant improvements in patient
outcome, with fewer deaths and less disability associated with hypothermia treatment.
Six major reviews of hypothermia studies were published between 2000 and 2008. Each review included
differing numbers of trials, with varying quality of randomisation and blinding procedures. All six reviews
found a trend towards positive effects of hypothermia on patient outcome, although only two reviews
could statistically prove this. The most recent review included eight trials that enrolled comparable patient
groups at entry to the trial (baseline). Hypothermia was found to reduce mortality by 20%, although this
was not statistically proven. Further analysis showed that this effect was greatest when hypothermia was
maintained for > 48 hours. Hypothermia was also associated with a trend towards improvement in patient
outcome when measured by the Glasgow Outcome Scale (GOS) at 6 months.
A criticism of these reviews is that most failed to take account of important differences in patient groups
(such as those with or without a build-up of pressure due to brain swelling) and differences in treatment
protocols, except the use of hypothermia. Only two assessed whether or not the length of hypothermia
treatment and speed of rewarming the body afterwards made a difference to the effectiveness of
hypothermia. Results suggested that hypothermia treatment lasting for > 48 hours and rewarming rates
of 24 hours, or 1 °C over 4 hours, may be factors that are important in reducing deaths and improving
disability. However, the studies included in the review did not enrol enough patients to prove this.
In summary, the evidence from previous research shows that hypothermia treatment may be an effective
therapy to improve outcome in patients who have suffered a TBI. Many trials have been carried out in this
patient group, but none has been extensive enough to prove whether or not hypothermia is effective in
preventing further brain damage and reducing death and disability. The Eurotherm3235 Trial aimed to
provide a clear answer to this question.
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Objectives
l Does therapeutic hypothermia (TH) (32–35 °C) improve patient outcome and reduce mortality
6 months after TBI as assessed by the Glasgow Outcome Scale – Extended (GOSE) questionnaire?
Secondary research questions:
l Does TH (32–35 °C) reduce intracranial hypertension?
l Is TH a cost-effective treatment to improve patient outcome after TBI?
Design
The Eurotherm3235 Trial was a pragmatic, multicentre randomised controlled trial (RCT) to examine the
effects of hypothermia (32–35 °C) on patient outcome after TBI. The study recruited for 41 months.
Randomisation
Participants were randomised as soon as possible after meeting the inclusion criteria. The randomisation
of participants to receive standard care with the addition of induced TH or standard care alone was
undertaken using a central internet-based randomisation service.
Treatment allocation was minimised using the following baseline covariates:
l trial centre
l aged < 45 years or ≥ 45 years
l post-resuscitation Glasgow Coma Scale (GCS) motor component score of 1 or 2 or 3–6
l time from injury < 12 hours or ≥ 12 hours
l pupils – both reacting or one or neither reacting.
Participants allocated to the standard-care group received usual care without TH. Participants randomised
to the intervention group received usual care with the addition of TH. Hypothermia was initiated with
20–30 ml/kg of refrigerated 0.9% saline given intravenously and maintained using the cooling technique
available at each centre.
The depth of hypothermia (32–35 °C) was guided by intracranial pressure (ICP), with a higher pressure
level warranting a cooler target temperature. TH of 32–35 °C was maintained for at least 48 hours and
continued for as long as was necessary to reduce and maintain ICP at < 20 mmHg.
Blinded outcome assessment
The primary end point was patient outcome 6 months after TBI, assessed using the GOSE questionnaire.
It was not possible to blind local investigators to allocation as it was clinically obvious which participants
were receiving hypothermia because of, for example, the equipment required, participant temperature,
blood results and fluid requirements. A blinded researcher therefore carried out participant outcome
data assessment.
Setting
Induced hypothermia is a specialist intervention; therefore, only neurological ICUs that were familiar with
the use of hypothermia treatment in this patient group were included. A total of 61 specialist neurological
ICUs were opened as recruiting centres across 18 countries between 2009 and 2015: Belgium (n = 8),
England (n = 21), Estonia (n = 1), Germany (n = 1), Greece (n = 6), Hungary (n = 1), India (n = 3), Ireland
(n = 1), Italy (n = 5), Northern Ireland (n = 1), the Netherlands (n = 1), Portugal (n = 1), Russia (n = 1),
Saudi Arabia (n = 1), Scotland (n = 3), Spain (n = 4), Abu Dhabi (n = 1) and Wales (n = 1).
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Participants
Patients were assessed for eligibility to enter the trial on admission to the ICU by the health-care team.
They continued to be screened for up to 10 days after the brain injury. If consent was given by the nearest
relative/welfare guardian on the patient’s behalf, the patient could enter the study and be randomised if/as
soon as he or she met the inclusion criteria.
Interventions
Participants who were allocated to the hypothermia treatment group continued to receive their usual care
along with having their temperature lowered to between 32 and 35 °C. The depth of cooling was guided
by the severity of brain swelling, with more severe brain swelling warranting a lower temperature.
The participant’s temperature was lowered in two stages.
Stage 1: induction of hypothermia
Participants were given 20–30 ml/kg of refrigerated 0.9% saline by a drip over 20–30 minutes. This quickly
reduced their temperature to around 35 °C.
Stage 2: maintenance of hypothermia
After induction of hypothermia, the participant’s temperature had to remain between 32 and 35 °C for at
least 48 hours. Temperature could be maintained by using a variety of methods including placing ice packs
under the arms and legs or using a special cooling machine. Each study centre used the available method
of cooling as this was the most practical way to run the trial in many centres.
Participants were closely monitored for any signs of shivering throughout this period and any observed
shivering was treated quickly. We provided a detection and management of shivering guideline to each
recruiting centre.
Rewarming phase
No maximum duration of cooling was specified, although the doctor in charge of patient care was asked
to consider rewarming the patient after 48 hours of hypothermia treatment. Rewarming was considered
if the patient’s ICP was stable and < 20 mmHg. Previous studies found that cooling for 48 hours and
rewarming within 24 hours reduced deaths and disability in survivors.
Participants allocated to the hypothermia group were rewarmed at a rate of 0.25 °C per hour (1 °C per
4 hours); hence, all participants were rewarmed to normal temperature levels (> 36 °C) within 24 hours.
Treatment escalation
Occasionally, patients who have suffered a brain injury have severe brain swelling that does not respond to
the usual treatment methods. These patients often require further treatment with other drugs or, sometimes,
surgery. A proportion of participants in the Eurotherm3235 Trial did develop severe brain swelling and
required further treatment.
Main outcome measures
The primary outcome was:
l patient outcome at 6 months after TBI, assessed using the GOSE questionnaire.
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The secondary outcomes were:
l 6-month mortality rate
l intracranial pressure control
l incidence of pneumonia across both groups
l length of stay in the ICU and hospital
l Modified Oxford Handicap Scale (MOHS) score at 1 month, discharge from the randomising hospital or
death, whichever took place first
l correlation between the predicted patient outcome using the MOHS score at hospital discharge and
the predicted patient outcome using the GOSE score at 6 months post injury.
Results
We enrolled 387 patients at 47 centres in 18 countries (195 assigned to TH and 192 assigned to standard
care) from November 2009 (pilot phase January 2009 to August 2011) to September 2014, when
recruitment was suspended following concerns raised by the Data and Safety Monitoring Committee.
The mean age of participants was 37 years (range 16–78 years). In total, 15% of TH patients and
18% of patients who received standard care alone were randomised within 12 hours of injury.
The adjusted common odds ratio (OR) for the primary statistical analysis of the GOSE score was 1.53
[95% confidence interval (CI) 1.02 to 2.30]. When the GOSE score was dichotomised, the adjusted
common OR was 1.81 (95% CI 1.12 to 2.92). Both ORs were in favour of standard care alone.
Conclusion
In patients with ICP of > 20 mmHg after TBI, titrated hypothermia to reduce ICP led to worse functional
outcomes. Future work should study targeted temperature management of < 38 °C and > 36 °C after
acute brain injury.
Knowledge landscape after the Eurotherm3235 Trial
We searched RCTs to update the evidence base on the use of TH when administered to adult patients in
intensive care following TBI. The main outcomes of interest were mortality, poor (unfavourable) outcomes
and new pneumonia.
Secondary aims were (1) comparison of control groups; (2) early (< 24 hours from injury) compared with
late (> 24 hours from injury) TH; (3) the effect of duration of follow-up on mortality outcomes; and
(4) whether or not the date of publication had any effect on the outcomes of TH trials.
Search methods for identification of trials
Searches were not restricted by date or publication status. Foreign articles published in English were
included. The following databases were searched from 1 January 2011 to 31 March 2016: Cochrane
Central Register of Controlled Trials (CENTRAL), MEDLINE, PubMed and EMBASE. The dates were chosen to
be complementary to, and have an overlap of 12 months with, the previous systematic review conducted by
one of the co-authors; this was to capture any trials that were in the process of publication.
Other sources
Reference lists of all included trials and relevant review articles were hand-searched by the authors.
When appropriate, authors were contacted directly for further information.
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Methodological criteria for selection of randomised controlled trials
The inclusion criteria were that trials must (1) be RCTs, (2) investigate adult moderate (i.e. a GCS score of
9–12) or severe (i.e. a GCS score of ≤ 8) TBI and (3) investigate TBI that was sustained following an acute,
closed head injury. The use of TH was the intervention of interest. RCTs that did not have two treatment
arms with TH compared with a control group were excluded. For the purpose of this review, TH was
defined as any intervention with the intention of reducing core body temperature to below the physiological
norm (36 °C). The method of temperature reduction was noted during data extraction. Patient outcomes at
follow-up were assessed using mortality and poor outcome data. There was a particular emphasis on
outcomes recorded on a scale, for example, the GOS, Ranchos Los Amigos Scale or an equivalent scale.
Poor outcome reporting includes mortality figures, as per the usual reporting methodology.
Results
The searches identified 21 trials, including data for two new trials. One trial included in the 2014 review
has now been published with additional data. These trials enrolled 2299 patients. Only one trial did not
include mortality data.
Mortality was reported in 20 studies. When the results of these 20 RCTs were statistically aggregated, there
was a significant reduction in mortality in the TH group [risk ratio (RR) 0.84, 95% CI 0.74 to 0.96; p = 0.01].
Twenty-one trials reported on poor outcome involving 2286 patients. There were significantly more poor
outcomes in the control group than in the TH group (RR 0.81, 95% CI 0.75 to 0.87; p < 0.00001).
Analysis of the two studies deemed to be at low risk of bias showed that poor outcomes were more likely
in the TH group (RR 1.16, 95% CI 1.02 to 1.32; p = 0.03). Conversely, analysis of the 19 studies with a
high risk of bias combined showed significantly more poor outcomes in the control group than in the TH
group (RR 0.70, 95% CI 0.64 to 0.77; p < 0.00001).
A subanalysis on mortality specifically assessed the methodology used for temperature management in the
control groups. There was no significant difference in mortality between the TH group and the control
group with controlled normothermia (RR 0.89, 95% CI 0.74 to 1.08; p = 0.25). However, there was
significantly greater mortality in the no temperature control group than in the TH group (RR 0.81, 95% CI
0.68 to 0.97; p = 0.02).
The studies were analysed separately depending on whether they ensured that their control group was
maintained at < 38 °C or included 38 °C within the ‘normothermia’ control range. Those studies that
stated that they used controlled normothermia without specifying the temperature range were placed in
the latter group. Studies that controlled temperature to < 38 °C showed no significant difference in
mortality outcomes between the control group and the TH group (RR 1.01, 95% CI 0.82 to 1.32;
p = 0.73). In contrast, in those studies that included 38 °C within the normothermia range, mortality was
significantly higher in the control group (RR 0.61, 95% CI 0.44 to 0.87; p = 0.005).
Discussion
When the temperature of the control group was controlled (controlled normothermia) and fever was
avoided, TH was no longer beneficial.
Conclusion
Overall, the results of this systematic review shed doubt on the outcome benefits of TH. Low-quality studies
are more likely to show that TH improves mortality. In addition, this review highlights the importance of
temperature management in the control group of TH trials and, in particular, the avoidance of fever.
Trial registration
This trial is registered as ISRCTN34555414.
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Chapter 1 Literature review: from bench
to bedside
Background and objectives
This chapter provides a summary of the evidence that has supported the design of the Eurotherm3235
Trial.1 This trial was a large, multinational, prospective, randomised controlled trial (RCT) of patients with
raised intracranial pressure (ICP) after traumatic brain injury (TBI).
Traumatic brain injury is a major cause of death and severe disability throughout the world and leads to
around 1 million hospital admissions per annum throughout the European Union (EU). It causes the
majority of the 50,000 deaths from road traffic accidents each year and leaves 10,000 patients severely
disabled; three-quarters of these victims are young people.2 Additionally, TBI results in 290,000 hospital
admissions and 51,000 deaths and leaves 80,000 patients with permanent neurological disabilities in the
USA annually.3 The consequence of TBI is both a devastating emotional and physical impact and an
enormous financial burden.4
Therapeutic hypothermia (TH) has been shown to improve outcome after cardiac arrest;4 therefore, both
the European Resuscitation Council5 and the American Heart Association guidelines6 recommend the use
of hypothermia in these patients. Hypothermia is also thought to improve neurological outcome after
neonatal birth asphyxia.7 Cardiac arrest and neonatal asphyxia patient populations present to health-care
services rapidly and without posing a diagnostic dilemma; therefore, systemic TH may be implemented
relatively quickly. As a result of this, the use of hypothermia in these two populations is similar to the
laboratory models in which systemic TH is commenced very soon after the injury and has shown so
much promise.8
The need for resuscitation and computed tomography (CT) imaging to confirm the diagnosis in patients
with TBI are factors that delay intervention with temperature reduction strategies. Treatments in TBI have
traditionally focused on restoring and maintaining adequate brain perfusion, surgically evacuating large
haematomas when necessary, and preventing or promptly treating oedema.4 Brain swelling can be
monitored by measuring ICP, and in most centres ICP is used to guide treatments and to monitor their
success. There is an absence of evidence for the five most commonly used treatments for raised ICP
(hypertonics, sedation, muscle relaxants, barbiturates and decompressive craniectomy) and all are potential
‘double-edged swords’ with significant disadvantages. The use of hypothermia in patients with TBI may
have beneficial effects in terms of both ICP reduction and possible neuroprotection.
Pathophysiology
Ischaemia has a key role in all forms of brain injury, and preventing ischaemic (or secondary) injury is at the
core of all neuroprotective strategies.4 A complex cascade of processes ensues at the cellular level after a
period of ischaemia, beginning from minutes to hours after injury and continuing for 72 hours or longer.
Thus, there may be a window of opportunity of several hours, or even days, during which injury can be
mitigated by treatments such as hypothermia.4
Early studies that used profound hypothermia in models of brain trauma used treatment paradigms that were
not feasible in clinical practice.9 More recent studies have shown that moderate/mild hypothermia appears
to be neuroprotective in well-characterised rodent models of TBI. The effects of systemic hypothermia
(30–36 °C) following fluid percussion brain injury in rats were first investigated by Clifton et al.,10 who showed
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that hypothermia of 33 °C resulted in reduced mortality rates and attenuated deficits in motor function and
weight loss compared with normothermia. Dietrich et al.8 showed that post-traumatic hypothermia (30 °C)
initiated 5 minutes after fluid percussion brain injury reduced overall contusion volume and preserved
survival of the overlying cortical neurons. Therefore, these studies demonstrated that cooling after a TBI
provided histological/cellular protection, improved motor and cognitive function and reduced mortality.
Moderate hypothermia (30 °C), initiated 5 minutes after TBI, improved hippocampal-dependent learning
and memory using the Morris water maze.11 An important predictor of outcome in TBI patients, traumatic
axonal pathology, is reduced with moderate post-injury hypothermia therapy.12 Therefore, post-traumatic
hypothermia modulates the major pathologies in TBI such as contusions, neuronal vulnerability and
traumatic axonal injury. Mild hypothermia is therefore potentially attractive as a treatment for TBI as it
modulates multiple mechanisms or pathways and has advantages over unipolar pharmacological attempts
to provide neurological protection.
Blood–brain barrier
Alterations in blood–brain barrier (BBB) permeability after acute injury result in water, electrolytes,
blood-borne substances and potential neurotoxic agents passing across the vascular system and into the
brain parenchyma. Many studies have demonstrated the importance of brain and body temperature on
the microvascular consequences of cerebral ischaemia and trauma. One study that assessed the effects of
intra-ischaemic brain temperature (mild hypothermia) on the BBB found a reduction in extravasation of the
protein tracer horseradish peroxidase.13 Brain water content is significantly reduced with hypothermia after
focal cerebral ischaemia.14,15 This has been assessed in imaging studies, with magnetic resonance imaging
finding that reductions in the apparent diffusion coefficient of water (cellular oedema) are also reduced
by hypothermia.16
In models of post-traumatic injury, hypothermia has also been shown to reduce BBB permeability. Hypothermia
may be attenuating BBB permeability by altering matrix metalloproteinases, which are critical extracellular
enzymes that can disrupt the BBB.17 Given that BBB permeability, formation of vasogenic oedema and the
extravasation of circulating inflammatory cells can adversely affect post-injury outcome, the effects of
hypothermia are an important underlying mechanism for the beneficial effects of hypothermia.
Inflammation and oedema
The inflammatory response after TBI is significantly attenuated by hypothermia in laboratory and clinical
studies. As well as attenuating the increase in BBB permeability and leucocyte margination, the endogenous
inflammatory response of the central nervous system (CNS) is also reduced by hypothermia. Astrocytes and
microglia respond to CNS injury by proliferating around the injury areas and releasing pro-inflammatory
communication molecules as an endogenous repair mechanism. Hypothermia significantly attenuates the
activation of both astrocytes and microglia.18–21 Combination therapy with the anti-inflammatory cytokine
interleukin 10 (IL-10) and hypothermia therapy was attempted in both TBI and focal cerebral ischaemia.22
Synergistic effects were seen in focal cerebral ischaemia but not in TBI, suggesting that the cellular biology
of inflammation in these two major CNS injuries has an influence on the effect of subsequent hypothermia.
Another major aspect of the inflammatory response to CNS injury is the release of reactive oxygen species
by astrocytes and microglia. Hypothermia reduces increases in tissue levels of superoxide, nitric oxide and
the hydroxyl radical.23,24 The level of the superoxide dismutase, the enzyme responsible for scavenging
superoxide, is increased by hypothermia,25,26 and the level of the enzyme responsible for synthesising nitric
oxide, nitric oxide synthase, is attenuated by hypothermia.27
Metabolism
By exploiting local measures of glucose metabolism using 2-deoxyglucose techniques, researchers
have shown that moderate hypothermia (30 °C) results in reduced glucose utilisation compared with
normothermia.28 Metabolic effects of mild hypothermia have also been demonstrated using nuclear
magnetic resonance spectroscopy.29 Therefore, hypothermia appears to lower metabolic and energy
demands, which has potentially beneficial effects on cytoplasmic adenosine triphosphate (ATP) and
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the maintenance of normal transmembrane ion and neurotransmitter gradients. The magnitude of
preservation of ATP levels depends on both the temperature reduction and the severity of the injury.
Therefore, an important mechanism for the neuroprotective effects of hypothermia is a reduction or delay
in metabolic demand during and after an acute CNS injury.
Excitotoxicity
The effects of moderate hypothermia on glutamate excitotoxicity were reported using microdialysis to assay
extracellular/extravascular concentrations of neurotransmitters after global ischaemia. A middle cerebral
artery occlusion model is considered a reasonable model for haemorrhagic contusion. Busto et al.30 showed
that intra-ischaemic hypothermia (33 °C and 30 °C) attenuated the rise in extracellular levels of glutamate
and dopamine after global cerebral ischaemia. These studies have been replicated in a variety of models of
ischaemia, indicating that one of the major mechanisms by which temperature affects neuronal vulnerability
is through reducing excitotoxicity following cerebral ischaemia.23,31,32 Delayed pharmacological treatments that
reduce excitotoxicity further improve outcome in combination with hypothermia;33 this may be a promising
strategy for further studies. The glutamatergic receptors alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA) and N-methyl-D-aspartate (NMDA) are also modulated by hypothermia. Expression of hippocampal
glutamate receptors is decreased after transient global ischaemia and this is completely blocked by
intra-ischaemic hypothermia.34
Other neurotransmitters are also modulated by hypothermia. Lyeth et al.35 demonstrated that hypothermia
(30 °C) reduced elevations in cerebrospinal levels of acetylcholine after TBI. Conversely, hypothermia
delayed decreases in dopamine, noradrenaline and serotonin after global cerebral ischaemia.36 However,
other studies have demonstrated that hypothermia (32 °C) can improve outcome after CNS injury without
attenuating extracellular levels of glutamate and aspartate.12,29,37 Although the neurotransmitter response
in various injury models may be temperature dependent, attenuating other injury cascades may be more
important in delivering possible beneficial effects of hypothermia.
Cerebrovascular effects
The effects of hypothermia on cerebral blood flow are controversial. In 1954, Rosomoff and Holaday38
demonstrated that systemic hypothermia at 25 °C significantly lowered cerebral blood flow. However, in a
model of selective brain cooling (30.9 °C), cortical blood flow measured by laser Doppler flowmetry was
shown to increase above control levels.39 Cerebrovascular changes secondary to cooling of the brain are
important because reductions in blood flow to critical levels could have adverse effects on tissue survival
and functional outcome.
Intracellular calcium-dependent signalling
There are pronounced changes in calcium-dependent intracellular signalling pathways after CNS injury.
Normal neuronal activity is mediated by signalling through protein kinases and several of these have been
documented to be disrupted by TBI and cerebral ischaemia. Temporary cerebral ischaemia inhibits the
activity of calcium/calmodulin-dependent protein kinase II (CaMKII), a key protein kinase that mediates
synaptic strength, and this is attenuated by hypothermia.40 Protein kinase C (PKC) translocates to the
membrane after cerebral ischaemia and undergoes inhibition; hypothermia rescues the inhibition of PKC
activity and its translocation to the membrane.41 Recently, various transcription factors that participate in
normal neuronal functioning have been shown to be sensitive to temperature. The immediate early gene
c-Fos, which regulates key genetic responses of neurons, is activated by hypothermia after transient
global ischaemia.18,42,43
These studies suggest that temperature may have profound effects on events associated with neuronal
injury as well as the normal processing of neuronal signals throughout brain circuits.
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Neuronal cell death
Although neuronal necrosis is commonly seen in most CNS injury models, evidence for apoptotic cell
death has also been documented using various histochemical and molecular techniques. As with necrosis,
apoptotic cell death appears to be sensitive to post-injury hypothermic treatment strategies. Recent studies
have indicated that apoptotic cell death is another important target by which temperature may affect
long-term outcome in various models of CNS injury. Various gene families [genes with a similar sequence
of deoxyribonucleic acid (DNA) nucleotides] have been shown to be sensitive to post-injury temperature
manipulations in models of ischaemia and trauma.44 The ability of post-injury temperature to affect
the acute and more delayed genetic response to injury is important because these genes may play an
important role in determining the cellular response(s) that results in secondary injury. Using high-
throughput screening and bioinformatics, genomic studies are ongoing in many laboratories; these
contemporary technologies will help to determine how hypothermia may protect, and potentially repair,
CNS tissues after injury.
The Collaborative Approach to Meta-Analysis and Review of Animal Data
from Experimental Studies
The Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies
(CAMARADES) group has a mission statement:
It is our contention that there is significant scope for improvements in the design, conduct, analysis
and reporting of animal experiments. By minimising bias, such improvements would improve the
amount of valid information gained from those animals used. By providing (using systematic review
and meta-analysis) a precise and robust overview of existing data the need for further experiments,
and the precise areas in which those experiments should focus, this approach would ensure that
unnecessary replication did not occur. The proposed research is therefore crucial to the development
of ‘reduction’ strategies.
Reproduced with permission from CAMARADES45
To date, this approach has not been rigorously applied to TBI models. Such an approach would enhance
translational research and, hopefully, reduce futile clinical studies.
Therefore, with the proviso above, numerous animal experiments across different species have shown that
induced hypothermia improves recovery outcome after experimental TBI. This has led to the undertaking
of a large number of clinical trials.4 Interpretation of these results is complicated by the fact that these
trials have enrolled different categories of patients, with different types of injuries, and have used widely
diverging treatment protocols.46 Most have used elevated ICP as an inclusion criterion, although some
have used CT scan criteria. The duration of cooling has varied from 24 hours to > 5 days and rewarming
rates have also varied. Some studies have used ICP to guide the depth and duration of treatment,
although responses to rebound intracranial hypertension have differed.4 Use of co-interventions such as
osmotic therapy, sedation, analgesia, paralysis and targets for mean arterial pressure (MAP) and cerebral
perfusion pressure (CPP) have also varied considerably.4 All of these factors can affect outcome after TBI in
general and the potential efficacy of cooling in particular. Thus, interpreting, comparing and aggregating
the results of these studies presents a number of complex challenges.
Review of clinical evidence
In total, 29 clinical studies have been performed to assess the effects of hypothermia in TBI.47–76 Twenty-seven
of these were performed in adult patients, 18 of which included a control group. Data from one pilot study
were subsequently included in a larger study, therefore leaving 17 studies. As outlined above, study protocols
have differed considerably and not all studies were properly randomised.
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Eighteen studies, with outcome data available for 2096 patients, used hypothermia in patients with high ICP
that was refractory to ‘conventional’ treatments (usually sedation/analgesia, paralysis, osmotic therapy and
sometimes barbiturates).58–61,63–71,73–77 All studies observed decreases in ICP during cooling. Thirteen of these
studies reported significant improvements in outcome associated with hypothermia.58–61,63,65,67–71,74,77 All of
these studies were performed in specialised neurotrauma centres with experience in applying hypothermia and
managing its side effects. Ten were single-centre studies58–60,65,67,68,70,71,74,77 and three (all performed in China)
were multicentre studies.61,63,69 Four additional studies observed a trend towards improved outcome, but these
differences were not statistically significant.61,64,66,73
In contrast, one of the two largest multicentre RCTs failed to show that induced hypothermia improved
outcome at 6 months after TBI [poor outcome RR (risk ratio) 1, 95% CI (confidence interval) 0.8 to 1.2;
p = 0.99].76 The proportion of patients experiencing a poor outcome was significantly higher among
those admitted to hospital with hypothermia who were randomised to normothermia and consequently
rewarmed (78%, n = 31) than among the group admitted with hypothermia and treated with hypothermia
(61%, n = 38) (p = 0.09).
On subsequent analysis, it became clear that, although this study was methodologically well designed,
there was marked intercentre variance in the treatment effect of hypothermia, age of participants, severity
of illness scoring between groups, management of intracranial hypertension and haemodynamic and fluid
management.10 Induced hypothermia in the hypothermia group was started relatively late, with a slow
speed of cooling (average time to target temperature > 8 hours) in all centres.
Hypotension (lasting > 2 hours) and hypovolaemia occurred three times more frequently in the hypothermia
group than in the normothermia group. Bradycardia associated with hypotension also occurred four times
more frequently in this group and electrolyte disorders and hyperglycaemia were also found more frequently
in the hypothermia group76 than in the normothermia group. All of these complications are known side
effects of hypothermia. Most are easily preventable with good intensive care and should not be regarded
as inevitable consequences of hypothermia treatment. As even very brief episodes of hypotension or
hypovolaemia can adversely affect outcome in TBI, these and other issues may have significantly affected
the results of this trial.10,78–80 One possible problem was that some of the participating centres had little or
no previous experience in using hypothermia; large centres, familiar with cooling, showed apparently
favourable neurological outcomes whereas smaller centres showed poor outcomes.
Induction of hypothermia
The most widely accepted use of hypothermia is after cardiac arrest. Two RCTs in this patient group found
significant neurological improvements in patients whose initial cardiac rhythm was ventricular fibrillation or
ventricular tachycardia and who were treated with hypothermia many hours after injury.81,82 Subsequent
data from a large study of patients treated after myocardial infarction suggest that infarct size was reduced
in patients who were cooled to < 35 °C before coronary intervention;83 therefore, these studies suggest
that faster cooling rates may be beneficial to patient outcome.
Methods of cooling can be broadly divided into two different techniques: surface cooling and core cooling.84
The above study used surface cooling devices alone and found that a large number of patients did not
reach the target temperature quickly enough before the start of the coronary intervention to demonstrate a
benefit.83 Despite advancing technology in surface cooling devices, and the introduction of endovascular
catheters for core cooling, average periods of 2–3 hours are still required to reach temperatures of 32–34 °C.84
The currently available surface cooling devices are also relatively large and cumbersome. This, coupled with
the need for staff with specialist knowledge of the management of induced hypothermia, may prevent its use
outside the intensive care unit (ICU).84
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One study has examined the feasibility, speed and complication rates of infusing refrigerated fluids
intravenously to quickly induce hypothermia in patients with various neurological injuries.84 The results
showed that a 1500-ml infusion of 0.9% saline in patients without cardiogenic shock, administered
over 30 minutes, reduced core temperature from 36.9 ± 1.9 °C to 34.6 ± 1.5 °C at 30 minutes and to
32.9 ± 0.9 °C at 60 minutes. Continuous monitoring of arterial blood pressure, heart rhythm, central
venous pressure, arterial blood gasses and serum levels of electrolytes, platelets and white blood cells
showed no significant adverse events (AEs).84
When hypothermia develops, the body will immediately try to counteract the temperature drop to
maintain homeostasis.85 One of the key mechanisms of heat production is shivering; this can lead to an
increased oxygen consumption of 40–100%, which may be detrimental in this patient population.
Sedation drugs are known to increase peripheral blood flow, which, in turn, will increase the transfer of
heat from the core to the peripheries, thus reducing the core temperature.85 Therefore, shivering may be
counteracted by the administration of sedatives, anaesthetic agents, opiates and/or paralysing agents.85
It should be noted, however, that the capacity and effectiveness of the mechanisms of controlling body
temperature decrease with age. Younger patients will therefore react earlier, and with greater intensity,
than older patients. For this reason, induction of hypothermia in younger patients often requires high
doses of sedation drugs to neutralise the counter-regulatory mechanisms.85
Together with TH therapy, all patients in the intervention group continued to be treated with stage 1
and 2 therapies as required to reduce intracranial hypertension.86,87 If raised ICP became resistant to
these therapies, even when the depth of hypothermia was increased, then care was escalated to include
stage 3 interventions. If this was required, TH treatment could be terminated for patients allocated to the
treatment group and the patients rewarmed using the rewarming guideline. The reason for treatment
escalation was then documented on the daily data collection form.
Meta-analyses
Six meta-analyses were published between 2002 and 2008.86–91 These included various numbers of trials
with varying quality of randomisation and blinding procedures. All found a trend towards positive effects
of hypothermia on neurological outcome, although statistical significance was reached in only two reviews
(improved neurological outcome: RR 0.78, 95% CI 0.63 to 0.98;86 RR 0.68, 95% CI 0.52 to 0.8987).
The most recent meta-analysis91 included eight trials that studied comparable patient groups at baseline.
Hypothermia was shown to reduce mortality by 20%, although this finding was not statistically significant
(RR 0.80, 95% CI 0.59 to 1.09). Subgroup analysis showed that this effect was most significant when
hypothermia was maintained for > 48 hours (RR 0.51, 95% CI 0.33 to 0.79). Hypothermia was also associated
with a non-significant increase of 25% in neurological outcome when measured by the Glasgow Outcome
Scale (GOS) at 6 months (RR 1.25, 95% CI 0.96 to 1.62). Despite not reaching statistical significance, the results
showed an increased likelihood of improved neurological outcome when cooling was maintained for > 48 hours
(RR 1.91, 95% CI 1.28 to 2.85). Another key finding of this meta-analysis was that hypothermia was only of
significant benefit to those patients who had not received barbiturate therapy (RR 0.58, 95% CI 0.40 to 0.85).
A criticism of these analyses is that most failed to take account of important differences in patient groups,
such as the presence or absence of intracranial hypertension, and differences in treatment protocols, with
the exception of the use of hypothermia. Only one differentiated between studies that enrolled patients
with normal ICP and those that enrolled patients with intracranial hypertension; this study found no
neurological improvement associated with hypothermia.90 Only two assessed the effects of treatment
duration and speed of rewarming,86,87 concluding that cooling for > 48 hours and rewarming rates of
24 hours, or 1 °C per 4 hours, were both key factors in reducing mortality (RR 0.70, 95% CI 0.56 to 0.87)
and improving neurological outcome (RR 0.79, 95% CI 0.63 to 0.98).
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In summary, the evidence from previous research shows that induced hypothermia may be effective in
patients with severe TBI and intracranial hypertension, provided that the treatment is continued for
long enough (between 48 hours and 5 days) and that patients are rewarmed slowly (1 °C per 4 hours).
Experience with cooling also appears to be important if complications, which may outweigh the benefits of
hypothermia, are to be avoided.
Rationale for the Eurotherm3235 Trial
One of the most harmful consequences of TBI is cell injury and cell death in the brain. When this occurs,
it starts a complex sequence of harmful, and potentially irreversible, processes at the cellular level. These
processes can cause swelling (oedema) in the brain. This swelling increases the pressure inside the head
and makes the injury worse. Preventing cell injury and cell death is therefore an important part of
treatment. Cell death can occur from minutes to hours after injury and the harmful effects can last for
72 hours or longer. Thus, there may be a window of opportunity of several hours, or even days, during
which cell death can be prevented by treatments such as hypothermia. Hypothermia treatment lowers the
patient’s temperature to below normal, which has a potentially beneficial effect on a number of problems
caused by injury to brain cells.
The evidence from previous research shows that hypothermia treatment may be an effective therapy to
improve outcome in patients who have suffered a TBI. Many trials have been carried out in this patient
group, but none has been large enough to prove whether or not hypothermia is effective in preventing
further brain damage and reducing death and disability. The Eurotherm3235 Trial aimed to provide a clear
answer to this question.
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Chapter 2 Trial design
Specific trial objectives and hypotheses
The Eurotherm3235 Trial tested the efficacy of hypothermia to reduce ICP after TBI and the effect
of hypothermia treatment on functional recovery at 6 months after injury compared with standard
care alone.
Hypothesis
Patients treated with TH (32–35 °C) will have reduced morbidity and mortality rates compared with those
receiving standard care alone after TBI.
Research questions
l Does TH (32–35 °C) reduce morbidity and mortality rates at 6 months after TBI as assessed by the
Glasgow Outcome Scale – Extended (GOSE) questionnaire?
l Does TH (32–35 °C) reduce intracranial hypertension?
l Is TH a cost-effective treatment to improve outcome after TBI?
Methods
Trial design
This was a pragmatic, multicentre RCT to examine the effects of hypothermia (32–35 °C) on outcome after
TBI. Participants were randomised to receive either standard care alone or standard care with the addition
of TH (Figure 1).
The experience from previous hypothermia trials underscores the potential difficulties in using TH
treatment for TBI.10 For this reason, and to reduce intercentre variance, only centres experienced in the
care of TBI patients and the use of hypothermia in this patient group were initiated.
At the time of designing the trial protocol in 2008, previous studies had found that TH lasting for at
least 48 hours showed a trend towards reduced mortality and improved neurological function after TBI.91
Hypothermia (32–35 °C) was therefore continued for at least 48 hours in the trial and for as long as was
necessary to reduce and maintain ICP at < 20 mmHg. This ICP threshold was used because the Brain
Trauma Foundation guidelines86 define intracranial hypertension as an ICP of > 20 mmHg. When ICP
was stable, patients were then slowly rewarmed at a rate of 0.25 °C per hour (1 °C per 4 hours).
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There are three recognised stages of TBI management (Figure 2).86,92
Participants in the hypothermia group continued to be treated with stage 1 and 2 therapies as required to
reduce intracranial hypertension.86,87 If raised ICP was resistant to these therapies, despite increasing the
depth of hypothermia, care could be escalated to include stage 3 interventions.
During the preparation of the protocol, evidence suggested that patients were three times more likely to
develop complications if hypothermia treatment was continued in conjunction with stage 3 interventions,
that is, surgery or continuous infusion of barbiturates (the drugs used to treat ICP). Thus, we advised that
the cooling intervention was withdrawn and the patient was rewarmed using the rewarming guideline as
soon as it was safe to do so when the patient’s care was escalated. The reason for treatment escalation
was then documented on the daily data collection form.
The primary end point of the Eurotherm3235 Trial was the outcome 6 months after TBI using the GOSE
questionnaire. Participants were sent the GOSE questionnaire with a covering letter by post 6 months after
randomisation by the co-ordinating centre.
TBI management
•  Admission to the ICU
•  Stage 1 therapy
•  ICP of > 20 mmHg within 10 days of injury: check eligibility, obtain
    consent and then randomise the patient
•  Standard care (stages 1 and 2) 
    without therapeutic 
    hypothermia
Control group Treatment group
•  Standard care (stages 1 and 2)
•  Hypothermia 32 – 35 ºC
    for ≥ 48 hours 20 – 30 ml/kg 
    infusion of refrigerated 
    0.9% saline and then a 
    cooling technique
•  Modified Oxford Handicap Scale
•  Length of stay in ICU and hospital
•  GOSE questionnaire
•  Continued medical care
•  Barbiturate therapy with processed 
    EEG monitoring
•  Decompressive craniectomy
Day 28, hospital discharge or death
Stage 3 options (if required)
6-month follow-up
FIGURE 1 Study flow chart. EEG, electroencephalogram.
TRIAL DESIGN
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Important changes to methods after trial commencement
The inclusion criteria were changed in January 2012, based on the pilot phase findings,93 to remove the
upper age limit (previously 65 years) and increase the time from injury from 72 hours to 10 days. These
changes provided important information on older patients and allowed patients with evolving brain
swelling up to 10 days from injury to be included.
Participants
A total of 387 patients were recruited between January 2009 and October 2014.
The inclusion/exclusion criteria for the trial are given in the following sections.
Eurotherm3235 Trial
 TBI management
All patients with TBI and ICP monitoring are screened
6-month follow-up
 Day 28, hospital discharge or death 
• Modified Oxford Handicap Scale, length of stay in ICU and hospital
• Barbiturate therapy with EEG monitoring
• Decompressive craniectomy
• Further surgical intervention if required
• Trial centre
• Aged < 45 years or ≥ 45 years
• Post-resuscitation GCS motor component score of 1 or 2 or 3 – 6
• Time from injury < 12 hours or ≥ 12 hours
• Both pupils reacting or one/neither reacting
• Admission to ICU
• Initial treatment measures: ventilation, sedation, analgesia with/without 
   paralysis, 30° head up tilt, inotropes for blood pressure support
   ventriculostomy with/without CSF drainage
• TBI management
• Barbiturates not permitted
Control group
• GOSE
Treatment group
Stage 1
Stage 2
Stage 3
Treatment allocation is minimised on baseline covariates
ICP of > 20 mmHg within 10 days of injury: check eligibility,
obtain consent and then randomise
Stage 3 options (if required)
• Hypothermia 32 – 35 °C for
   ≥ 48 hours
• TBI management
• Barbiturates not permitted
FIGURE 2 Three stages of ICP management after TBI. CSF, cerebrospinal fluid; EEG, electroencephalogram;
GCS, Glasgow Coma Scale.
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Inclusion criteria
l Believed to be legal age to consent to take part in research.
l Primary closed TBI.
l Raised ICP of > 20 mmHg for ≥ 5 minutes after first-line treatments with no obvious reversible cause
(e.g. patient position, coughing, inadequate sedation).
l ≤ 10 days from the initial head injury.
l Cooling device or technique available for > 48 hours.
l Core temperature of ≥ 36 °C (at the time of randomisation).
l An abnormal CT scan of the brain, defined as one that shows haematoma, contusion, swelling,
herniation or compressed basal cisterns.
Exclusion criteria
l Patient already receiving TH treatment.
l Administration of barbiturate infusion prior to randomisation.
l Unlikely to survive for the next 24 hours in the opinion of the ICU consultant or consultant
neurosurgeon treating the patient.
l Temperature of ≤ 34 °C at hospital admission.
l Pregnancy.
All female patients of childbearing age who met the inclusion criteria underwent a urine pregnancy test.
This was performed by the investigator or research nurse in the ICU as part of the screening for
eligibility procedure.
The Eurotherm3235 Trial enrolled patients after TBI who had an ICP of > 20 mmHg for ≥ 5 minutes,
despite first-line treatments, with no obvious reversible cause, for example patient position, coughing or
inadequate sedation. Although early cooling after injury is considered to be beneficial, this is offset by
failure to show benefit from hypothermia in the absence of raised ICP. Enrolment to the Eurotherm3235
Trial was therefore allowed up to 10 days following injury.
The trial recruited incapacitated adult patients who were admitted to the neurological ICU. It was not
possible to obtain consent from the patients before enrolment to the study as they were sedated and
attached to a ventilator. Information booklets were therefore made available in the waiting area of the
ICU and the patient’s legal surrogate decision-maker, their next of kin/nearest relative/welfare guardian
(in accordance with the laws of each country) was informed about the study by the ICU team soon after
their relative was admitted. If they wanted further information about the trial or wished for their relative
to participate, then the relative/welfare guardian contacted the researcher.
During this discussion, all stages of the trial were explained and the researcher explained that the patient
may not have been eligible at that time, as they must have developed brain swelling before entering the
study. Brain swelling can cause further brain damage if not treated quickly, so it was desirable that consent
was obtained before any brain swelling occurred so that treatment could be allocated and started very
soon after meeting the eligibility criteria. Patients who were consented early entered the study only if they
developed brain swelling and met all the inclusion criteria for the trial at that time.
In accordance with the Good Clinical Practice guidelines,94 the patient’s nearest relative or welfare guardian was
given the opportunity to ask questions and was given a copy of the trial information sheet to read and keep.
In some cases, the patient’s nearest relative/welfare guardian was not present when the patient was
admitted to the ICU. In usual circumstances, the health-care team contacted them to update them on the
patient’s condition soon after the patient was admitted. During this call, basic information was provided
about the trial and they were asked if they would like more information. If further information was
TRIAL DESIGN
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requested, the local investigator or research nurse obtained telephone consent and followed this up with
written consent as soon as possible afterwards.
Premature withdrawal
Participation in any research trial is voluntary; therefore, the participant or their legal representative was
able to withdraw from the trial at any point. In this case, it was clearly documented on the premature
withdrawal form whether or not any previously collected data could still be used in the analysis and which
part of the trial the participant was being withdrawn from, using the following options:
1. withdraw entirely – the hypothermia intervention will be safely terminated, no further data will be
collected and previously collected data will not be used in the analysis
2. withdraw entirely – the intervention will be safely terminated and no further data will be collected,
but previously data collected may be used in the analysis
3. withdraw from the intervention but be willing to be followed up
4. withdraw from being followed up only.
Settings and locations where the data were collected
Induced hypothermia treatment is a specialist intervention; therefore, this study involved only neurological
ICUs that were familiar with the use of hypothermia treatment in this patient group. Potential centres were
asked to complete a centre survey that allowed the trial management team to assess the expertise at each
centre before allowing a centre to take part.
A total of 61 specialist neurological ICUs were opened as recruiting centres across 18 countries between
2009 and 2015: Belgium (n = 8), England (n = 21), Estonia (n = 1), Germany (n = 1), Greece (n = 6),
Hungary (n = 1), India (n = 3), Ireland (n = 1), Italy (n = 5), Northern Ireland (n = 1), the Netherlands (n = 1),
Portugal (n = 1), Russia (n = 1), Saudi Arabia (n = 1), Scotland (n = 3), Spain (n = 4), Abu Dhabi (n = 1) and
Wales (n = 1). Of these initiated centres, 54 centres screened patients and 46 centres randomised patients.
Once it was confirmed by the trial management team that a centre was eligible to participate, the process
of obtaining ethics and hospital approvals varied between UK and non-UK centres. In the UK, ethics
approval was obtained for the whole of the UK at the beginning of the trial, so that only hospital
management approval was required for each new centre. To obtain this, the trial manager completed a
site-specific information (SSI) form for each hospital and amended the consent documents to include the
local hospital logos, contact details, etc. The trial manager then contacted the National Institute for Health
Research Coordinated System for gaining NHS permission (NIHR CSP) network to ask for each hospital to
be added to the list of participating centres. When this was approved, the local documents and SSI form
were submitted to the local hospital research and development office for approval.
The process of obtaining approval in the non-UK centres was different as ethics approval was required for
each hospital and the documents needed to be completed in the language of the country. For this reason,
the local principal investigator (PI) had to complete the application form while the trial manager arranged
for the trial documents to be translated into the appropriate language by an external translation company.
The only exception to this was in Belgium, where the ethics process is centralised and, therefore, similar
to that in the UK: one ethics application is submitted with a list of possible participating centres. When
approval was given, each hospital submitted its own consent documents with its logo and contact details
to its local hospital research office or independent review board for approval.
Trial site initiation visits
As soon as hospital approval was given for a site to participate in the trial, the trial manager contacted the
PI and research team to arrange a site initiation visit. In the UK, the trial manager visited each site in person
to conduct this visit. The visit lasted approximately 2 hours, during which time the staff were taught the
DOI: 10.3310/hta22450 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 45
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Andrews et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
13
inclusion and exclusion criteria, the consenting process, how to randomise a patient, the trial interventions,
how to complete the data collection forms on the internet-based electronic database, how to complete a
serious adverse event (SAE) form and how to report a SAE. Staff were also given access to the test database
to practise completing data input. Follow-up procedures were also discussed and staff were told about the
importance of maintaining contact details for the participants and their nearest relative after discharge
from the ICU. The procedure for withdrawing a participant from the trial if required was also discussed.
Site initiation visits for the non-UK sites
Owing to the variability of access to the non-UK sites, we developed an alternative method for site initiation
in these centres. When it was feasible in terms of travel time, cost and language barrier, the trial manager
visited each of the non-UK centres to carry out the trial initiation visit. When this was not feasible, the trial
manager arranged a web conference with the PI and research team at each hospital. This meeting lasted for
at least 2 hours and was conducted in English.
The countries that we visited were:
l Belgium – as the process of ethics approval was centralised for Belgian centres, we arranged a single
site initiation meeting in Brussels and invited all centres to attend. Two additional centres joined the
trial after this meeting. In this case, the trial manager arranged one meeting in one of the hospitals
and both PIs and research staff from the two hospitals attended.
l Germany and Italy – because of the language barrier in two sites, we felt that the staff at these sites
would benefit more from a face-to-face meeting rather than a teleconference.
l Republic of Ireland – the trial manager visited the site in Ireland as it was very similar to centres in the
UK and was very easy to travel to.
l Portugal – a trial initiation meeting was possible at this site because the chief investigator was invited
to attend the Portuguese Intensive Care Society meeting and so carried out the visit while attending
the local conference.
l Spain – because of the language barrier in one site, we felt that the local staff would benefit more
from a face-to-face meeting rather than a teleconference.
Once a site was initiated and activated on the database system, hospital staff could start to screen and
recruit patients. Ongoing support was provided to the sites by the chief investigator and trial managers,
either by e-mail or office telephone (available Monday–Friday, 09.00–17.00). We also set up a trial helpline
using a separate mobile phone account, which was available out of hours and at weekends. The helpline
was held by the chief investigator and trial managers on a rotational basis.
Interventions
Participants were randomised using minimisation criteria to either standard care (including ventilation,
increased sedation and osmotherapy) or standard care with titrated TH (range 32–35 °C).
Prior to the induction of hypothermia, participants:
l were sedated and attached to a ventilator
l had probes inserted to monitor their blood pressure, fluid status and intracranial (brain) pressure
l had been assessed, including measurement of all laboratory values, by the doctor in charge of their care
l had continuous core body temperature monitoring in place using a probe in the pulmonary artery,
oesophagus, bladder or rectum.
Hypothermia was then initiated with a bolus of 20–30 ml/kg of intravenous, refrigerated sodium chloride
(0.9%) and maintained using each site’s usual cooling technique. The core temperature was reduced by
the minimum required to control ICP at ≤ 20 mmHg, within the limits of 32–35 °C. This ICP threshold was
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used as intracranial hypertension is defined as an ICP of > 20 mmHg in the Brain Trauma Foundation
guidelines.86 If a participant’s ICP was not controlled after cooling to 35 °C, then the temperature was
incrementally decreased to a minimum temperature of 32 °C to control ICP.
Hypothermia was maintained for at least 48 hours and continued for as long as necessary to maintain ICP
at < 20mmHg. Rewarming was considered after 48 hours at a rate of 0.25 °C per hour provided ICP was
≤ 20mmHg. The reason for this timeline was that previous studies have reported that TH that lasts for at least
48 hours showed a trend towards a reduction in mortality and improved neurological function after TBI.86,87,91
A flow chart was designed for the induction and maintenance of TH in the intervention group (see Appendix 1).
The depth of hypothermia (32–35 °C) was guided by ICP, with a higher pressure level warranting a cooler target
temperature. A guideline was also designed for the detection and treatment of shivering (see Appendix 2).
This was designed specifically for this trial, drawing on:
l the hospital protocol of the Mission Hospital, Orange County, CA, USA (permission given by
Mary Kay Bader, Neuroclinical Nurse Specialist, Mission Hospital, Orange County, CA, USA)
l the hospital protocol of the University Medical Centre, Utrecht, the Netherlands (permission given by
Dr Kees Polderman, University Medical Centre, Utrecht, the Netherlands)
l the Bedside Shivering Assessment Scale.95
All participants in the intervention group also continued to be treated with stage 1 and 2 therapies as
required to reduce intracranial hypertension.86,87 If ICP became resistant to these therapies, and despite
increasing the depth of hypothermia, care was then escalated to include stage 3 interventions.
Evidence suggests, however, that a patient is three times more likely to develop complications if
hypothermia treatment is given in conjunction with stage 3 interventions, namely surgery or the drugs
used to treat severe brain swelling (known as barbiturates).91 If care was escalated, the participant was
rewarmed using the rewarming guideline as soon as it was safe to do so. The reason for treatment
escalation was then documented on the daily data collection form.
Outcomes
Primary
l Outcome at 6 months using the GOSE questionnaire.
Secondary
l Six-month mortality rate.
l Intracranial pressure control.
l Incidence of pneumonia across both groups.
l Length of stay in the ICU and hospital.
l Modified Oxford Handicap Scale score at 1 month, discharge from the randomising hospital or death,
whichever took place first.
l Correlation between the predicted outcome using the MOHS score at hospital discharge and the
predicted outcomes using the GOSE score at 6 months post injury.
l Health economics.
Primary end-point data collection
l Outcome at 6 months using the GOSE questionnaire.
To collect this information, a questionnaire was sent to all participants 6 months after injury.
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This study recruited a very challenging patient group; patients who have suffered a head injury can have
personality changes after the injury, which can make it challenging to follow them up. Therefore, drawing
on our previous experience of the follow-up of brain-injured patients who had been admitted to the ICU,
we knew that it was unlikely that all patients would be able to complete and return the questionnaire
by themselves. Depending on the severity of their injury, many patients would still be in hospital at the
6-month follow-up. For this reason, we designed the follow-up procedures very carefully and included
these processes in the initial consenting discussion.
At the same time as sending the questionnaire to participants at 6 months, we also sent a letter to those
who gave consent for participants to enter the study. This letter informed them that the questionnaire had
been sent to participants and asked them to help with completion of the questionnaire.
This procedure was discussed with those giving consent at the time of providing consent for a patient to
enter the study. This procedure was also discussed with patients at the time of obtaining their subsequent
consent (if applicable).
The procedures for the follow-up of participants varied between those who were recruited in the UK and
those who were recruited in non-UK centres.
Follow-up procedure for UK centres
The first process for follow-up, before we sent anything to participants, was for the trial manager to
ask the research nurse at each participant’s centre to check the participant’s vital status by determining
whether the participant was still an inpatient or had been transferred to a rehabilitation centre. If the
participant had been discharged home, the research nurse was then asked to contact the participant’s
GP to find out their vital status.
A GOSE questionnaire was then sent by post from the trial office in Edinburgh to all surviving participants
6 months after injury. At this time, we also sent a letter to those who gave consent for participants to
enter the study, asking them to help with completion of the questionnaire.
In the pilot stage of the trial, if we did not receive a response from a participant within 3 weeks, we sent
a shorter GOS questionnaire to the participant by post. If this was not returned after 2 weeks, then an
independent and blinded researcher based in Edinburgh telephoned the participant to complete the short
questionnaire with them over the telephone. The steps taken if a participant could not be contacted at this
time varied depending on whether or not the participant had regained capacity and had given subsequent
consent themselves:
l If the participant had regained capacity and had given retrospective consent, then the process ended
here and the participant was documented as lost to follow-up.
l If the participant had not regained capacity and had not given follow-on consent, then the
independent researcher telephoned the person who had given consent and asked them to complete
the short questionnaire over the telephone.
This process was streamlined at the beginning of the main phase of the trial in January 2012. At this time,
we decided to remove the process of sending the shorter questionnaire to participants and instead moved
straight to telephoning participants if the first GOSE questionnaire was not returned after 3 weeks. In this
case, the independent/blinded researcher based in Edinburgh telephoned participants if they had been
discharged from hospital and completed the longer GOSE questionnaire with them over the telephone.
If a participant was still in hospital and had not regained capacity to give follow-on consent, then the
independent researcher telephoned the person who gave consent for the participant to enter the study
and completed the longer GOSE questionnaire with them over the telephone.
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Follow-up procedure for non-UK centres
Owing to the language barrier in the participating non-UK centres, it was not possible for the
independent/blinded researcher in Edinburgh to contact the non-UK patients for follow-up. We therefore
devised a slightly different process for the non-UK centres depending on their local procedures.
The procedure for follow-up was specifically outlined and discussed by the trial manager at the trial
initiation meeting with the PI and research team at each of the non-UK centres.
Each PI was asked to identify someone in their hospital who would be blind to the participants’ intervention
and could carry out the follow-up. All centres, except those in Belgium, had an independent person at their
hospital who carried out the follow-up over the telephone at 6 months. Belgium had a similar procedure
to that in the UK in that a letter was sent to both the participant and the person who gave consent at
6 months and, if this was not returned after 3 weeks, an independent person at the centre contacted the
participant by telephone and completed the longer GOSE questionnaire with them over the telephone.
Secondary end-point data collection
Data collection for the secondary end points comprised:
l intracranial pressure control
l incidence of pneumonia across both groups
l length of stay in the ICU and hospital
l Modified Oxford Handicap Scale score at 1 month, discharge from the randomising hospital or death,
whichever took place first, collected using the daily data collection forms that were completed by the
research team at each centre
l correlation between the predicted outcome using the MOHS score at hospital discharge and the
predicted outcome using the GOSE score at 6 months post injury; this correlation was conducted by
the trial statistician during the final analysis of the data
l health economics.
Owing to the unexpected result of the trial, with a higher rate of poor outcome in the hypothermia group,
a health economic analysis was not deemed to be necessary.
Any changes to trial outcomes after the trial commenced, with reasons
No changes were made to the trial outcomes after commencement of the trial.
Sample size
The main evidence for the sample size calculation was the six meta-analyses published between 2002 and
2008.86–91 These included varying numbers of clinical trials and examined each trial based on an assessment
of the quality of randomisation and blinding procedures. All meta-analyses found a trend towards positive
effects of hypothermia on neurological outcome, but statistical significance was reached in only two.86,87
With a conventional dichotomous analysis of the GOSE, comparing the proportions of participants with an
unfavourable outcome in the two groups, a 600-patient trial had 81% power at the 5% significance level
(two-sided) to detect an absolute reduction of 12% (60% reducing to 48%). There was 87% power to
detect an absolute reduction of 13% (60% reducing to 47%).
These calculations are conservative compared with the Peterson et al.91 systematic review of optimised
therapeutic cooling.
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Using an ordinal analysis of the GOSE together with covariate adjustment, there was the potential to increase
the statistical efficiency of the analysis. If we achieve the efficiency gains suggested by simulations run by the
IMPACT (International Mission on Prognosis and Clinical Trial Design in Traumatic Brain Injury) investigators96
and demonstrated in a reanalysis of the CRASH (Corticosteroid Randomisation After Significant Head Injury)
trial,97 then a trial of 600 patients would have equivalent power to a trial of 1000 patients. This would give
80% power at the 5% significance level (two-sided) to detect an absolute reduction of 9% (60% reducing
to 51%).
Data monitoring
The trial did not include any predefined interim analyses. The trial Data and Safety Monitoring Committee
(DSMC) met regularly, however, to discuss the unblinded trial data and monitor the progress of the trial.
This committee was assembled using the Medical Research Council (MRC) guidelines for the development
of a Data Monitoring and Ethics Committee (DMEC) and comprised three members:
l an expert clinician in intensive care (chairperson)
l an expert trial statistician
l an expert triallist.
A DSMC charter was developed and agreed by all members at the first DSMC meeting in 2010 (see
Appendix 3). This charter included the guidelines for early termination, the quorum for decision-making
and the reporting of the DSMC recommendations.
Statistical guidelines for termination: Data and Safety Monitoring Committee charter
The DSMC has the responsibility for deciding whether, while randomisation is in progress, the unblinded
results (or the unblinded results for a particular subgroup) should be revealed to the Trial Steering Committee.
The DSMC terms of reference stated that it would do this if, and only if, two conditions were satisfied:
1. The blinded results provide proof beyond reasonable doubt that treatment is, on balance, either
definitely harmful or definitely favourable for all, or for a particular category of, patients in terms of the
major outcome.
2. The blinded results would, if revealed, be expected to substantially change the prescribing patterns of
doctors who are already familiar with any other trial results that exist.
Exact criteria for ‘proof beyond reasonable doubt’ are not, and cannot be, specified by a purely
mathematical stopping rule, but they are strongly influenced by such rules. DSMC members expressed
sympathy with the stopping rule proposed in Part I of the 1976 report to the MRC Leukaemia Committee,98
whereby an interim analysis of major end points would generally need to involve a difference between
treatment and control of at least three standard errors to justify premature disclosure. An interim subgroup
analysis would, of course, have to be even more extreme to justify disclosure. This rule has the advantage
that the exact number and timing of interim analyses need not be prespecified. In summary, the stopping
rules as specified in the CRASH trial protocol99 (as successfully applied in other trials including the MRC
International Stroke Trial,100 which randomised 19,436 acute stroke patients) require extreme differences to
justify premature disclosure and involve an appropriate combination of mathematical stopping rules and
scientific judgement.
The DSMC met a total of nine times between February 2010 and October 2014. Of note is that the data
showed a trend towards harm in the hypothermia group during the seventh and eighth DSMC meetings
but the results did not become significant (difference of three standard errors) until the data were
reviewed during the ninth meeting in October 2014.
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NIHR Journals Library www.journalslibrary.nihr.ac.uk
18
At this time, the DSMC came to the following conclusions:
l There is no evidence of benefit for the patient group receiving the treatment to be evaluated.
l At best, a result of futility can be expected if the study is continued.
l There are signs of harm by the new treatment investigated including differences in mortality rate and a
smaller number of patients achieving a relatively good outcome in the new treatment group, for those
surviving the 6-month period after inclusion.
The DSMC therefore proposed that ‘appropriate action is taken rapidly, as a consequence of the analysis
done . . . in order to protect patients to be potentially included in this trial from now on’ (abbreviated
excerpt from the DSMC letter to the Trial Steering Committee).
This recommendation was sent to the chairperson of the Trial Steering Committee who convened an
urgent Trial Steering Committee meeting. The meeting concluded that recruitment to the trial should be
stopped early on the basis of futility and possible harm to participants. Recruitment was therefore stopped
on 14 October 2014.
Randomisation
The randomisation of participants to either the hypothermia or the standard-care group was undertaken
using a central internet-based randomisation service provided by Lincoln (Paris, France).
Type of randomisation
Participant allocation to either the hypothermia or the standard-care group by the online randomisation
service used a minimisation technique with a random element using the following stratification variables:
l trial centre
l aged < 4–5 years or ≥ 45 years
l post-resuscitation Glasgow Coma Scale (GCS) motor component 1 or 2 or 3–6
l time from injury of < 12 hours or ≥ 12 hours
l pupils – both reacting or one or neither reacting
l allocation concealment mechanism.
It was not possible to conceal the allocated group from local investigators and study teams as it was
clinically obvious which participants were receiving hypothermia, for example from the equipment
required, participant temperature, blood results and fluid requirements.
To overcome potential bias, outcome data assessment were blinded.
Implementation
The central internet-based randomisation service provided by Lincoln generated the random allocation
sequence (using minimisation with a random element) and assigned participants to groups.
Patients at each site were enrolled by either the PI or their deputy (e.g. research nurse or research doctor).
Blinding
It was not possible to blind local investigators, study teams or the participants’ next of kin to group
allocation as it was clinically obvious which participants were receiving hypothermia.
Outcome data assessment was blinded as the GOSE questionnaire was, in the first instance, posted to
participants by the trial office in Edinburgh. If it was not returned in the post within 3 weeks, then an
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independent researcher who was blind to treatment allocation telephoned the participant and/or their next
of kin to complete the questionnaire with them over the telephone.
There were some similarities between interventions in the hypothermia group and interventions in the
standard-care group of this trial. Both groups received stage 1 and stage 2 therapy (see Figure 2)
throughout the trial period. It was also possible that participants in the standard-care group received
temperature reduction, to a minimum of 36 °C, to treat fever using the same cooling technique as for
participants in the hypothermia group. If this was required, the centres followed their local guidelines for
fever management; no guidelines were provided as part of the trial.
Statistical methods
Overall statistical principles
The trial statistician performed the statistical programming and analysis to produce all summary tables and
figures using the statistical package SAS® (version 9.2 or a more recent version; SAS Institute Inc., Cary,
NC, USA; SAS and all other SAS Institute Inc. product or service names are registered trademarks or
trademarks of SAS Institute Inc. in the USA and other countries. ® indicates USA registration).
In general terms, categorical data are presented using counts and percentages, whereas continuous
variables are presented using the mean, median, standard deviation (SD), minimum, maximum, interquartile
points at 25% and 75% (Q1 and Q3) and number of participants with an observation (n). Data are split by
time point when applicable.
All applicable statistical tests are two-sided and have been performed using a 5% significance level,
leading to 95% (two-sided) CIs, unless otherwise specified.
Distributional assumptions underlying the statistical analyses are assessed by visual inspection of residual
plots. Normality is examined by normal probability plots. If the distributional assumptions for the
parametric approach were not satisfied, further data transformation (for achieving normality), or other
suitable methods, were considered.
The intention-to-treat (ITT) and per-protocol (PP) populations are used to summarise all data and all
analyses unless otherwise specified.
There has been no imputation of the data with regard to missing values or withdrawals for the statistical
summaries and statistical analysis unless otherwise specified.
Statistical analysis plan
A detailed statistical analysis plan, setting out full details of the proposed analyses, was finalised before the
trial database was locked for analysis.
As a result of the internal pilot phase,93 the sample size for the full trial was reduced from 1800 to
600 participants. Two factors contributed to this decision:
1. The original sample size may have underestimated the possible benefit of hypothermia as, unlike
participants in most previous hypothermia trials, participants in the Eurotherm3235 Trial had to have
evidence of brain swelling (raised ICP of > 20 mmHg) to be eligible for randomisation.
2. We showed that an enhanced cooling intervention could be delivered, as described by Peterson et al.91
These data therefore informed the revised power calculation.
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Population for analysis
Intention-to-treat population
The ITT population included all participants randomised into the Eurotherm3235 Trial. Participants were
analysed in the group to which they were randomised, regardless of treatment received.
Per-protocol population
The PP population comprised those members of the ITT population who completed the study without a
major protocol violation and who adequately complied with the administered treatment. Participants were
analysed depending on the treatment that they actually received.
List of analyses
Recruitment and retention
No formal statistical testing was performed to look at recruitment and retention. A Consolidated Standards
of Reporting Trials (CONSORT) flow chart is provided in Chapter 3. The numbers of participants screened,
consented, randomised, treated, completed and discontinued by treatment and overall are also presented
in Chapter 3. The number of participants discontinued early from the study is summarised by reason for
withdrawal and treatment.
Baseline data: demographics and baseline/clinical characteristics
No formal statistical testing was performed. The following baseline characteristics are presented and
summarised in the ITT report by treatment and overall (see Chapter 3):
l characteristic used in minimisation algorithm
l time from TBI to randomisation
l age and gender
l ICP, body temperature, post-resuscitation GCS and diagnosis details.
Protocol deviations/violations
No formal statistical testing was performed. All protocol deviations/violations are listed in the ITT statistical
report (see Chapter 3).
Compliance with allocated treatment
Treatment compliance was determined using the following strategy:
l Step 1 – if a participant was allocated to a treatment then he or she should have received the
allocated treatment.
l Step 2 – if a participant was allocated to the control then his or her core temperature should be
≥ 36 °C for all of the temperature observations for the first 48 hours from randomisation or until death
(whichever event happens first).
l Step 3 – if a participant was allocated to the hypothermia group then his or her core temperature should
strictly be ≥ 32 °C and < 35 °C for all of the temperature observations from 4 hours after hypothermia
started until the first 48 hours from randomisation or until death (whichever event happens first).
Additionally, the participant could not have a barbiturate infusion within the first 48 hours from
randomisation.
No formal statistical testing was performed. The number of treatment-compliant participants is summarised
by treatment group as part of the ITT statistical report (see Chapter 3).
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Primary outcome
Using an ordinal analysis of the GOSE scores, together with covariate adjustment (primary efficacy
analysis), we were able to increase the statistical efficiency of the analysis101,102 so that a trial involving
600 participants would have power equivalent to that of a trial involving 1000 participants that assessed
a binary outcome. We calculated that, with such an analysis, the study would have the equivalent of 80%
power to detect a rate of unfavourable outcome (GOSE score of 1–4) that was 9 percentage points lower
with hypothermia than with standard care (51% vs. 60%) at the 5% significance level (two-sided).
Data were analysed on an ITT basis. All randomised participants for whom outcome data were available
were therefore included.
Participants were analysed depending on their allocated intervention, irrespective of whether or not their
actual management complied with the allocated intervention.
The distributions of the 6-month GOSE scores between the two randomised groups (hypothermia vs.
standard care) were compared using ordinal regression, adjusting for the following baseline covariates that
were included in the minimisation algorithm:
l age (included as a continuous variable using a linear term in the regression model)
l post-resuscitation GCS motor component 1 or 2 compared with 3–6
l time from injury of < 12 hours compared with ≥ 12 hours
l pupils: both reacting compared with one reacting compared with neither reacting (included as an
unordered categorical variable in the regression model).
As the covariates specified for the statistical analyses were required to inform the minimisation algorithm,
there were no missing data for baseline covariates. A strenuous effort by the trial managers was also made
to obtain complete outcome data at 6 months.
For this analysis, the eight-point GOSE was collapsed to six categories by pooling the ‘death with
vegetative state’ and ‘lower severe disability’ categories. This was carried out to ensure that the analysis
could not give ‘credit’ to an intervention that reduces mortality at the expense of increasing the proportion
of severely disabled survivors.
The treatment effect was reported as an estimated adjusted common odds ratio (OR) with its corresponding
95% CI. The treatment groups are ordered in such a way that a common OR of < 1 corresponds to a
benefit for hypothermia over standard care.
If there is strong evidence that the treatment effect does not satisfy the proportional odds assumption, which
is required for the ordinal analysis, then this in itself will demonstrate that the distribution of the GOSE score
differs between the two randomised groups. In such a situation, the distribution of the GOSE score in the
two groups will be explored descriptively to give an insight into the nature of the treatment effect.
Sensitivity analyses
The unadjusted common OR and its corresponding 95% CI, derived by fitting an ordinal regression model
with treatment as the only covariate included, is reported as a sensitivity analysis.
A binary logistic regression, using the same baseline covariates as set out in List of analyses, was also
performed, using the conventional split of the GOSE as ‘lower moderate disability’ or better (‘favourable’)
compared with ‘upper severe disability’ or worse (‘unfavourable’).
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In a further exploratory analysis, the impact of missing outcome data was examined using an imputation
technique, based on the simple IMPACT model96 and the MOHS value and/or shorter GOS, if available,
for imputing the missing GOSE data.
Secondary outcomes
The following outcome measures were tested for differences between the two treatment groups:
Six-month mortality rate
Survival from ICU admission to 6 months post randomisation (analysis of mortality) is presented using a
Kaplan–Meier plot split by treatment group. The two survival curves have been compared formally using
a log-rank test. If distributional assumptions hold, this will be analysed using Cox proportional hazards
regression and the result presented as an estimated hazard ratio (HR) with its corresponding 95% CI.
Intracranial pressure control
The proportion of recorded ICP measurements of ≤ 20 mmHg were calculated for each participant.
These proportions are summarised by treatment group in the ITT statistical report (see Chapter 3).
The effect of the intervention was estimated using a linear model adjusted by the minimisation
variables. The effect of treatment allocation is reported as an adjusted mean difference with its
corresponding 95% CI.
The above analysis was also repeated for an ICP of ≤ 25 mmHg as a sensitivity analysis.
Incidence of pneumonia across both groups
The number and proportion of participants who developed pneumonia were calculated by treatment
group. The effect of the intervention was then estimated using binary logistic regression adjusted by
minimisation variables. The effect of treatment allocation is reported as an adjusted OR with its
corresponding 95% CI in the ITT statistical report (see Chapter 3).
Additionally, the first time (from day 3 to day 7) that pneumonia manifested is reported but statistical
significance was not assessed.
Length of stay in the intensive care unit and hospital
The length-of-stay variables were calculated as follows:
l date/time from TBI (inclusion visit form) to randomisation
l date/time from randomisation to discharge from hospital (follow-up form)
l date/time from TBI (inclusion visit form) to discharge from hospital (follow-up form)
l studied ICU stay = date/time from randomisation to discharge from ICU (follow-up form)
l overall ICU stay= date/time of admission to ICU (inclusion visit form) to discharge from ICU (follow-up form)
l hospital stay = date/time from TBI (inclusion visit form) to discharge from hospital (follow-up form).
A linear regression model has been used to compare the mean lengths of stay between groups, adjusting
by minimisation variables. The result are presented as an adjusted difference in mean length, together with
its corresponding 95% CI, in the ITT statistical report (see Chapter 3).
Modified Oxford Handicap Scale score at 28 days, discharge from the randomising
hospital or death, whichever took place first
This outcome was analysed as per the primary outcome using an adjusted ordinal regression. In this
analysis, the six-point MOHS was collapsed to four categories by pooling ‘death’ with ‘fully dependent,
requiring attention day and night’ and ‘dependent, but not requiring constant attention’.
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Correlation between the predicted outcome using the Modified Oxford Handicap Scale
score at hospital discharge and the predicted outcome using the Glasgow Outcome Scale –
Extended score at 6 months post injury
The Kendall tau-b correlation coefficient with its 95% CI between the MOHS score and the GOSE score is
presented as part of the ITT statistical report (see Chapter 3).
A priori subgroups for the primary analysis were explored as follows:
l aged < 45 years compared with ≥ 45 years
l post-resuscitation GCS motor component 1 or 2 compared with 3–6
l time from injury of < 12 hours compared with ≥ 12 hours
l pupillary response: both or one reacting compared with none reacting
l UK centres compared with non-UK centres
l centres with high numbers of patients (i.e. 10 patients) compared with centres with low numbers
(i.e. 10 patients).
These analyses were performed by including an interaction term between treatment and the relevant
covariate in the ordinal regression model described above. A stricter level of statistical significance
(p < 0.01) has been used in these analyses to reflect their exploratory nature.
Quality control of summary tables and statistical analysis
Isolated data errors, detected in the database as a result of the quality control checks, that were deemed
significant were submitted for enquiry to the trial manager or designee.
Systematic data errors in the data reporting were investigated further; the data were corrected if necessary
and the appropriate table was then rechecked.
Quality control/validation: summary tables
A random selection of unique analysis and summary tables was quality controlled using manual methods
(e.g. comparison of results in the table with results calculated using a calculator, spreadsheet, database
output or any alternative summarisation tool).
Quality control/validation: statistical analysis
Quality control/validation of statistical analyses was performed by peer review of program code, log and
output. Additionally, the primary outcome analysis was replicated independently by a second statistician.
Unblinding procedures
Unblinding procedures were not applicable.
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Chapter 3 Results
Results
Participant flow
Of the 2498 participants who were assessed for trial eligibility, 387 were randomly assigned, 386 received
the intended treatment (after a withdrawal pre intervention) and 387 were analysed for the primary outcome
(Figure 3). The most common reasons for exclusion from the trial were that ICP remained at ≤ 20mmHg
(41% of 2111 exclusions), the participant was unlikely to survive (8%) or the participant was already
receiving hypothermia treatment (6%).
Recruitment
A total of 64 centres were initiated in 18 countries worldwide, with a target recruitment at each centre of
four participants per year. A total of 387 participants were randomised from 47 of these centres between
November 2009 (pilot phase from 10 January 2009 to 15 September 201193) and October 2014, when
recruitment was stopped. Of these 387 participants, 53% (n = 205) were recruited in the UK. Follow-up
ended 6 months after recruitment stopped, in April 2015.
Figure 4 shows the predicted versus actual recruitment throughout the trial.
Why the trial was ended
Recruitment was stopped in October 2014 when the Trial Steering Committee, in concurrence with the
original recommendations of the DMEC, concluded that there were signs of harm with the induced
hypothermia treatment and, at best, a result of futility would be expected if the trial were to continue.
These findings were apparent when the study’s designated primary outcome measure, analysed in
accordance with the study’s pre-stated statistical analysis plan, was examined.
Baseline data
On an ITT basis, a total of 195 participants were randomised to hypothermia and 192 participants were
randomised to standard care. Table 1 shows that there were no significant differences between groups in
baseline characteristics.
Numbers analysed
Table 2 shows the breakdown of recruitment and treatment allocation by centre and Table 3 shows the
total number of participants screened and recruited at each centre.
The breakdown of participants recruited in the UK and non-UK centres was 53% and 47%, respectively.
Outcomes and estimation
All analyses were performed with SAS software. Analyses were performed on an ITT basis, incorporating all
participants who underwent randomisation and for whom outcome data were available, with participants
evaluated depending on their assigned intervention.
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Patients screened
(n = 2498)
Potentially eligible
(n = 601)
Declined consent 
(n = 81)
Exclusions
(n = 133)
Exclusions
(n = 1897)
Early trial consent
(n = 520)
Randomised
(n = 387)
Allocated hypothermia
(n = 195)
Reached follow-up
(6 months after TBI)
(n = 193)
Analysed
(n = 188)
Fulfilled inclusion/met exclusion criteria or other 
reason for non-participation
• Failed inclusion criterion of ICP of < 20 mmHg, 
   n = 111
• Failed other inclusion criteria, n = 22
Reason for not reaching follow-up
• Lost to follow-up, n = 1
Excluded from primary analysis
• Primary outcome data could not
   be collected, n = 2
• GOS data collected instead, n = 3
• Received treatment, n = 194
• Withdrawn pre treatment, n = 1
Allocated control
(n = 192)
Reached follow-up
(6 months after TBI)
(n = 191)
Analysed
(n = 188)
Reason for not reaching follow-up
• Lost to follow-up, n = 1
Excluded from primary analysis
• Primary outcome data could not
   be collected, n = 2
• GOS data collected instead, n = 1
• Received treatment, n = 192
• Failed inclusion criterion of ICP of < 20 mmHg, 
   n = 756
• Failed other inclusion criteria, n = 234 
   • Age, n = 88
   • > 10 days from injury, n = 74
   • Open TBI, n = 40
   • Normal CT scan, n = 16
   • Other, n = 16  
• Met exclusion criteria, n = 476
   • Unlikely to survive, n = 167
   • Receiving hypothermia, n = 130
   • Temperature of < 34 ºC, n = 121
   • Barbiturates, n = 55
   • Other, n = 3
• Operational reasons, n = 376
   • Enrolled in other trial, n = 132
   • Decompressive craniectomy, n = 95
   • Woken and extubated, n = 77
   • No relatives, n = 33
   • No research staff, n = 25
   • Other, n = 14
• Other reasons, n = 52
• Unknown reason, n = 3
FIGURE 3 The CONSORT flow diagram. Adapted with permission from Andrews et al.1 Copyright © (2015)
Massachusetts Medical Society.
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FIGURE 4 Recruitment graph. Adapted with permission from Andrews et al.1 Copyright © (2015) Massachusetts
Medical Society.
TABLE 1 Baseline demographic and clinical characteristics for each group. Adapted with permission from
Andrews et al.1 Copyright © (2015) Massachusetts Medical Society
Demographic details
Treatment group
Overall
(N= 387) p-value
Hypothermia
(N= 195)
Control
(N= 192)
Exact age (years), mean (SD) 37.4 (15.4) 36.7 (14.9) 37.0 (15.1) 0.65
Age compliance, n (%)
< 45 years 131 (67.2) 131 (68.2) 262 (67.7)
≥ 45 years 64 (32.8) 61 (31.8) 125 (32.3)
Gender, n (%)
Male 157 (80.5) 164 (85.4) 321 (82.9) 0.20
Female 38 (19.5) 28 (14.6) 66 (17.1)
Time from TBI (hours), mean (SD) 77.96 (267.7) 211.9 (1421.7) 144.58 (1021.5) 0.50
Time from TBI compliance, n (%)
< 12 hours 19 (9.7) 15 (7.8) 34 (8.8)
≥ 12 hours 176 (90.3) 177 (92.2) 353 (91.2)
ICP at randomisation (mmHg), mean (SD) 25.2 (4.8) 25.5 (6.4) 25.3 (5.6) 0.77
Temperature at randomisation (°C), mean (SD) 37.01 (0.7) 37.10 (0.72) 37.05 (0.7) 0.19
continued
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TABLE 1 Baseline demographic and clinical characteristics for each group. Adapted with permission from
Andrews et al.1 Copyright © (2015) Massachusetts Medical Society (continued )
Demographic details
Treatment group
Overall
(N= 387) p-value
Hypothermia
(N= 195)
Control
(N= 192)
GCS eyes,a n (%)
None 117 (60.0) 113 (58.9) 230 (59.4) 0.96
To pain 17 (8.7) 24 (12.5) 41 (10.6)
To sound 29 (14.9) 26 (13.5) 55 (14.2)
Spontaneous 32 (16.4) 29 (15.1) 61 (15.8)
GCS verbal,a n (%)
None 109 (55.9) 108 (56.3) 217 (56.1) 0.91
Incomprehensible 36 (18.5) 35 (18.2) 71 (18.3)
Inappropriate 21 (10.8) 14 (7.3) 35 (9.0)
Confused 21 (10.8) 25 (13.0) 46 (11.9)
Orientated 8 (4.1) 10 (5.2) 18 (4.7)
GCS motor,a n (%)
None 38 (19.5) 38 (19.8) 76 (19.6) 0.61
Extension 18 (9.2) 12 (6.3) 30 (7.8)
Abnormal flexion 13 (6.7) 18 (9.4) 31 (8.0)
Normal flexion 22 (11.3) 32 (16.7) 54 (14.0)
Localises 70 (35.9) 61 (31.8) 131 (33.9)
Obeys command 34 (17.4) 31 (16.1) 65 (16.8)
GCS sum (eyes + verbal +motor), n (%)
3–8 125 (64.1) 129 (67.2) 254 (65.6) 0.70
9–12 45 (23.1) 34 (17.7) 79 (20.4)
13–15 25 (12.8) 29 (15.1) 54 (14.0)
Isolated TBI, n (%)
Yes 123 (63.1) 133 (69.3) 256 (66.1) 0.20
No 72 (36.9) 59 (30.7) 131 (33.9)
Mechanism of injury, n (%)
Missing 1 0 1 0.87
Road traffic accident – pedestrian 22 (11.3) 31 (16.1) 53 (13.7)
Road traffic accident – motor vehicle 68 (35.1) 51 (26.6) 119 (30.8)
Push bike 7 (3.6) 10 (5.2) 17 (4.4)
Fall 78 (40.2) 78 (40.6) 156 (40.4)
Sports injury 1 (0.5) 1 (0.5) 2 (0.5)
Assault 18 (9.3) 21 (10.9) 39 (10.1)
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TABLE 1 Baseline demographic and clinical characteristics for each group. Adapted with permission from
Andrews et al.1 Copyright © (2015) Massachusetts Medical Society (continued )
Demographic details
Treatment group
Overall
(N= 387) p-value
Hypothermia
(N= 195)
Control
(N= 192)
CT scan appearance – Marshall classification,b n (%)
Diffuse injury Ic (no visible pathology) 2 (1.0) 0 2 (0.5) 0.47
Diffuse injury IId 31 (15.9) 36 (18.8) 67 (17.3)
Diffuse injury IIIe (swelling) 39 (20.0) 42 (21.9) 81 (20.9)
Diffuse injury IVf (shift) 21 (10.8) 15 (7.8) 36 (9.3)
Any lesion surgically removed 46 (23.6) 52 (27.1) 98 (25.3)
High- or mixed-density lesion 56 (28.7) 47 (24.5) 103 (26.6)
Any neurosurgery this admission, n (%)
Yes 83 (42.6) 73 (38.0) 156 (40.3) 0.36
No 112 (57.4) 119 (62.0) 231 (59.7)
Number of neurosurgeries, n (%)
0 112 (57.4) 119 (62.0) 231 (59.7) 0.61
1 68 (34.9) 51 (26.6) 119 (30.7)
2 12 (6.2) 18 (9.4) 30 (7.8)
3 3 (1.5) 4 (2.1) 7 (1.8)
a GCS motor score was measured on hospital admission.
b The Marshall classification of TBI is based on a review of CT scans that were obtained at the screening visit. A diffuse
injury indicates that no high-density or mixed-density lesions of > 25mm3 are present.
c Diffuse injury I indicates no visible intracranial pathological features.
d Diffuse injury II indicates that cisterns are present with a midline shift of 0–5 mm or that lesion densities are present.
e Diffuse injury III indicates that cisterns are compressed or absent with a midline shift of 0–5mm.
f Diffuse injury IV indicates a midline shift of ≥ 5 mm.
TABLE 2 Recruitment and treatment allocation by centre
Trial centre
Treatment group, n (%)
Overall,
n (%)
(N= 387)
Hypothermia
(N= 195)
Control
(N= 192)
Western General Hospital, Edinburgh, UK 24 (12.3) 18 (9.4) 42 (10.9)
Aberdeen Royal Infirmary, Aberdeen, UK 2 (1.0) 3 (1.6) 5 (1.3)
Charing Cross Hospital, London, UK 1 (0.5) 2 (1.0) 3 (0.8)
Derriford Hospital, Plymouth, UK 9 (4.6) 7 (3.6) 16 (4.1)
Royal Berkshire Hospital, Reading, UK 0 1 (0.5) 1 (0.3)
Hull Royal Infirmary, Hull, UK 2 (1.0) 4 (2.1) 6 (1.6)
Royal Hallamshire Hospital, Sheffield, UK 2 (1.0) 1 (0.5) 3 (0.8)
University Hospital of North Staffordshire, UK 6 (3.1) 6 (3.1) 12 (3.1)
Leeds General Infirmary, Leeds, UK 2 (1.0) 4 (2.1) 6 (1.6)
Royal Victoria Infirmary, Newcastle upon Tyne, UK 8 (4.1) 4 (2.1) 12 (3.1)
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TABLE 2 Recruitment and treatment allocation by centre (continued )
Trial centre
Treatment group, n (%)
Overall,
n (%)
(N= 387)
Hypothermia
(N= 195)
Control
(N= 192)
North Estonia Medical Centre, Tallinn, Estonia 7 (3.6) 12 (6.3) 19 (4.9)
Thriassio General Hospital of Eleusis, Magoula, Greece 2 (1.0) 3 (1.6) 5 (1.3)
Albert Szent-Gyorgyi Medical Centre, Szeged, Hungary 3 (1.5) 2 (1.0) 5 (1.3)
Hurstwood Park Neurological Centre, Haywards Heath, UK 1 (0.5) 0 1 (0.3)
Royal Victoria Hospital, Belfast, UK 4 (2.1) 3 (1.6) 7 (1.8)
CHU de Charleroi, Charleroi, Belgium 2 (1.0) 2 (1.0) 4 (1.0)
Evangelismos General Hospital, Athens, Greece 1 (0.5) 3 (1.6) 4 (1.0)
Cliniques Universitaires UCL de Mont-Godinne, Dinant, France 3 (1.5) 2 (1.0) 5 (1.3)
University Hospital Brussels, Brussels, Belgium 2 (1.0) 3 (1.6) 5 (1.3)
CSL Clinique Saint Joseph, Arlon, Spain 0 2 (1.0) 2 (0.5)
CHR Citadelle, Liege, Belgium 0 1 (0.5) 1 (0.3)
St Mary’s Hospital, London, UK 3 (1.5) 5 (2.6) 8 (2.1)
King’s College Hospital, London, UK 14 (7.2) 16 (8.3) 30 (7.8)
Hôpital ERASME, Brussels, Belgium 14 (7.2) 13 (6.8) 27 (7.0)
Istituto Clinico Humanitas, Milan, Italy 3 (1.5) 1 (0.5) 4 (1.0)
Sklifosovsky Research Institute, Moscow, Russia 1 (0.5) 0 1 (0.3)
University Hospital of Ioannina, Ioannina, Greece 0 1 (0.5) 1 (0.3)
Cork University Hospital, Cork, Ireland 6 (3.1) 5 (2.6) 11 (2.8)
University Hospital of Thessaly, Larissa 5 (2.6) 5 (2.6) 10 (2.6)
BG Kliniken Bergmannstrost, Halle, Germany 1 (0.5) 1 (0.5) 2 (0.5)
Salford Royal NHS Trust, Salford, UK 8 (4.1) 7 (3.6) 15 (3.9)
Complejo Universitario de Burgos, Burgos, Spain 6 (3.1) 6 (3.1) 12 (3.1)
University Hospital of Coventry and Warwickshire, Coventry, UK 0 1 (0.5) 1 (0.3)
Policlinico A. Gemelli, Rome, Italy 2 (1.0) 0 2 (0.5)
General Hospital of Kavala, Greece 2 (1.0) 0 2 (0.5)
Jai Prakash Narain Apex Trauma Centre, AIIMS, New Delhi, India 20 (10.3) 18 (9.4) 38 (9.8)
University Hospital of Wales, UK 9 (4.6) 11 (5.7) 20 (5.2)
Sheikh Khalifa Medical City, United Arab Emirates 1 (0.5) 1 (0.5) 2 (0.5)
Erasmus University Medical Center, Rotterdam, the Netherlands 4 (2.1) 4 (2.1) 8 (2.1)
UCIP, Hospital de Santo Antonio, Portugal 1 (0.5) 4 (2.1) 5 (1.3)
Queen’s Hospital, Romford, UK 3 (1.5) 1 (0.5) 4 (1.0)
Royal London Hospital, UK 3 (1.5) 4 (2.1) 7 (1.8)
Royal Preston Hospital, UK 3 (1.5) 2 (1.0) 5 (1.3)
King Abdulaziz Medical City, Saudi Arabia 2 (1.0) 1 (0.5) 3 (0.8)
Hospital Clinico San Carlos, Madrid, Spain 1 (0.5) 0 1 (0.3)
The Walton Centre, Liverpool, UK 0 1 (0.5) 1 (0.3)
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TABLE 3 Participant recruitment by centre and country
Trial centre
Participants (n)
Randomised Screened
Western General Hospital, Edinburgh, UK 42 137
Jai Prakash Narain Apex Trauma Centre, AIIMS, New Delhi, India 38 38
King’s College Hospital, London, UK 30 144
Hôpital Erasme, Brussels, Belgium 27 27
University Hospital of Wales, UK 20 115
North Estonia Medical Centre, Estonia 19 107
Derriford Hospital, Plymouth, UK 16 143
Salford Royal NHS Trust, UK 15 155
Royal Stoke University Hospital, UK 12 127
Royal Victoria Infirmary, Newcastle, UK 12 112
Complejo Universitario de Burgos, Spain 12 25
Cork University Hospital, Ireland 11 58
University Hospital of Thessaly, Larissa, Greece 10 13
St Mary’s Hospital, London, UK 8 157
Erasmus University Medical Center, Rotterdam, the Netherlands 8 81
Royal Victoria Hospital, Belfast, UK 7 98
Royal London Hospital, UK 7 142
Leeds General Infirmary, UK 6 83
Hull Royal Infirmary, UK 6 74
Aberdeen Royal Infirmary, UK 5 77
Thriassio General Hospital of Eleusis, Attica, Greece 5 43
Albert Szent-Gyorgyi Medical Centre, Hungary 5 7
Cliniques Universitaires UCL de Mont Goddine, Belgium 5 5
UCIP Hospital de Santo António, Porto, Portugal 5 8
University Hospital Brussels, Belgium 5 20
Royal Preston Hospital, UK 5 59
CHU de Charleroi, Belgium 4 10
Evangelismos General Hospital, Greece 4 22
Istituto Clinico Humanitas, Milan, Italy 4 9
Queen’s Hospital, Romford, UK 4 31
Charing Cross Hospital, London, UK 3 23
King Abdulaziz Medical City, Riyadh, Saudi Arabia 3 35
Royal Hallamshire Hospital, Sheffield, UK 3 20
G. Gennimatas General Hospital of Athens, Greece 3 3
Policlinico A. Gemelli, Rome, Italy 2 11
CSL Clinique St Joseph Arlon, Belgium 2 11
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For the primary analysis, the distribution of the 6-month GOSE scores between the two groups
(hypothermia vs. control) was compared with the use of ordinal logistic regression and with adjustment for
the following baseline covariates:
l age (included as a continuous variable with the use of a linear term in the regression model)
l post-resuscitation GCS motor score [1 or 2 (no response or extensor response) vs. 3 to 6 (flexion or
better response)]
l time from injury (< 12 hours vs. ≥ 12 hours)
l pupillary response (both reacting vs. one reacting vs. neither reacting; included as an unordered
categorical variable in the regression model).
For this analysis, we collapsed the eight-point GOSE to six categories by pooling ‘death with a vegetative
state’ and ‘lower severe disability’. This ensured that the analysis would not favour an intervention that
reduced mortality at the expense of increasing the proportion of severely disabled survivors. Figure 5 shows
the survival curves between groups.
Table 4 shows a detailed breakdown of the score category per group for both the full eight-point GOSE,
the collapsed six-category GOSE and the dichotomised GOSE.
Table 5 shows the results of the primary analysis and primary subgroup analyses for the ITT population.
TABLE 3 Participant recruitment by centre and country (continued )
Trial centre
Participants (n)
Randomised Screened
BG Kliniken Bergmannstrost, Halle, Germany 2 12
General Hospital of Kavala, Greece 2 5
Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates 2 4
Royal Berkshire Hospital, Reading, UK 1 5
Hurstwood Park Neurological Centre, Haywards Heath, UK 1 31
CHR Citadelle, Liège, Belgium 1 2
Sklifosovsky Research Institute, Moscow, Russia 1 23
University Hospital of Ioannina, Greece 1 1
University Hospital of Coventry and Warwickshire, UK 1 115
Hospital Clinico San Carlos, Madrid, Spain 1 2
The Walton Centre, Liverpool, UK 1 1
Ospedale San Gerardo di Monza, Italy 0 15
Medisch Centrum Haaglanden, the Netherlands 0 11
Hospital Germans Trias I Pujol, Badalona, Spain 0 10
University General Hospital of Alexandroupolis, Greece 0 9
Queen’s Medical Centre, Nottingham, UK 0 9
Southern General Hospital, Glasgow, UK 0 8
St George’s Hospital, London, UK 0 3
CHL-Apollo Hospitals, India 0 2
All centres 387 2498
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FIGURE 5 Kaplan–Meier survival curves per group.
TABLE 4 Detailed breakdown of the score category per group for both the full eight-point GOSE, the collapsed
six-category GOSE and the dichotomised GOSE
Parameter Categories
Treatment group, n (%)
Overall,
n (%)
(N= 387)
Hypothermia
(N= 195)
Control
(N= 192)
GOSE score
at 6 months
Dead 68 (34.9) 51 (27.3) 119 (31.7)
Vegetative state 0 3 (1.6) 3 (0.8)
Lower severe disability 46 (24.5) 43 (23.0) 89 (23.7)
Upper severe disability 26 (13.8) 21 (11.2) 47 (12.5)
Lower moderate disability 16 (8.5) 17 (9.1) 33 (8.8)
Upper moderate disability 12 (6.4) 15 (8.0) 27 (7.2)
Lower good recovery 10 (5.3) 20 (10.7) 30 (8.0)
Upper good recovery 10 (5.3) 17 (9.1) 27 (7.2)
GOSE score 2: vegetative state 0 1 (0.5) 1 (0.3)
GOSE score 3: severe disability 2 (1.0) 1 (0.5) 3 (0.8)
GOSE score 4: moderate disability 1 (0.5) 0 1 (0.3)
Lost to follow-up 1 (0.5) 1 (0.5) 2 (0.5)
Alive at follow-up, GOSE data not available 2 (1.0) 2 (1.0) 4 (1.0)
Withdrawn pre treatment 1 (0.5) 0 1 (0.3)
GOSE score
at 6 months:
collapseda
Dead, vegetative state, lower severe disability 114 (60.6) 98 (52.1) 212 (56.4)
Upper severe disability 26 (13.8) 21 (11.2) 47 (12.5)
Lower moderate disability 16 (8.5) 17 (9.0) 33 (8.8)
Upper moderate disability 12 (6.4) 15 (8.0) 27 (7.2)
Lower good recovery 10 (5.3) 20 (10.6) 30 (8.0)
Upper good recovery 10 (5.3) 17 (9.0) 27 (7.2)
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The results of the primary analysis were unexpected and showed that participants in the hypothermia
group had significantly poorer outcomes at 6 months (p = 0.04) and a higher mortality rate (p = 0.05) than
those treated with standard care alone. Furthermore, the primary subgroup analysis showed that age and
post-resuscitation GCS motor component were specifically linked to outcome; in this patient population,
these findings would be expected.
Secondary analyses
Secondary outcomes of the trial were:
l 6-month mortality rate
l intracranial pressure control
l incidence of pneumonia across both groups
l length of stay in the ICU and hospital
TABLE 4 Detailed breakdown of the score category per group for both the full eight-point GOSE, the collapsed
six-category GOSE and the dichotomised GOSE (continued )
Parameter Categories
Treatment group, n (%)
Overall,
n (%)
(N= 387)
Hypothermia
(N= 195)
Control
(N= 192)
Dichotomised
GOSE scorea
Unfavourable: dead, vegetative state, lower severe disability,
upper severe disability
142 (74.3) 120 (63.5) 262 (68.9)
Favourable: lower moderate disability, upper moderate
disability, lower good recovery, upper good recovery
49 (25.7) 69 (36.5) 118 (31.1)
a These scores refer to the collapsed and dichotomised GOSE scores only.
TABLE 5 Results of the primary analysis (hypothermia vs. standard care) and primary subgroup analyses using the
ITT population. Adapted with permission from Andrews et al.1 Copyright © (2015) Massachussets Medical Society
Analysis Estimate (95% CI) p-value
Adjusted common ORa for GOSE score at 6 monthsb,c 1.53 (1.02 to 2.30) 0.04
Adjusted ORa for unfavourable outcomeb,d 1.69 (1.06 to 2.70) 0.03
Treatment with hypothermia vs. control (unadjusted) 1.53 (1.02 to 2.30) 0.04
Treatment with hypothermia vs. control (collapsed) 1.55 (1.05 to 2.29) 0.03
Treatment with hypothermia vs. control (dichotomised) 1.67 (1.06 to 2.70) 0.027
Subgroup analyses
Aged < 45 vs. ≥ 45 yearsd 1.03 (1.01 to 1.04) < 0.001
Post-resuscitation GCS motor component [score of 1 or 2 (or no extension
or response) vs. 3–6 (flexion or better response)]d
0.23 (0.13 to 0.40) < 0.001
Time from injury (< 12 hours vs. ≥ 12 hours)d 0.71 (0.35 to 1.44) 0.34
Pupillary response (both reacting vs. one reacting vs. neither reacting)d 0.91 (0.36 to 2.31) 0.0029
a An OR or common OR of < 1 corresponds to a benefit for hypothermia over control.
b Results were adjusted for age, post-resuscitation GCS motor score, time from injury and pupillary response.
c The eight-point GOSE was collapsed to six categories by pooling death (score of 1) with vegetative state (score of 2) and
lower severe disability (score of 3).
d The eight-point GOSE was collapsed to two categories: favourable outcome (score of 5–8) and unfavourable outcome
(score of 1–4).
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l modified Oxford Handicap Scale score at 1 month, discharge from the randomising hospital or death,
whichever took place first
l correlation between the predicted outcome using the MOHS at hospital discharge and the GOSE score
at 6 months post injury
l health economics.
The results of the secondary end-point analyses are shown in Table 6.
The physiological measures detailed in Table 5 are also shown as trends in Figures 6 and 7.
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FIGURE 6 Intracranial pressure control per group. Adapted with permission from Andrews et al.1 Copyright © (2015)
Massachussets Medical Society.
TABLE 6 Results of the secondary end-point analyses
Analysis of secondary outcomes: hypothermia vs. control Estimate (95% CI) p-value
Unadjusted HR for death incidence between randomisation and 6 months 1.45 (1.01 to 2.10) 0.047
Physiological measuresa
Adjusted mean difference in ICP on days 1–7 (mmHg) –0.48 (–2.04 to 1.08) 0.55
Adjusted mean difference in core temperature on days 1–7 (°C) –2.14 (–2.34 to –1.94) < 0.001
Adjusted mean difference in MAP on days 1–7 (mmHg) 1.20 (–0.46 to 2.86) 0.16
Adjusted mean difference in CPP on days 1–7 (mmHg) 1.61 (–0.36 to 3.58) 0.11
Adjusted mean difference in squared proportion of ICP measurements of ≤ 20mmHg
on days 1–7
440 (–1.60 to 1000) 0.47
Incidence of patients who had presence of pneumonia on days 3–7 1.04 (0.69 to 1.58) 0.84
Adjusted mean difference in log-transformed length of ICU stay (log-hours)c 0.05 (0.11 to 0.22) 0.54
Adjusted common ORb for MOHS grade at 28 daysc,d 1.65 (0.91 to 3.02) 0.10
a Values were calculated with the use of a repeated-measures model adjusted for age, postresuscitation GCS motor score,
time from injury, pupillary response, study day and (when available) baseline value. These are post hoc analyses.
b An OR or common OR of < 1 corresponds to a benefit for hypothermia over control.
c Results were adjusted for age, post-resuscitation GCS motor score, time from injury and pupillary response.
d The six grades of the MOHS were collapsed to four categories by pooling dependent, fully dependent and death.
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Per-protocol analysis
We also carried out a PP analysis. Participants from the ITT population were included in this analysis if they
completed the study without a major protocol violation and adequately complied with the prescribed
treatment group. Participants were analysed depending on the treatment they actually received. A total of
257 participants were included in this analysis: 125 in the hypothermia group and 132 in the control group.
Table 7 shows that, as with the ITT population (see Table 5), there were no significant differences in
baseline characteristics in the PP population. Table 8 shows the breakdown of GOSE score category for the
full eight-point GOSE, the collapsed six-point GOSE and the dichotomised GOSE in this population.
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FIGURE 7 Temperature control per group. Adapted with permission from Andrews et al.1 Copyright © (2015)
Massachussets Medical Society.
TABLE 7 Baseline demographic and clinical characteristics for each PP group
Demographic details
Treatment group
Overall (N= 257) p-value
Hypothermia
(N= 125) Control (N= 132)
Exact age (years), mean (SD) 38.3 (15.5) 37.0 (15.0) 37.6 (15.2) 0.46
Age compliance, n (%)
< 45 years 83 (66.4) 90 (68.2) 173 (67.3) 0.76
≥ 45 years 42 (33.6) 42 (31.8) 84 (32.7)
Gender, n (%)
Male 98 (78.4) 115 (87.1) 213 (82.9) 0.06
Female 27 (21.6) 17 (12.9) 44 (17.1)
Time from TBI (hours), mean (SD) 91.54 (332.71) 264.68 (1315.76) 180.82 (974.83) 0.63
Time from TBI compliance, n (%)
< 12 hours 10 (8.0) 8 (6.1) 18 (7.0) 0.02
≥ 12 hours 115 (92.0) 124 (93.9) 239 (93.0)
ICP at randomisation (mmHg), mean (SD) 25.1 (4.8) 25.1 (6.0) 25.1 (5.5) 0.86
Temperature at randomisation (°C), mean (SD) 37.01 (0.74) 37.17 (0.67) 37.09 (0.71) 0.65
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TABLE 7 Baseline demographic and clinical characteristics for each PP group (continued )
Demographic details
Treatment group
Overall (N= 257) p-value
Hypothermia
(N= 125) Control (N= 132)
GCS eyes,a n (%)
None 78 (62.4) 76 (57.6) 154 (59.9) 0.39
To pain 10 (8.0) 16 (12.1) 26 (10.1)
To sound 23 (18.4) 17 (12.9) 40 (15.6)
Spontaneous 14 (11.2) 23 (17.4) 37 (14.4)
GCS verbal,a n (%)
None 67 (53.6) 73 (55.3) 140 (54.5) 0.93
Incomprehensible 26 (20.8) 24 (18.2) 50 (19.5)
Inappropriate 13 (10.4) 10 (7.6) 23 (8.9)
Confused 16 (12.8) 16 (12.1) 32 (12.5)
Orientated 3 (2.4) 9 (6.8) 12 (4.7)
GCS motor,a n (%)
None 22 (17.6) 25 (18.9) 47 (18.3) 0.67
Extension 10 (8.0) 10 (7.6) 20 (7.8)
Abnormal flexion 9 (7.2) 10 (7.6) 19 (7.4)
Normal flexion 17 (13.6) 24 (18.2) 41 (16.0)
Localises 48 (38.4) 41 (31.1) 89 (34.6)
Obeys command 19 (15.2) 22 (16.7) 41 (16.0)
GCS sum (eyes + verbal +motor), n (%)
3–8 82 (65.6) 89 (67.4) 171 (66.5) 0.93
9–12 29 (23.2) 20 (15.2) 49 (19.1)
13–15 14 (11.2) 23 (17.4) 37 (14.4)
Isolated TBI, n (%)
Yes 74 (59.2) 96 (72.7) 170 (66.1) 0.23
No 51 (40.8) 36 (27.3) 87 (33.9)
Mechanism of injury, n (%)
Missing 1 0 1 0.91
Road traffic accident – pedestrian 13 (10.5) 19 (14.4) 32 (12.5)
Road traffic accident – motor vehicle 46 (37.1) 37 (28.0) 83 (32.4)
Push bike 3 (2.4) 8 (6.1) 11 (4.3)
Fall 49 (39.5) 54 (40.9) 103 (40.2)
Sports injury 0 1 (0.8) 1 (0.4)
Assault 13 (10.5) 13 (9.8) 26 (10.2)
CT scan appearance – Marshall classification,b n (%)
Diffuse injury Ic (no visible pathology) 1 (0.8) 0 1 (0.4) 0.59
Diffuse injury IId 19 (15.2) 27 (20.5) 46 (17.9)
Diffuse injury IIIe (swelling) 21 (16.8) 25 (18.9) 46 (17.9)
Diffuse injury IVf (shift) 17 (13.6) 10 (7.6) 27 (10.5)
Any lesion surgically removed 37 (29.6) 39 (29.5) 76 (29.6)
High- or mixed-density lesion 30 (24.0) 31 (23.5) 61 (23.7)
continued
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TABLE 7 Baseline demographic and clinical characteristics for each PP group (continued )
Demographic details
Treatment group
Overall (N= 257) p-value
Hypothermia
(N= 125) Control (N= 132)
Any neurosurgery this admission, n (%)
Yes 60 (48.0) 52 (39.4) 112 (43.6) 0.16
No 65 (52.0) 80 (60.6) 145 (56.4)
Number of neurosurgeries, n (%)
0 65 (52.0) 80 (60.6) 145 (56.4)
1 49 (39.2) 35 (26.5) 83 (32.7)
2 8 (6.4) 14 (10.6) 22 (8.6)
3 3 (2.4) 3 (2.3) 6 (2.3)
a GCS motor score was measured on hospital admission.
b The Marshall classification of TBI is based on a review of CT scans that were obtained at the screening visit. A diffuse
injury indicates that no high-density or mixed-density lesions of > 25mm3 are present.
c Diffuse injury I indicates no visible intracranial pathologic features.
d Diffuse injury II indicates that cisterns are present with a midline shift of 0–5 mm or that lesion densities are present.
e Diffuse injury III indicates that cisterns are compressed or absent with a midline shift of 0–5mm.
f Diffuse injury IV indicates a midline shift of > 5mm.
TABLE 8 The outcome per group for the full eight-point GOSE, the collapsed six-category GOSE and the
dichotomised GOSE in the PP population
Parameter Categories
Treatment group, n (%)
Overall
(N= 257)
Hypothermia
(N= 125)
Control
(N= 132)
GOSE score at
6 months
Dead 41 (33.6) 29 (22.7) 70 (28.0)
Vegetative state 0 1 (0.8) 1 (0.4)
Lower severe disability 30 (24.6) 32 (25.0) 62 (24.8)
Upper severe disability 16 (13.1) 15 (11.7) 31 (12.4)
Lower moderate disability 11 (9.0) 9 (7.0) 20 (8.0)
Upper moderate disability 10 (8.2) 12 (9.4) 22 (8.8)
Lower good recovery 6 (4.9) 16 (12.5) 22 (8.8)
Upper good recovery 8 (6.6) 14 (10.9) 22 (8.8)
GOSE score at
6 months: collapsed
Dead, vegetative state, lower severe disability 71 (58.2) 62 (48.4) 133 (53.2)
Upper severe disability 16 (13.1) 15 (11.7) 31 (12.4)
Lower moderate disability 11 (9.0) 9 (7.0) 20 (8.0)
Upper moderate disability 10 (8.2) 12 (9.4) 22 (8.8)
Lower good recovery 6 (4.9) 16 (12.5) 22 (8.8)
Upper good recovery 8 (6.6) 14 (10.9) 22 (8.8)
Dichotomised GOSE
score
Unfavourable: dead, vegetative state, lower severe
disability, upper severe disability
88 (71.0) 78 (60.5) 166 (65.6)
Favourable: lower moderate disability, upper moderate
disability, lower good recovery, upper good recovery
36 (29.0) 51 (39.5) 87 (34.4)
RESULTS
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Tables 9 and 10 show the results of the primary analysis (hypothermia vs. standard care), primary subgroup
analyses and secondary analyses of the PP population.
For binary outcomes, presentation of both absolute and relative effect sizes is recommended103
(see Tables 6–10 for all data).
TABLE 10 Results of the secondary end-point analyses for the PP population
Analysis of secondary outcomes: hypothermia vs. control Estimate (95% CI) p-value
Unadjusted HR for death incidence between randomisation and 6 months 1.62 (1.01 to 2.60) 0.05
Adjusted mean difference in squared proportion of ICP measurements of
≤ 20mmHg on days 1–7
183.30 (–545.32 to 911.92) 0.62
Incidence of patients who had presence of pneumonia on days 3–7 1.04 (0.62 to 1.73) 0.89
Adjusted mean difference in log-transformed length of ICU stay (log-hours)a 0.02 (–1.16 to 0.20) 0.80
Adjusted common OR for MOHS grade at 28 daysa,b 1.93 (0.93 to 4.00) 0.08
a Results were adjusted for age, post-resuscitation GCS motor score, time from injury and pupillary response.
b The six grades of the MOHS were collapsed to four categories by pooling dependent, fully dependent and death.
TABLE 9 The results of the primary analysis (hypothermia vs. standard care) and primary subgroup analyses in the
PP population
Analysis of primary outcome for hypothermia vs. control Estimate (95% CI) p-value
Adjusted common OR for GOSE score at 6 monthsa,b,c 1.61 (0.98 to 2.61) 0.06
Adjusted OR for unfavourable outcomea,b,d 1.62 (0.93 to 2.83) 0.09
Treatment hypothermia vs. control (unadjusted) 1.63 (1.02 to 2.62) 0.04
Treatment hypothermia vs. control (collapsed) 1.61 (0.98 to 2.61) 0.06
Treatment hypothermia vs. control (dichotomised) 1.62 (0.93 to 2.83) 0.09
Subgroup analyses
Aged < 45 vs. ≥ 45 yearsd NP 0.03
Post-resuscitation GCS motor component [score of 1 or 2 (or no extension or
response) vs. 3–6 (flexion or better response)]d
NP 0.79
Time from injury (< 12 hours vs. ≥ 12 hours)d NP 0.02
Pupillary response (both reacting vs. one reacting vs. neither reacting)d NP 0.64
NP, not performed.
a An OR or common OR of < 1 corresponds to a benefit for hypothermia over control.
b Results were adjusted for age, post-resuscitation GCS motor score, time from injury and pupillary response.
c The eight-point GOSE was collapsed to six categories by pooling death (score of 1) with vegetative state (score of 2) and
lower severe disability (score of 3).
d The eight-point GOSE was collapsed to two categories: favourable outcome (score of 5–8) and unfavourable outcome
(score of 1–4).
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Ancillary analyses
Prespecified subgroups for the primary analysis were defined on the basis of the baseline covariates
described (see Table 1), the location of the centre (UK vs. non-UK) and the volume of the centre (≥ 10 vs.
< 10 participants). We performed these analyses by including an interaction term between each
intervention and the relevant covariate in the ordinal logistic–regression model; a stricter level of statistical
significance (p < 0.01) was used because of their exploratory nature.
The results of this subanalysis showed no statistically significant difference in patient outcome between UK
centres and non-UK centres (p = 0.17) and no statistically significant difference in outcome between
high-volume recruiting centres and low-volume recruiting centres (p = 0.12).
Modified Oxford Handicap Scale grades were analysed in the same way as GOSE scores, but we collapsed
the six grades to four categories by grouping together dependent, fully dependent and death. In the
analysis of the between-group difference in mortality, Cox proportional hazards regression was used to
estimate the intervention effect.
Other continuous outcomes were tested with an analysis of covariance; for binary outcomes, logistic
regression was used. ICP, core temperature, MAP and CPP on days 1–7 were analysed post hoc with the
use of a linear model, with study days as repeated measurements with a compound symmetry covariance
matrix. All of these analyses used the same covariates as were prespecified for GOSE scores, together with
the baseline value of the relevant variable.
Occasionally, participants who have suffered a brain injury have severe brain swelling that does not
respond to the usual treatment methods. In these cases, participants require further treatment with either
drugs (barbiturates) or surgery (decompressive craniectomy).
A further covariance analysis that was carried out was the incidence of treatment escalation or stage 2
therapy failure across groups. Table 11 shows the proportion of participants in the Eurotherm3235 Trial
who developed severe brain swelling and the days on which the therapy failure occurred.
TABLE 11 Incidence of treatment escalation or stage 2 therapy failure across groups
Parameter
Treatment group, n (%)
Overall, n (%) (N= 387)Hypothermia (N= 195) Standard care (N= 192)
First occurrence
Day 1 15 (7.8) 31 (16.4) 46 (12.1)
Day 2 15 (7.8) 22 (11.6) 37 (9.7)
Day 3 14 (7.3) 17 (9.0) 31 (8.1)
Day 4 13 (6.8) 14 (7.4) 27 (7.1)
Day 5 7 (3.6) 7 (3.7) 14 (3.7)
Day 6 11 (5.7) 4 (2.1) 15 (3.9)
Day 7 9 (4.7) 7 (3.7) 16 (4.2)
Missing 3 (1.5) 3 (1.6) 6 (1.6)
Never occurred 108 (56.3) 87 (46.0) 195 (51.2)
RESULTS
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Harms
An AE is any untoward medical occurrence in a clinical trial subject. Many untoward events are expected in
patients admitted to the ICU because of the severity of their illness and/or injury.
The treatment of any untoward medical occurrence is part of the standard care for patients admitted to
the ICU. Therefore, the decision was made in the design stage of the trial that no AE data would be
collected in this study.
A SAE is defined by the National Research Ethics Service in the UK104 as any AE that:
l results in death
l is life-threatening
l necessitates hospitalisation or prolongation of existing hospitalisation
l results in persistent or significant disability or incapacity
l is a congenital abnormality or birth defect.
Death is an expected outcome in approximately 25% of all critically ill patients with severe TBI105 and,
therefore, it was not reported as a SAE in this study.
The specific SAE data that we collected were:
l bleeding – defined as a new haemorrhage requiring ≥ 2 units of packed red cells
l cardiovascular instability – defined as a systolic blood pressure of < 90 mmHg for ≥ 30 minutes86
(of note, terminal hypotension data was not collected)
l thermal burns on > 5% of body surface area using the Lund–Browder chart
l cerebral perfusion pressure of < 50 mmHg for ≥ 15 minutes.
Unexpected events considered to be SAEs, that are not described above, could also be collected by
investigators by using the ‘other’ option on the SAE form. Table 12 shows all SAEs that were collected
throughout the trial.
TABLE 12 Details of all SAEs that were collected throughout the trial
Parameter Category
Treatment group, n (%)
Overall,
n (%)
(N= 387)
Hypothermia
(N= 195)
Control
(N= 192)
Participants who had at
least one SAEa
All 19 (9.7) 10 (5.2) 29 (7.5)
Number of SAEs All 33 10 43
Number of specific
SAEs
Bleeding – defined as a new haemorrhage
requiring ≥ 2 units of packed red cells
3 (9.1) 0 3 (7.0)
Cardiovascular instability – defined as a MAP of
≤ 90mmHg for ≥ 30 minutes
5 (15.2) 2 (20.0) 7 (16.3)
CPP of < 50mmHg for ≥ 15 minutes 11 (33.3) 6 (60.0) 17 (39.5)
Other 14 (14.2) 2 (20.0) 16 (37.2)
SAE causality Not related 25 (75.8) 9 (90.0) 34 (79.1)
Possibly related 8 (24.2) 1 (10.0) 9 (20.9)
a A single patient might have multiple AEs.
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Reporting of SAEs was low throughout the trial, with an overall incidence of 7.5%. Most of these events
were collected in the hypothermia group. We believe that the reason for this is that the four specific SAEs
that we outlined were all possible side effects of hypothermia; therefore, these SAEs may have been
thought to be physiological effects of the brain injury in the standard-care group rather than being related
to the trial, especially as treatment in the standard-care group was not protocolised.
Economic evaluation
Owing to the early stopping of this trial, as a result of likely futility and possible harm, it was considered
by the investigators and Trial Steering Committee that an economic analysis would not make a useful
contribution to the outcomes of the study; the results of the ITT analysis supported this view.
RESULTS
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Chapter 4 Discussion
Discussion
The use of induced hypothermia in addition to standard care did not result in improved patient outcomes
at 6 months after injury compared with standard care alone. Consequently, the trial was stopped early,
after 387 of the intended 600 participants had been randomised, when the Trial Steering Committee and
the trial sponsor agreed with the recommendations of the DSMC:
l At best, a result of futility would be expected if the trial were to continue.
l There were signs of harm with the treatment being evaluated.
l These signs included increased mortality in participants assigned to the treatment being evaluated and
fewer participants assigned to the treatment being evaluated achieving ‘good recovery’ on the GOSE at
the designated outcome assessment point of 6 months after inclusion.
l These findings were apparent when examining the study’s designated primary outcome measure
analysed in accordance with the study’s pre-stated statistical analysis plan.
We acknowledge that the early termination of recruitment to this trial introduces the risk of bias; however,
the reason for termination was accepted by the authors.
The Eurotherm3235 Trial was a large RCT that tested TH as the primary (stage 2) intervention to reduce
ICP after TBI. Literature at the time of protocol development indicated that at least one episode of ICP
of > 20 mmHg occurred in 50% of participants with TBI who received mechanical ventilation and ICP
monitoring.10 In contrast to this, participant screening data collected during this trial indicated that fewer
participants than expected (only 16% of screened participants) developed raised ICP of > 20 mmHg.
Standard care followed the best practice recommended in the Brain Trauma Foundation guidelines86 but
was not prescribed in the protocol. Guidelines for induction and maintenance of hypothermia and for
control of shivering were developed and discussed with centres during their site initiation meeting. It should
be noted that the hypothermia guideline only prescribed the technique for the induction of hypothermia
rather than the maintenance; centres were able to use whichever cooling technique they would normally
use for maintenance of hypothermia. If a participant was randomised to the hypothermia group, copies of
these guidelines were given to the relevant centre to use.
We found no significant between-group difference regarding to the time from injury to initiation of
hypothermia (< 12 or ≥ 12 hours). This differs from a previous review, which found that outcome was
improved when hypothermia was initiated within 12 hours of injury.36 However, there were not enough
participants randomised within 12 hours after injury in this trial to be confident of having excluded a
subgroup effect for the time from injury. Those trials in which hypothermia for neuroprotection was
induced very soon after injury and which were judged to be of higher quality and to have a lower risk of
bias13 also showed trends towards unfavourable outcomes15,16 or were stopped for futility.17,18
In this trial, barbiturate infusion was reserved for participants who had uncontrolled raised ICP despite
treatment with all stage 1 and 2 treatments. We found that barbiturate infusion to reduce ICP was used
more frequently, and earlier, in the control group than in the hypothermia group. It is plausible that
barbiturate infusion may have somehow been beneficial to participants in the control group, but this
hypothesis is not within the remit of this trial and requires further testing. There was no statistical difference
in the use of decompressive craniectomy between the two groups.
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The trial was designed to be pragmatic and to focus on functional outcome rather than on detailed
mechanistic pathways throughout the participants’ ICU stays. In usual practice, the intensity of a stage 2
therapy is adjusted in the ICU setting depending on its effect on haemodynamic variables: ICP, MAP and
CPP. As there were no, or limited, data on the benefits and harms of standard stage 2 interventions at the
time of writing the protocol, we decided not to record which and/or how many stage 2 therapies were
delivered to participants. Our findings show that there were no clinically important differences in these
variables between the two groups.
We accept that the result, which suggests the possible harm of hypothermia, could be attributable to a
biological effect of hypothermia or to the harms or benefits of the other therapies used differentially in the
two groups. This trial did not assess the biological effects of other treatments administered during
hypothermia; therefore, no conclusion regarding this hypothesis could be made. Furthermore, the main
entry criterion for this trial was raised ICP of ≥ 20 mmHg, which is the definition of raised ICP given in the
Brain Trauma Foundation guidelines.86 Consequently, the benefits and risks of hypothermia, when used to
treat severe intracranial hypertension that is not responsive to any stage 2 treatments applied before
initiation of hypothermia, were not assessed as part of this trial.
This trial found that ICP was well controlled in both groups (see Figure 6). Detailed results show, however,
that ICP was more difficult to control in the standard-care group, with more stage 2 therapy failures
observed in this group. This suggests that TH was effective in reducing ICP; however, it did not improve
functional recovery more than treatment with standard care alone. The benefits and harms of any other
interventions that successfully reduce ICP have not been assessed as part of this trial. We now believe
that more adequately powered clinical trials of common therapies used to reduce ICP, such as hypertonic
therapy, barbiturates and hyperventilation, are required to assess their potential benefits and risks
to patients.
Limitations
A limitation of this study was the inability to blind the hypothermia intervention. This is problematic for any
trial of TH and is primarily because of the equipment required and the obvious physiological differences
between groups including, but not limited to, participants’ core temperature. Cooling to normothermia
was, however, permitted in the standard-care group; therefore, it is possible that some relatives were
masked from the intervention/allocated group. We believe that this limitation was overcome, however,
by blinding the follow-up and GOSE scoring.
A further limitation in the design of the trial is that we allowed SAEs to be collected in both groups when
the four specific SAEs that we outlined (see Chapter 3, Harms) were all possible side effects of induced
hypothermia. This resulted in more frequent SAE reporting in the hypothermia group and introduced
reporting bias. The same clinical events may have been seen in the control group but may have been
considered expected consequences of admission to intensive care following severe brain injury, and may
not have been reported as SAEs linked to being in the trial.
Generalisability
The Trial Steering Committee and trial sponsor accepted the recommendation of the DSMC after its ninth
meeting in full and terminated recruitment early. Early stopping of any trial can potentially reduce the
external validity of the results; however, the burden of proof required for early stopping for possible harm
is considerably lower than that for overwhelming evidence of efficacy.106 In this case, the GOSE scores
collected after the decision to terminate confirmed the result of the trial detailed earlier.
DISCUSSION
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Although the trial was open, we believe that the external validity was strong, as centres:
1. were able to use their own technique for maintenance of hypothermia
2. could rewarm the participant based on their physiological parameters and condition from day 3 onwards
3. could cool participants to normothermia in the control group for fever control
4. could escalate care to stage 3 interventions if/as soon as was required in both groups.
The prescribed induction of hypothermia means that the same technique was used to initiate hypothermia
in all participants. We know that compliance with the guideline was good, as Figure 7 shows the rapid
reduction in temperature to 35 °C, and treatment compliance showed that 97.1% of core temperature
observations were within range in the hypothermia group. This strengthens the internal validity of the trial
and its result. The use of a blinded outcome assessor also improved the internal validity of the trial as the
same method for scoring was used for all GOSE questionnaires and scoring was carried out by the same
researcher throughout the trial. Furthermore, the imputed algorithm in the trial online database was used
to ensure that there was no human error/bias in scoring.
The trial involved 387 participants from 47 centres across 18 countries worldwide, and all were able to use
their own maintenance technique for hypothermia without a protocolised control group. We therefore
believe that the results can be generalised to any global setting. The cooling intervention studied was
already being used in clinical practice in each of these centres and was tested in the way that centres
normally used it.
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Chapter 5 Updated systematic review of
therapeutic hypothermia for adult patients following
traumatic brain injury
The protocol and Cochrane domain-based assessment of bias for this systematic review can be found inReport Supplementary Material 1 and 2.
Evidence before this study
Therapeutic hypothermia is commonly used in the treatment of adult TBI. There has been debate over the
efficacy of TH following the publication of two multicentre RCTs107,108 that showed either harm or no
clinical benefit from the use of TH.
The following databases were searched from 1 January 2011 to 31 March 2016: CENTRAL (Cochrane
Central Register of Controlled Trials), MEDLINE, PubMed and EMBASE. Only foreign articles published in
the English language were included. Only articles that were RCTs investigating adult TBI sustained
following an acute, closed head injury were included. Quality was assessed using the Cochrane
Collaboration’s tool109 for assessing the risk of bias and a modified Jadad score.
Added value of this study
This study adds key knowledge to the evidence base that may go some way to explain discrepancies in
results between the most recent published RCTs and reviews. When high-quality studies are analysed
together, they do not support the role of TH as a treatment for adult TBI with respect to resultant mortality,
outcomes and incidences of pneumonia. Crucially, this review is able to highlight the importance of the
control group, as fever in the control group led to significantly more poor outcomes; therefore, potentially
overemphasising the benefit of TH.
Implications of all the available evidence
Overall, this systematic review of RCTs does not support the role of TH in adult TBI patients, which is in
keeping with the conclusions of the two most recent RCTs.1,107
Introduction
There has been debate over both the overall efficacy of TH and the degree of hypothermia required
to gain any positive clinical effect in the treatment of adult TBI. A previous study found some clinical benefit
to TH in TBI,110 however the Eurotherm3235 Trial1 was stopped early concerns over participant safety.1,110
Additionally, a RCT published in 2016111 showed that strict fever control resulted in similar clinical outcomes
as prolonged TH. The most recent systematic reviews1,112 have also reported conflicting results.110 A 2016
meta-analysis111 was unable to demonstrate improved survival and suggested that TH may increase the
risk of new pneumonia and cardiovascular complications. Conversely, a large meta-analysis reported
a benefit of TH but it was discussed that this benefit may be attributable to the fact that a large number of
observational studies were included in this analysis.113 Despite this discourse, TH is still routinely used in
the treatment of raised ICP in the context of adult TBI.
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Aims
The primary aim of this systematic review was to use RCTs to update the evidence base on the use of TH
when administered to adult patients in intensive care following TBI. The main outcomes of interest were
mortality, poor (unfavourable) outcomes and new pneumonia.
Secondary aims were (1) comparison of control group, (2) early (< 24 hours from injury) compared with late
(> 24 hours from injury) TH, (3) the effect of duration of follow-up on mortality outcomes and (4) whether or
not the date of publication had any effect on the outcomes of TH trials.
Materials and methods
Search methods for identification of trials
Searches were not restricted by date or by publication status. The search strategy is recorded in the protocol
(see Report Supplementary Material 1). The dates were chosen to be complementary to, and have an
overlap of 12 months with, the previous systematic review110 conducted by one of the co-authors; this was
to capture any trials that were in the process of publication.
Other sources
Reference lists of all included trials and relevant review articles were hand-searched by the authors.
When appropriate, authors were contacted directly for further information.
Ethics approval and consent
This study did not require ethics approval or individual participant consent.
Methodological criteria for selection of randomised controlled trials
The inclusion criteria were that trials must (1) be RCTs, (2) investigate adult moderate (i.e. a GCS of 9–12) or
severe (i.e. a GCS of ≤ 8) TBI and (3) investigate TBI that was sustained following an acute, closed head
injury. The use of TH was the intervention of interest. RCTs that did not have two treatment arms with TH
compared with a control group were excluded. For the purpose of this review TH is defined as any
intervention with the intention of reducing core body temperature to below the physiological norm (36 °C).
The method of temperature reduction was noted during data extraction. Participant outcomes at follow-up
were assessed using mortality and poor outcome data. There was a particular emphasis on outcomes
recorded on a scale, for example the GOS, the Ranchos Los Amigos Scale or an equivalent scale. Reporting
of poor outcomes includes mortality figures, in accordance with the usual reporting methodology.
Participants/population
To be included in the review, participants must be adults and must have sustained an acute, closed head
injury. Adults were defined as being at the legal age for consent in the country the study was conducted
in. Articles were excluded if they contained only neonatal or paediatric participants or participants with
open head injuries (including gunshot wounds).
Only trials that met all inclusion criteria, and that did not meet any of the exclusion criteria, were included.
Data extraction
The output of all searches was exported into Microsoft Word (Microsoft Corporation, Redmond, WA,
USA) and two co-authors were involved at each stage of review. The PRISMA statement114 was followed at
all three stages of review. First, duplicates from across the databases were removed. Following duplicate
removal, the abstracts and titles were assessed against our inclusion and exclusion criteria. Second,
abstracts were read in detail against the defined criteria. Third, the remaining articles were read in full
and the final decision on inclusion or exclusion was made. A third reviewer was available to resolve any
discrepancies in agreement. See Figure 9 for the PRISMA flow diagram.
UPDATED SYSTEMATIC REVIEW
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Bias
The Cochrane Collaboration’s tool for assessing the risk of bias109 was used during the data extraction
process. The following areas were assessed: selection, performance, detection, attrition and reporting bias.
This covered the relevant areas of allocation concealment, blinding, ITT analysis and completeness of
follow-up. In comparison to the previous review,110 academic bias was also included at this stage; academic
bias was considered to be present if two or more RCTs included in this systematic review were by the
same author.
The included RCTs were put into a domain-based assessment of risk of bias (see Report Supplementary
Material 2), which included potential confounding factors. The maximum score available was 18 points,
with a high score equating to the least risk of bias. Those scoring 14–18 (top quartile) had a low risk of
bias and those scoring < 14 had a high risk of bias, as assessed by the domains.
Quality
A modified Jadad score was used to assess the quality of the included RCTs.14 Blinding was not possible
because of the nature of the intervention. Regarding randomisation, 1 point was awarded for randomisation
being mentioned and a further point was awarded if randomisation was appropriate. No points were
awarded if randomisation was not stated. Then, 1 point was given if all participants entered into the trial
were accounted for at the end of the trial. This gave a maximum modified quality score of 3 points per RCT.
Studies scoring 0, 1 or 2 points were considered low quality, with those scoring 3 points considered high
quality. The quality of included RCTs was also assessed using the Cochrane Collaboration’s tool for assessing
the risk of bias.109
Data synthesis
Review Manager (RevMan; version 5.3; Cochrane Collaboration, The Nordic Cochrane Centre,
Copenhagen, Denmark) was used for data analysis.
Statistical analyses
Mortality, poor outcomes (including mortality) and pneumonia data were extracted and the RR and
corresponding 95% CIs were calculated. The Mantel–Haenszel approach was used to assess the significance
of the overall RR (RRoverall) as an effect estimate using the null hypothesis RRoverall = 1 using the z-test.
As per the Cochrane Handbook,109 both fixed and random effects were generated in the first instance for
each analysis.
Statistical heterogeneity was assessed using the chi-squared and I2-index tests to estimate the degree of trial
variability. Thresholds for interpretation of heterogeneity were also taken from the Cochrane Handbook, with
0–40% representing possible low heterogeneity, 30–60% representing possible moderate heterogeneity,
50–90% representing possible substantial heterogeneity and 75–100% representing possible high
heterogeneity.
Sensitivity analysis
Forest plot analyses were performed for all studies and were performed separately for those deemed at
least risk of bias as assessed using a Cochrane-based evaluation.
Results
The final analyses included 21 trials,1,48,59,60,63,64,69,71,73–77,107,108,115–120 including data for two new trials.1,107 Figure 8
shows the PRISMA flow diagram for inclusion. One trial included in the 2014 review has now been published
with additional data.107 These trials enrolled 2299 participants. Only one trial did not include mortality data.48,107
The quality of included RCTs and the characteristics and data extraction of the included studies is shown in
Appendix 5 . The primary and secondary aims are addressed below. All subgroup analyses had fixed- and
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random-effects models generated. There was no difference in statistical significance so fixed-effects models
have been used throughout. When RCTs had ‘not estimable’ in the RevMan plots, they were removed from the
graph as they did not contribute statistically. Appendix 6 details the RCT inclusion differences between this
systematic review and previous large reviews.
Risk of bias of included randomised controlled trials
There were two methods used for assessing the quality of included RCTs: the Cochrane Collaboration’s
tool for assessing the risk of bias and a modified Jadad score.109
Using the Cochrane Collaboration’s tool for assessing the risk of bias, each RCT was given a score out
of 18. Two RCTs scored ≥ 14 (top quartile) so were considered as having a low risk of bias. Conversely,
18 RCTs scored ≤ 13 and so were considered as having a high risk of bias. See Appendix 7 on assessment of
bias. These scores were used for further analysis of risk of bias for the primary outcomes of mortality, poor
outcomes and new pneumonia.
Quality of included randomised controlled trials
On the modified Jadad score, those scoring 3 were high quality and those scoring 0, 1 or 2 were low
quality. In total, six of the included studies were classed as high quality and 14 studies were classed as low
quality. These scores were used for further analysis of quality for the primary outcomes of mortality, poor
outcomes and new pneumonia.
Duplicates removed
(n = 1300)
The following databases were searched: 
CENTRAL, MEDLINE, EMBASE, 
and PubMed 
(n = 1564)
Stage 1: title review
(n = 88)
Stages 1, 2 and 3: any records that did not meet
all of the inclusion criteria or met any of the
exclusion criteria were excluded. All foreign-language 
articles were excluded, as per protocol
Stage 2: abstract review
(n = 21)
Stage 3: full-text review
(n = 8)
Included
(n = 2)
Plus 19 trials included
from 2014
FIGURE 8 The PRISMA flow diagram.
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Primary aims
Mortality results
Mortality was reported in 20 studies. Figure 9 shows mortality data for 20 studies, totalling 2270
participants. When the results of these 20 RCTs were statistically aggregated, there was a significant
reduction in mortality in the TH group (RR 0.84, 95% CI 0.74 to 0.96; p = 0.01). A fixed-effects model was
used and supported by a moderate I2-index (I2 = 43%).
Mortality results with quality and risk-of-bias analysis
Six of the included studies were classed as high quality and 14 studies were classed as low quality, as per
the modified Jadad score assessment of risk of bias (Figure 10). The high-quality studies showed a higher
mortality in the TH group (RR 1.22, 95% CI 0.99 to 1.57), but this result was not significant (p = 0.06).
The low-quality studies showed a higher mortality in the control group (RR 0.69, 95% CI 0.58 to 0.81;
p < 0.00001). There was significant heterogeneity between the two subgroups (I2 = 94.2%).
Risk-of-bias assessment was also undertaken using the Cochrane Collaboration’s tool and again affected
mortality outcomes (Figure 11). Two studies had a low risk of bias and showed a higher mortality in the TH
group (RR 1.37, 95% CI 1.04 to 1.79; p = 0.02), whereas the 18 studies having a high risk of bias showed
a higher mortality in the control group (RR 0.72, 95% CI 0.62 to 0.84; p < 0.0001).
Poor outcomes
Twenty-one trials reported on poor outcome involving 2286 participants. There were significantly more
poor outcomes in the control group than in the TH group (RR 0.81, 95% CI 0.75 to 0.87; p ≤ 0.00001)
(Figure 12), with possible substantial heterogeneity (I2 = 72%).
Poor outcome results with quality and risk-of-bias analysis
There were six high-quality studies that showed no significant difference in poor outcomes between the
control and TH groups (RR 1.03, 95% CI 0.92 to 1.16; p = 0.56). However, when the 15 low-quality
studies were analysed together, they showed more poor outcomes in the control group (RR 0.69, 95% CI
0.62 to 0.76; p < 0.00001).
When the two low-risk-of-bias studies were analysed, they showed that poor outcomes were more likely in
the TH group (RR 1.16, 95% CI 1.02 to 1.32; p = 0.03). Conversely, when the 19 studies with a high risk
of bias were analysed together, they showed significantly more poor outcomes in the control than the TH
group (RR 0.70, 95% CI 0.64 to 0.77; p < 0.00001).
New pneumonia results
Thirteen studies reported new pneumonia, accounting for 1128 participants. There was significantly more
new pneumonia in the TH group (RR 1.43, 95% CI 1.15 to 1.78; p = 0.001) (Figure 13) when all studies
were analysed together.
New pneumonia results with quality and risk-of-bias analysis
There were three high-quality studies that, when analysed together, showed no significance in new
pneumonia between the two groups (RR 1.33, 95% CI 0.79 to 2.25; p = 0.28). In contrast, the 10
low-quality studies suggested significantly more new pneumonia in the TH group (RR 1.35, 95% CI 1.07
to 1.69; p = 0.01).
The two low-risk-of-bias studies showed no significant difference in new pneumonia between the two
groups (RR 1.41, 95% CI 0.72 to 1.84; p = 0.32), whereas the 11 studies having a high risk of bias
suggested significantly more new pneumonia in the TH group (RR 1.47, 95% CI 1.17 to 1.84; p = 0.0008).
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FIGURE 12 Forest plot of poor outcome. M–H, Mantel–Haenszel.
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FIGURE 13 Forest plot of new pneumonia data. M–H, Mantel–Haenszel.
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Secondary aims
Mortality: comparison of control groups and comparison of controlled normothermia
temperature ranges
The first subanalysis on mortality specifically assessed the methodology used for temperature management
in the control groups. There was no significant difference in mortality between the TH group and the
control group with controlled normothermia (RR 0.89, 95% CI 0.74 to 1.08; p = 0.25) with possible
low heterogeneity (I2 = 25%). However, there was significantly greater mortality in the no temperature
control group than in the TH group (RR 0.81, 95% CI 0.68 to 0.97; p = 0.02) with possible substantial
heterogeneity (I2 = 63%).
The results for those RCTs that implemented controlled normothermia of any degree were analysed in
isolation. The groups were split into those that ensured that their control groups were < 38 °C and
those that included 38 °C within their normothermia control range. Those studies that stated controlled
normothermia without specific temperature ranges were placed in the latter group. Those studies that
controlled to < 38 °C showed no significant difference in mortality outcomes between the control group
and TH group (RR 1.01, 95% CI 0.82 to 1.32; p = 0.73). Contrastingly, those control groups that included
38 °C within their normothermia range showed significantly more mortality in their control groups
(RR 0.61, 95% CI 0.44 to 0.87; p = 0.005).
Early therapeutic hypothermia compared with late therapeutic hypothermia
When mortality was analysed accounting for timing of TH from time of TBI, there were significant differences
between the subgroups (Figure 14). For those participants with early hypothermia (< 24 hours from injury),
there was significantly greater mortality in the control group than in the TH group [RR 0.76, 95% CI 0.64
to 0.90; p = 0.001 (1542 participants)] with possible low heterogeneity (I2 = 2%). Whereas, among those
participants with TH induced ≥ 24 hours after injury, there was no significant difference in mortality
between the control and TH groups [RR 1.08, 95% CI 0.86 to 1.34; p = 0.51 (641 participants)] with
possible substantial heterogeneity (I2 = 79%). There was also possible substantial heterogeneity
(I2 = 83.5%) between the early and late hypothermia subgroups.
Mortality: effect of duration of follow-up
There was variation between the RCTs regarding duration of follow-up. Two groups were created that
analysed those RCTs with follow-up for 3 months (five studies; 271 participants) compared with those
with follow-up for > 6 months (14 studies; 1999 participants) (Figure 15). For those followed up for
3 months, there was no significant difference in mortality between the control and TH groups (RR 0.73,
95% CI 0.47 to 1.17; p = 0.20) with possible low heterogeneity (I2 = 0%), whereas studies with follow-up
for > 6 months showed significantly greater mortality in the control group (RR 0.85, 95% CI 0.74 to 0.98;
p = 0.02), there was possible moderate heterogeneity in this subgroup (I2 = 55%). There was no
heterogeneity between the two subgroups (I2 = 0%).
Mortality: date of publication
Those studies that reported mortality data were split into two groups: five were published before 2000
(223 participants) and 15 were published in or after 2000 (2047 participants). Those published before
2000 showed no significant difference in mortality between the groups (RR 0.71, 95% CI 0.49 to 1.04;
p = 0.08), whereas those studies published in or after 2000 found higher mortality in the control group
than the TH group (RR 0.86, 95% CI 0.74 to 0.99; p = 0.03) (Figure 16).
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FIGURE 14 Forest plot of mortality analysed accounting for timing of TH from time of TBI. M–H, Mantel–Haenszel.
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FIGURE 15 Forest plot of the effect of duration of follow-up on trial results. M–H, Mantel–Haenszel.
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Discussion
Summary of results
Overall, the results of this systematic review shed doubt on the overall outcome benefits of TH. Low-quality
studies are more likely than high-quality studies to show that TH improves mortality. In addition, this review
also highlights the importance of temperature management in the control group of TH trials and, in
particular, the avoidance of fever.
Explanation of results
Adding to the literature, this review has shown that the control group management is important in assessing
the efficacy of TH. When the temperature of the control group is controlled (controlled normothermia),
avoiding fever, then TH was no longer beneficial. Furthermore, when controlled normothermia included
‘fever’ temperatures then the control group had a greater mortality. This is significant because it suggests
that it is not just the implementation of TH that is important, but also the maintenance of adequate fever
control. The importance of fever control has implications for the conclusions suggested by RCTs; for
example, the Eurotherm3235 Trial had a control population with values of normothermia and the results
showed harm from TH. Studies that do not adequately maintain normothermia in their control groups may
be overestimating the benefits of TH, as worse overall outcomes in the control groups may be down to poor
fever control rather than lack of TH.
Subgroup heterogeneity appears to be important in a variety of analyses. When looking at the induction of
TH, there is a lower mortality in those who had TH implemented within 24 hours; however, cooling after
24 hours conferred no mortality benefit compared with the control treatment. This could suggest that
cooling early is most beneficial or that there are differences between the subgroups; this is supported by
the possible substantial heterogeneity. The results of the ongoing POLAR (Prophylactic Hypothermia trial
to Lessen Traumatic Brain Injury) study123 of early hypothermia for neuroprotection could provide further
evidence to support this hypothesis. Those patients with late TH may have more severe injuries with more
difficult to control ICP meaning that treatment was less likely to be successful regardless of time of TH
onset. The two most recent RCTs both investigated late-onset TH.1,107
Other studies have shown that subgroup differences are important in relation to surgical intervention;
this is not always accounted for during statistical analysis of mortality and poor outcomes. These studies
have provided evidence that TH may be more beneficial in those patients who are cooled after surgical
haematoma evacuation than in those with diffuse brain injury. This review was unable to investigate this
further because diffuse and focal TBI patients were commonly grouped together during data analysis.
Overall, this finding is important as it suggests that there may be certain subgroups of TBI patients who are
more likely to benefit from TH. Differences could depend on the type of injury, surgical intervention before
TH, early or late cooling and the temperature management within the control group. With all of these
possible confounding factors, it is unsurprising that there are conclusion discrepancies among the most
recent reviews.
Quality of evidence
Two methods were used to assess quality and the risk of bias: a modified Jadad score was used in conjunction
with a domain-based assessment for risk of bias. The two latest RCTs1,107 were of high quality and had a
low risk of bias. However, all other studies showed a high risk of bias as assessed by the objective domains.
Previously, concern has been expressed that small, single-centre studies are distorting the conclusions.110 This
review highlights the importance of this as, when the larger, higher-quality RCTs were analysed separately,
they showed consistently different conclusions to other trials.
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Deviation from systematic review protocol
The original primary and secondary outcomes remained as published in the protocol (see Report
Supplementary Material 1). However, several additional subgroup analyses were added as secondary
outcomes following protocol publication.
Of the original secondary aims, some subgroup analyses could not take place because of a lack of information
supplied within RCTs or homogeneity between the studies. These were depth of cooling on outcomes, effect
of rate of rewarming, the duration of cooling on outcomes and the use of propofol sedation.
Data extraction was completed as per protocol. There was always agreement between the two co-authors
undertaking the data extraction but a reason for exclusion of an article was not always documented.
The Cochrane Collaboration’s tool for assessing the risk of bias109 was used rather than the 1998 Downs
and Black checklist.124 The modified Jadad score for trial quality was added to increase the objectivity for
claims of quality and risk of bias.
Limitations of the review
The main limitations of the previous reviews were the inclusion of many single-centre, low-quality RCTs;
this has now been partly addressed with the addition of the two latest RCTs. However, as discussed above,
underlying subgroup differences may be affecting the overall conclusions.
There was significant variation in the length of follow-up post injury, ranging from 3 months to 2 years.
This has also been a factor in other systematic reviews. It is not possible to control this confounder because
of the variations in the standalone RCT protocols. In the context of hypothermia after cardiac arrest, it has
been suggested that 6 months is the earliest time point that neurological status should be assessed.125
This review updated some of the original data used in the Crossley et al.110 paper and these data extraction
amendments have been included and analysed in this paper.
Similarities to, and differences from, other reviews
Although this review has several similarities to recent review papers, it also has some significant differences.
Crossley et al.110 were able to demonstrate a significant reduction in mortality and poor outcomes with the
use of TH. However, Zhu et al.111 found no difference in either of these outcomes between the TH and
control groups. The latter systematic review is in agreement with other RCTs published since 2015: the
Eurotherm3235 Trial found evidence of harm from TH,1 whereas B-HYPO (Brain Hypothermia study)107 found
no improvement in outcomes from TH when compared with strict fever control or controlled normothermia;
both studies assessed the use of late TH post TBI. Importantly, both of these RCTs avoided fever in their control
groups, which does differ from the control groups of previous RCTs.110,111 Previous systematic reviews reported
a general belief that TH was associated with new pneumonia. However, until this review, only Zhu et al.111 had
been able to show significance from this result. This current systematic review has gone some way to explain
the varying conclusions on the effectiveness of TH in TBI by analysing the main subgroups.
Ongoing trials of therapeutic hypothermia for traumatic brain injury
There are two ongoing RCTs that are yet to be published: the POLAR RCT126 and the RCT of Long-term
Mild Hypothermia for Severe Traumatic Brain Injury trial (LTH-1).127 Both author groups were contacted
during the production of this systematic review.
The POLAR RCT is a neuroprotection study, the results of which may support the finding of this review that
early hypothermia is beneficial.
In the earlier 2014 systematic review,110 the B-HYPO107 investigators kindly provided preliminary data
from their RCT. The full RCT has now been published and has been included in this updated
systematic review.
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Conclusions
Overall, this updated systematic review shows that, when high-quality studies of the use of TH in TBI are
reviewed together, they show no significant differences in mortality, poor outcomes or new pneumonia;
therefore, the use of TH is not evidenced. Conversely, the low-quality studies are more likely to show a
benefit of TH in TBI. In addition, this review highlights the importance of fever control as, in those studies
that included control groups with no temperature control, there was a higher rate of mortality than in
those controlled to normothermia.
Key messages
l High-quality studies show no significant difference in mortality, poor outcomes or new pneumonia.
l When temperature in the control group is controlled normothermia, there is no difference in mortality.
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Chapter 6 A biological effect or an imbalance of
co-interventions? Exploratory analyses of the
Eurotherm3235 Trial
Introduction
The Eurotherm3235 Trial was pragmatic and data collection was not overburdensome. We believe that this is
one reason for the success of the trial; however, our data collection was not sufficiently comprehensive to
allow investigation of possible mechanisms of the unexpected result. We are grateful to the National Institute
for Health Research Health Technology Assessment programme for extending our funding to allow us to
conduct a separate, retrospective study of the details of individual patient care in the main trial and mode of
death, when appropriate. We considered this ‘additional data collection’ to be an important exercise for
allowing full implementation of the trial results.
Background
Although early trials of TH after TBI showed that this treatment improved functional outcome, two recent
multicentre trials, NABISH (National Acute Brain Injury Study: Hypothermia) and B-HYPO,76,107 have failed
to confirm a neuroprotective effect. In a systematic review, Crossley et al.110 reported that TH might be
beneficial in the treatment of TBI, although most of the positive trials that were included were of low quality
and probably overestimated the effects of hypothermia. Madden and DeVon128 showed that controlled
normothermia, avoiding fever, improved functional outcomes, whereas hypothermia was associated with
unfavourable outcomes. Additionally, three large, paediatric multicentre trials have not found evidence of
benefit of TH, showing an increment in mortality in this population.129–131
The Eurotherm3235 Trial was not designed to investigate why TH was associated with a poorer outcome;
however, this relationship may arise because of either a biological effect of TH or an imbalance in
co-interventions used in the hypothermia or control groups.
We therefore undertook a retrospective additional data collection exercise with the following aims:
l to assess the mode of death by treatment allocation
l to compare aspects of clinical management by treatment allocation including surgical intervention(s),
medical treatments and drug dosages for management of raised ICP
l to compare the incidence of comorbidities and complications of care by treatment allocation
l to compare the available physiological data (not available in the original study) by treatment allocation.
Material and methods
Ethics approval for the collection of additional data through a bespoke case report form (CRF) was obtained
from the Scotland Research Ethics Committee and the Bradford Research Ethics Committee in November
2015. A total of 47 centres in 18 countries that had randomised 387 participants from November 2009 to
October 2014 were contacted. A total of 21 UK recruiting sites were invited to participate on 4 December 2015,
whereas the 26 non-UK centres were required to obtain permission from their ethics/hospital committee prior to
beginning participation.
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The data collection started on 1 January 2016 and the deadline for completion of the CRFs was set
to 31 July 2016. This was 6 years and 2 months after the beginning of the main trial and 1 year and
3 months after the last 6-month outcome assessment. Paper CRFs were used for the retrospective data
collection and they were completed from the participant’s medical notes, imaging and 24-hour ICU
charts. There were 15 areas of interest, including comorbidities, (likely) cause of death and, for days 1–7,
post randomisation information on medical and surgical interventions for raised ICP (ICP of > 20 mmHg),
sedation and analgesia regimes, cardiovascular support, blood results and infection(s).
The additional data collection exercise provided sufficient information to calculate a modified and
abbreviated sequential organ failure assessment (SOFA) to assess organ dysfunction. The full SOFA is
composed of six domains, scoring respiratory, cardiovascular, hepatic, coagulation, renal and neurological
systems, graded from 0 to 4 depending on the degree of dysfunction/failure. For this exploratory analysis,
we defined a modified SOFA excluding the respiratory and neurological domains. The rationale for this
was that in the Eurotherm3235 Trial all participants were sedated (masking neurological assessment) and
mechanically ventilated (affecting respiratory system SOFA) to control ICP at stage I. Formal assessment of
GCS was not practical in many cases as a result of concerns about the likely effect of a sedation break on
ICP. For the abbreviated SOFA, each of the remaining four organ domains were scored either as normal (0)
or abnormal (1) and the sum of these was calculated. These scores were then used to characterise
participants as having either minimal organ dysfunction (modified SOFA score of ≤ 1) or significant
organ dysfunction (SOFA score of > 1).
Completed CRFs were sent by e-mail or post to the Eurotherm3235 Trial office at the Western General
Hospital in Edinburgh. Eurotherm3235 Trial staff (Claire Battison, Trial Manager, and Irene Puddu, Research
Fellow) worked closely with local clinicians to obtain complete and accurate data within the set time frame.
Statistical analysis
For all data collected, descriptive statistics by allocated treatment and dichotomised by GOSE outcome
(favourable vs. unfavourable) were generated.
Results
Data
Responses were received from a total of 33 centres out of the 47 centres in the main trial, of which
16 (48%) were UK and 17 (52%) were non-UK sites. A total of 286 anonymised CRFs (UK, n = 163; and
non-UK, n = 123) were returned by e-mail or post to the Eurotherm3235 Trial office by 31 July 2016.
Data were returned on 143 participants randomised to TH and 143 participants randomised to the control
groups. This distribution was similar to the main trial.
Demographics and baseline characteristics
The demographics of this sample were well matched between the TH and control group and were very
similar to those of the main trial ITT population. Table 13 shows that the baseline characteristics of the two
‘additional data collection’ groups were similar in all respects. Furthermore, the TH and control groups
were well balanced for comorbidities (see Table 13).
The incidence of pre-ICU admission of secondary brain injuries because of either hypoxia [n = 27 (20.9%)
in TH vs. n = 17 (13.2%) in the control group; p = 0.136] or hypotension [n = 15 (12.0%) in TH vs. n = 11
(8.6%) in the control group; p = 0.493] was not different between the groups. However, clinical signs of
hypoxia were proportionally more frequent in the TH group (n = 12, 44.4%) than in the control group
(n = 1, 6.3%), and blood gas evidence of hypoxia was more frequent in the control group [13 (48.2%)
in TH vs. 13 (81.3%) in the control group; p = 0.031], although the absolute number of arterial gases
identifying hypoxia were identical in both groups (see Table 13).
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TABLE 13 Summary of baseline demographic, mechanism of injury, time from injury, clinical and radiological
presentation, comorbidities and pre-ICU secondary insults data
Data
Treatment group
p-valueHypothermia (N= 143)a Control (N= 143)
Characteristic
Aged < 45 years, n (%) 95 (66.4) 95 (66.4) 0.900
Age (years), median (interquartile range) 35 (24–49) 36 (26–48) 0.966
Male, n (%) 115 (80.4) 120 (83.9) 0.537
Mechanism of injury, n (%)
Road traffic accident: pedestrian 17 (12.0) 22 (15.4) 0.319
Road traffic accident: motor vehicle 46 (32.4) 34 (23.8)
Cycling accident 5 (3.5) 9 (6.3)
Fall 62 (43.7) 61 (42.7)
Sports injury 1 (0.7) 0 (0.0)
Assault 11 (7.7) 17 (11.9)
Isolated TBI, n (%) 88 (61.5) 99 (69.2) 0.214
GCS motor score, n (%)
1 or 2 41 (28.7) 35 (24.5) 0.503
3–6 102 (71.3) 108 (75.5)
Pupillary response, n (%)
Both reacting 106 (74.1) 107 (74.8) 1.0
One or neither reacting 37 (25.9) 36 (25.2)
Marshall classification, n (%)
Diffuse axonal injury I–III 55 (38.5) 58 (40.6) 0.918
Diffuse axonal injury IV 16 (11.2) 13 (9.1)
Any lesion surgically removed 32 (22.4) 34 (23.8)
High-density or mixed-density lesion 40 (28.0) 38 (26.6)
At randomisation
Time from injury ≥ 12 hours, n (%) 130 (90.9) 133 (93.0) 0.664
Intracranial pressure at randomisation (mmHg),
median (interquartile range)
24 (22–27) 23 (22–26) 0.473
Core temperature at randomisation (°C),
median (interquartile range)
36.9 (36.4–37.4) 37.1 (36.6–37.6) 0.051
Comorbidities
Arthritis, n (%)
Yes 3 (2.2) 5 (3.6) 0.712
No 135 (97.8) 132 (96.4)
Osteoporosis, n (%)
Yes 1 (0.7) 0 (0.0) 0.997
No 138 (99.3) 140 (100)
Asthma, n (%)
Yes 8 (5.8) 5 (3.6) 0.561
No 129 (94.2) 133 (96.4)
continued
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TABLE 13 Summary of baseline demographic, mechanism of injury, time from injury, clinical and radiological
presentation, comorbidities and pre-ICU secondary insults data (continued )
Data
Treatment group
p-valueHypothermia (N= 143)a Control (N= 143)
COPD/emphysema, n (%)
Yes 6 (4.3) 4 (2.9) 0.739
No 133 (95.7) 136 (97.1)
Angina, n (%)
Yes 1 (0.7) 1 (0.7) 0.481
No 138 (99.3) 139 (99.3)
CCF, n (%)
Yes 4 (2.9) 3 (2.1) 0.992
No 135 (97.1) 137 (97.9)
MI, n (%)
Yes 3 (2.2) 0 (0.0) 0.243
No 136 (97.8) 140 (100)
Neurological disease, n (%)
Yes 6 (4.3) 3 (2.1) 0.491
No 133 (95.7) 137 (97.9)
Stroke/TIA, n (%)
Yes 1 (0.7) 2 (1.4) 0.995
No 138 (99.3) 138 (98.6)
PVD, n (%)
Yes 2 (1.4) 2 (1.4) 0.62
No 137 (98.6) 138 (98.6)
Diabetes mellitus, n (%)
Yes 8 (5.8) 5 (3.6) 0.561
No 131 (94.2) 135 (96.4)
GI disease, n (%)
Yes 5 (3.6) 2 (1.4) 0.438
No 134 (96.4) 138 (98.6)
Depression, n (%)
Yes 16 (11.5) 12 (8.6) 0.537
No 123 (88.5) 128 (91.4)
Anxiety, n (%)
Yes 6 (4.3) 8 (5.7) 0.795
No 133 (95.7) 132 (94.3)
Visual impairment, n (%)
Yes 1 (0.7) 0 (0.0) 0.997
No 138 (99.3) 140 (100)
Hearing impairment, n (%)
Yes 1 (0.7) 1 (0.7) 0.481
No 138 (99.3) 139 (99.3)
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Additional data collection sample mortality
Hypothermia was associated with a statistically significant increased risk of death at 6 months (Figure 17).
In the additional data collection sample, a total of 78 participants died: 46 participants in the TH group
(32.2%) and 32 participants in the control group (22.5%) (HR 1.624, 95% CI 1.025 to 2.573; p = 0.0388).
These data were consistent with the ITT study population and suggest no reporting bias in this
retrospective cohort.
Cause of death
Table 14 shows that the number of deaths due to brain stem death (BSD) was the same in both groups,
but because of other causes of death with TH, BSD represented a greater proportion in the control group
[12 (28.6%) deaths in TH vs.12 (42.3%) deaths in control group]. In the TH group, pathologies with a
strong inflammatory component, including multiorgan failure (MOF), infection and acute respiratory
distress syndrome (ARDS), were more commonly attributed to causing death in the TH group [15 (35.7%)
deaths in TH vs. 5 (19.1%) deaths in control group; p = 0.618].
TABLE 13 Summary of baseline demographic, mechanism of injury, time from injury, clinical and radiological
presentation, comorbidities and pre-ICU secondary insults data (continued )
Data
Treatment group
p-valueHypothermia (N= 143)a Control (N= 143)
Disc disease, n (%)
Yes 1 (0.7) 2 (1.4) 0.995
No 137 (99.3) 137 (98.6)
BMI of > 30 kg/m2, n (%)
Yes 4 (2.9) 6 (4.3) 0.756
No 135 (97.1) 134 (95.7)
Secondary insults pre ICU admission
Hypoxia, n (%)
Yes 27 (20.9) 17 (13.2) 0.136
No 102 (79.1) 112 (86.8)
Hypoxia detected, n (%)
Arterial gases 13 (48.2) 13 (81.3) 0.031
Clinical signs 12 (44.4) 1 (6.3)
Both 2 (7.4) 2 (12.5)
Hypotension, n (%)
Yes 15 (12.0) 11 (8.6) 0.493
No 110 (88.0) 117 (91.4)
Hypotension detected, n (%)
Blood pressure 10 (55.6) 7 (53.9) 0.638
Clinical signs 1 (5.6) 2 (15.4)
Both 7 (38.9) 4 (30.8)
BMI, body mass index; CCF, congestive cardiac failure; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal;
MI, myocardial infarction; PVD, peripheral vascular disease; TIA, transient ischaemic attack.
Note
a Participants may have no or multiple comorbidities.
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Clinical management and interventions
Intracranial pressure management: medical therapy
The main trial results showed that the mean daily ICP was similar in the two groups. During the first 4 days
after randomisation, there were fewer failures of stage II therapy to control ICP in TH than in the control
group (57 vs. 84 participants). In this exploratory analysis, the use of medical treatments to control ICP was
similar in both groups over days 1–7 after randomisation: 128 participants (92.1%) in the TH group received
medical treatments for raised ICP compared with 124 participants (91.9%) in the control group (p = 0.88) (see
Table 15). There was no significant difference in the average number of participants treated with hypertonic
saline per day [mean 35.0 (SD 6.2) in the TH group vs. mean 39.6 (SD 10.9) in the control group; p = 0.353]
or the average number of daily treatments given [mean 1.9 (SD 0.7) in TH group vs. mean 2.5 (SD 0.9) in the
control group; p= 0.15]. Similarly, for mannitol, the average number of participants treated (mean 37.0
(SD 9.4) in the TH group vs. [mean 43.3 (SD 16.0) in the control group; p = 0.388)] and the average number
of daily treatments [2.0 (2.0–2.0) in the TH group vs. 2.0 (2.0–2.0) in the control group; p = 0.71] were not
significantly different. The average number of daily treatments with furosemide was statistically significantly
higher in the control group than the TH group [mean 1.2 (SD 0.4) in the TH group vs. mean 1.9 (SD 0.4) in the
control group; p= 0.004], but there was no difference in the average number of participants treated per day
[mean 13.3 (SD 4.3) in the TH group vs. mean 15.7 (SD 5.6) in the control group; p = 0.384] (Table 15).
Intracranial pressure management: surgical treatment
The surgical management of raised ICP was also similar between groups. The number of participants
undergoing decompressive craniectomy before randomisation was 21 (15.4%) in the TH group, compared
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FIGURE 17 Survival curve between randomisation and 6 months by treatment allocation in the additional data
collection cohort.
TABLE 14 Primary outcome of the additional data collection population: likely causes of death
Cause of Death
Treatment group, n (%)
p-valueHypothermia Control
BSD 12 (28.6) 11 (42.3) 0.618
MOF/sepsis/ARDS 15 (35.7) 5 (19.2)
Neurological/withdrawal 11 (26.2) 7 (26.9)
Cardiac event 2 (4.8) 2 (7.7)
Other 2 (4.8) 1 (3.9)
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with 23 (16.3%) in the control group (p = 0.952), and after randomisation was 34 (24.8%) in the TH group,
compared with 37 (26.2%) in the control group (p = 0.893) (see Table 15). The proportion of participants
undergoing hemicraniectomy was slightly greater in the control group than in the TH group [29 (58.0%) in
TH group vs. 37 (64.9%) in the control group], whereas bifrontal craniectomy was more common in the TH
group than in the control group [21 (42.0%) in the TH group vs. 20 (35.1%) in the control group]. Only one
participant in each group underwent decompressive craniectomy before and after randomisation. However,
these distributions were not significantly different between the groups (p = 0.593) (see Table 15).
Follow-up computed tomography
Follow-up CT was performed in significantly more participants in the control group than the TH group:
105 (80.8%) in TH group compared with 120 (90.2%) in the control group (p = 0.045) (Table 16).
The distribution of Marshall scores based on the second CT scan was similar in both groups, with no
statistically significant differences (p = 0.323). In both the TH and CG groups of the additional collection
exercise, type II diffuse injury and high- or mixed-density lesion not evacuated were the most common
pathologies observed [26 participants (24.8%) in the TH group vs. 31 participants (26.7%) in the control
group, for both] (see Table 16). For both the TH group and the control group, the distribution of Marshall
scores with the type of decompressive craniectomy was not significantly different (p = 0.506 in the TH
group; p = 0.189 in the control group) (see Table 16). In the TH group, removable lesions were most
frequently associated with both hemicraniectomy and bifrontal craniectomy [10 participants (41.7%) had a
hemicraniectomy vs. five participants (38.5%) who had a bifrontal procedure]. By contrast, in the control
group, removable lesions were most commonly associated with hemicraniectomy (14 participants, 46.7%),
but a type II diffuse injury was slightly more common in those receiving bifrontal craniectomy (four participants,
TABLE 15 Medical and surgical management for raised ICP after randomisation
Management
Treatment group
p-valueHypothermia Control
Treatment for raised ICP, mean (SD)
Yes 128 (92.1) 124 (91.9) 0.88
No 11 (7.9) 11 (8.1)
ICP treatments
Hypertonic saline, mean (SD) 35.0 (6.2) 39.6 (10.9) 0.353
Hypertonic saline (treatments/day), mean (SD) 1.9 (0.7) 2.5 (0.9) 0.15
Mannitol, median (SD) 37.0 (9.4) 43.3 (16) 0.388
Mannitol (treatments/day) (range) 2.0 (2.0–2.0) 2.0 (2.0–2.0) 0.71
Frusemide, mean (SD) 13.3 (4.3) 15.7 (5.6) 0.384
Frusemide (treatments/day), mean (SD) 1.2 (0.4) 1.9 (0.4) 0.004
Decompressive craniectomy, mean (SD)
Before randomisation
Yes 21 (15.4) 23 (16.4) 0.952
No 115 (84.6) 117 (83.6)
After randomisation
Yes 34 (24.8) 37 (26.2) 0.893
No 103 (75.2) 104 (73.8)
Craniectomy type, mean (SD)
Hemicraniectomy 29 (58.0) 37 (64.9) 0.593
Bifrontal 21 (42.0) 20 (35.1)
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TABLE 16 Marshall classification on follow-up CT and type of craniectomy
CBT classification of TBI lesion
Craniectomy type, n (%)
p-valueHypothermia Control
Follow-up CT
Yes 105 (80.8) 120 (90.2) 0.045
No 25 (19.2) 13 (9.8)
Marshall classification
Diffuse injury I (no visible pathology) 2 (1.9) 2 (1.7) 0.323
Diffuse injury II 26 (24.8) 31 (26.7)
Diffuse injury III (swelling) 18 (17.1) 8 (6.9)
Diffuse injury IV (shift) 13 (12.4) 16 (13.8)
Any lesion surgically removed 20 (19.0) 28 (24.1)
High- or mixed-density lesion 26 (24.8) 31 (26.7)
Hypothermia, n (%)
Hemicraniectomy Bifrontal
Marshall classification
Diffuse injury I (no visible pathology) 1 (4.2) 0 (0.0) 0.506
Diffuse injury II 3 (12.5) 2 (15.4)
Diffuse injury III (swelling) 1 (4.2) 3 (23.1)
Diffuse injury IV (shift) 4 (16.7) 2 (15.4)
Any lesion surgically removed 10 (41.7) 5 (38.5)
High- or mixed-density lesion 5 (20.8) 1 (7.7)
Control, n (%)
Hemicraniectomy Bifrontal
Marshall classification
Diffuse injury I (no visible pathology) 0 (0.0) 1 (7.1) 0.189
Diffuse injury II 2 (6.7) 4 (28.6)
Diffuse injury III (swelling) 3 (10.0) 1 (7.1)
Diffuse injury IV (shift) 5 (16.7) 3 (21.4)
Any lesion surgically removed 14 (46.7) 3 (21.4)
High- or mixed-density lesion 6 (20.0) 2 (14.3)
Treatment group, n (%)
Hypothermia Control
Marshall classification
Diffuse injury I (no visible pathology) 1 (4.2) 0 (0.0) 0.787
Diffuse injury II 3 (12.5) 2 (6.7)
Diffuse injury III (swelling) 1 (4.2) 3 (10.0)
Diffuse injury IV (shift) 4 (16.7) 5 (16.7)
Any lesion surgically removed 10 (41.7) 14 (46.7)
High- or mixed-density lesion 5 (20.8) 6 (20.0)
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28.6%). For both hemicraniectomy and bifrontal craniectomy, the distribution of Marshall scores by treatment
allocation was also not significantly different (p= 0.787 for hemicraniectomy; p= 0.598 for bifrontal
craniectomy) (see Table 16).
Sedation and analgesia
Midazolam infusion was used more often in the TH group: the mean number of participants per day was
96.0 (SD 12.8) in the TH group compared with 78.7 (SD 16.0) in the control group (p = 0.046), with
the same hourly infusion rate in both groups [median 10.0 (IQR 10.0–10.0) mg/hour in the TH group
vs. median 10.0 (IQR 10.0–10.0) mg/hour in the control group; p = 0.71) (Table 16). Alfentanil and fentanyl
were the most commonly used opioids in all centres. The number of participants receiving alfentanil each
day was higher in the TH group than in the control group [mean 37.1 (SD 4.7) in the TH group vs. mean 27.7
(SD 5.2) in the control group; p= 0.004], but the hourly dose was the same in both groups [median 2.5
(IQR 2.5–2.5) mg/hour in the TH group vs. median 2.5 (IQR 2.5–2.5) mg/hour in the control group; p= 1.0].
In contrast, the number of participants treated per day with fentanyl was not significantly different between
groups [mean 56.0 (SD 6.9) in the TH group vs. mean 58.4 (SD 7.7) in the control group; p= 0.545] or the
hourly dose [median 250 (IQR 250–250) µg/h in the TH group vs. median 250 (IQR 250–250) µg/h in the
control group; p= 0.71] (see Table 17).
The average number of participants sedated with propofol per day was similar in both groups: a total
of 89.9 (SD 14.2) participants in the TH group, compared with 79.1 (SD 17.8) participants in the control
group (p = 0.236). The mean daily dose of 4615.3 (SD 658.8) mg/day in the TH group compared with
4801.4 (SD 657.0) mg/day in the control group (p = 0.606) (see Table 15). Correcting the daily dose for
the participants’ weight did not reveal any between-group difference: 60.0 (SD 8.6) mg/kg/day in the TH
group compared with 62.7 (SD 5.4) mg/kg/day in the control group (p = 0.5). After adjustment for age,
post resuscitation GCS motor component, time from injury and pupil reactivity, no significant differences
in the average daily dose of propofol in each group were found. A potentially toxic level infusion rate of
propofol (> 5mg/kg/hour) was used in a few participants per day in both groups [median 3.0 participants
(IQR 2.3–5.3) in the TH group and median 4.0 participants (IQR 3.0–4.0) in the control group; p = 0.535].
Atracurium was the predominant neuromuscular blocking agent used in all 33 centres. The number of
participants receiving atracurium was significantly greater in the TH group [mean 31.1 (SD 6.8)] than in
the control group [mean 22.0 (SD 4.5)] (p = 0.012) after randomisation. However, the median hourly
infusion rate was slightly higher in the control group than in the TH group: median 50.0 (IQR 50.0–50.0)
mg/hour in the TH group, compared with median 60.0 (IQR 50.8–60.0) mg/hour in the control group
(p = 0.017) (see Table 17).
TABLE 16 Marshall classification on follow-up CT and type of craniectomy (continued )
Bifrontal: treatment group, n (%)
p-valueHypothermia Control
Marshall classification
Diffuse injury I (no visible pathology) 0 (0.0) 1 (7.1) 0.598
Diffuse injury II 2 (15.4) 4 (28.6)
Diffuse injury III (swelling) 3 (23.1) 1 (7.1)
Diffuse injury IV (shift) 2 (15.4) 3 (21.4)
Any lesion surgically removed 5 (38.5) 3 (21.4)
High- or mixed-density lesion 1 (7.7) 2 (14.3)
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Cardiovascular support
The use of drugs to support the cardiovascular system was greater in the TH group than in the control group.
The average number of participants receiving noradrenaline per day [mean 95.4 (SD 12.9) in the TH group
vs. mean 78.1 (SD 18.7) in the control group] and the daily infusion rate [mean 15.3 (SD 3.5) mg/day in the
TH group vs. mean 12.2 (SD 2.5) mg/day in the control group] were not significantly different (p = 0.067
and p = 0.078, respectively) (Table 18). Dobutamine was used in more TH participants [mean 7.3 (SD 3.1)
participants/day] than control group participants [mean 2.3 (SD 1.0) participants/day] (p = 0.002), although
the daily infusion rates were similar [median 292.5 (IQR 221.3–466.9) mg/day in the TH group vs. median
315.0 (IQR 193.9–441.9) mg/day in the control group; p = 0.71]. Similarly, more participants received daily
vasopressin in the TH group [mean 5.7 (SD 2.4)] than in the control group [mean 1.9 (SD 0.9)] (p = 0.002),
TABLE 17 Sedation and analgesia used after randomisation
Intervention
Treatment group
p-valueHypothermia Control
Sedation
Midazolam, mean (SD) 96.0 (12.8) 78.7 (16.0) 0.046
Midazolam (mg/hour), median (IQR) 10.0 (10.0–10.0) 10.0 (10.0–10.0) 0.71
Analgesia
Fentanyl, mean (SD) 56 (6.9) 58.4 (7.7) 0.545
Fentanyl (µg/hour), median (IQR) 250.0 (250.0–250.0) 250.0 (250.0–250.0) 0.71
Alfentanil, mean (SD) 37.1 (4.7) 27.7 (5.2) 0.004
Alfentanil (mg/hour), median (IQR) 2.5 (2.5–2.5) 2.5 (2.5–2.5) 1
Sedation, mean (SD)
Propofol 89.9 (14.2) 79.1 (17.8) 0.236
Propofol (mg/day) 4615.3 (658.8) 4801.4 (657.0) 0.606
Propofol (mg/kg/day), mean (SD) 60.0 (8.6) 62.7 (5.4) 0.5
Propofol (mg/kg/hour), mean (SD) 2.5 (0.4) 2.6 (0.2) 0.495
Propofol number reaching toxic dose
(> 5 mg/kg/hour), median (IQR)
3.0 (2.3–5.3) 4.0 (3.0–4.0) 0.535
NMB
Atracurium, mean (SD) 31.1 (6.8) 22.0 (4.5) 0.012
Atracurium (mg/hour), median (IQR) 50.0 (50.0–50.0) 60.0 (50.8–60.0) 0.017
NMB, neuromuscular blocking agent.
TABLE 18 Cardiovascular support after randomisation
Cardiovascular support
Treatment group
p-valueHypothermia Control
Noradrenaline, mean (SD) 95.4 (12.9) 78.1 (18.7) 0.067
Noradrenaline (mg/day), mean (SD) 15.3 (3.5) 12.2 (2.5) 0.078
Dobutamine, mean (SD) 7.3 (3.1) 2.3 (1.0) 0.002
Dobutamine (mg/day), median (IQR) 292.5 (221.3–466.9) 315.0 (193.9–441.9) 0.71
Vasopressin, mean (SD) 5.7 (2.4) 1.9 (0.9) 0.002
Vasopressin (units/day), median (IQR) 24.9 (16.7–31.6) 60.4 (6.0–778.8) 0.71
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with a daily dose of median 24.9 (IQR 16.7–31.6) UI/day in the TH group compared with median 60.4
(IQR 6.0–778.8) UI/day in the control group (p = 0.71) (see Table 18).
Steroids
The number of participants receiving steroids was greater in the TH group [23 (17.8%)] than in the control
group [9 (6.7%)] (p = 0.01) (Table 19). The most frequently used steroid was hydrocortisone: 20 participants,
with a median daily dose of 100 mg (range 25–600 mg), used this steroid in the TH group compared with
six participants, with a median daily dose of 125 mg (range 50–200mg), in the control group.
Fluid balance
Daily fluid balance was similar in both groups. The number of participants per day with a positive fluid balance
[mean 84.4 participants (SD 19.2) in the TH group vs. mean 87.3 (SD 17.0) in the control group; p = 0.773]
or negative fluid balance [mean 32.9 (SD 13.9) in the TH group vs. mean 30.9 (SD 11.3) in the control
group; p = 0.773] was similar. Average daily fluid balance was also similar between the groups [mean 781.7
(SD 409.9) ml in TH vs. mean 657.3 (SD 406.6) ml in control group; p = 0.579] (Table 19).
Laboratory results and organ failure
There were no significant differences in the average daily haemoglobin [mean 102.4 (SD 2.8) g/l in the
TH group vs. mean 102.8 (SD 4.6) g/l in the control group; p = 0.839], haematocrit [mean 0.3 (SD 0.0)
in the TH group vs. mean 0.3 (SD 0.0) in the control group; p = 0.139] or platelet count [mean 163.1
(SD 15.2) × 109/l in the TH group vs. mean 195.5 (SD 36.9) × 109/l in the control group; p = 0.053]
between the two groups (Table 20).
Liver function was not significantly different in the two groups. There were no significant differences between
the two groups for average daily bilirubin [mean 8.2 (SD 0.7) µmol/l in the TH group vs. mean 8.3 (SD 1.3)
µmol/l in the control group; p = 0.832], alanine transaminase (ALT) [median 32.0 (IQR 29.3–41.5) U/l in
the TH group vs. median 30.5 (IQR 29.0–44.8) U/l in the control group; p = 1.0] and albumin [median 25.8
(IQR 25.5–27.4) g/l in the TH group vs. median 26.9 (IQR 26.5–28.5) g/l in the control group; p = 0.128]
(see Table 20). Average daily APTT (activated partial thromboplastin time) [mean 33.2 (SD 2.1) seconds in
the TH group vs. mean 31.2 (SD 1.3) seconds in the control group; p = 0.046] and APTTr (activated partial
thromboplastin time ratio) [mean 1.2 (SD 0.1) in the TH group vs. mean 1.1 (SD 0.0) in the control group;
p = 0.037] were significantly increased in the TH group.
Renal function was not significantly different in the two groups for average daily serum urea [mean 4.30
(SD 0.83) mmol/l in the TH group vs. mean 4.33 (SD 1.0) mmol/l in the control group; p = 0.959] or
creatinine [mean 54.9 (SD 4.9) µmol/l in the TH group vs. mean 57.9 (SD 3.3) µmol/l in the control group;
p = 0.205] (see Table 20). Electrolyte concentrations were identical in the TH and control groups: serum
TABLE 19 Corticosteroids prescribed during ICU admission and fluid balance after randomisation
Intervention
Treatment group
p-valueHypothermia Control
Receiving steroids, n (%)
Yes 23 (17.8) 9 (6.7) 0.01
No 106 (82.2) 125 (93.3)
Receiving hydrocortisone, n (%) 2.9 (3.19) 0.9 (0.90) 0.136
Fluid balance during randomisation
Patients with a positive daily balance, n (%) 84.4 (19.2) 87.3 (17.0) 0.773
Patients with a negative daily balance, n (%) 32.9 (13.9) 30.9 (11.3) 0.773
Fluid balance (ml/day) mean (SD) 781.7 (409.9) 657.3 (406.6) 0.579
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sodium was median 145.2 (range 144.2–145.4) mmol/l in the TH group, compared with median 145.0
(range 142.8–145.6) mmol/l in the control group (p = 0.62) and potassium was mean 4.03 (SD 0.14)
mmol/l in the TH group, compared with mean 4.03 (SD 0.11) mmol/l in the control group; p = 1].
There was no difference in the number of participants requiring renal replacement therapy (RRT). Seven
participants (5.5%) in the TH group required RRT, compared with three participants (2.4%) in the control
group (p= 0.33) (see Table 20). Evidence of rhabdomyolysis was reported in the same number of participants
in each group [11 (9.1%) in the TH group vs. 11 (8.9%) in the control group; p= 0.87]. Additionally, elevated
levels of creatine kinase and/or troponin T were reported in a similar proportion of participants across the
two groups [37 (33.9%) in the TH group vs. 30 (28.6%) in the control group; p= 0.484]. The average serum
creatinine kinase level was median 753 (IQR 505–1280) U/l in the TH group, compared with median 1013
(IQR 606–1554) U/l in the control group (p= 0.336), and the troponin T level was median 41.0 (IQR 10.0–142.0)
ng/l in the TH group, compared with median 15.0 (IQR 3.755–38.3) ng/l in the control group (p= 0.46).
Acid–base estimation
Metabolic acidosis was reported significantly more often in the TH group than in the control group
[45 participants (36.9%) in the TH group vs. 27 participants (22.1%) in the control group; p = 0.017], as
was the use of an infusion of bicarbonate [17 (13.7%) in the TH group vs. 5 (4.2%) in the control group;
TABLE 20 Laboratory results at randomisation
Analysis
Treatment group
p-valueHypothermia Control
Haemoglobin (g/l), mean (SD) 102.4 (2.8) 102.8 (4.6) 0.839
Haematocrit (%), mean (SD) 0.3 (0.0) 0.3 (0.0) 0.139
White cell count (× 109/l), mean (SD) 9.9 (0.9) 11.0 (0.7) 0.031
Neutrophils (× 109/l), mean (SD) 7.8 (0.6) 9.0 (0.7) 0.005
Platelets (× 109/l), mean (SD) 163.1 (15.2) 195.5 (36.9) 0.053
APTT (seconds), mean (SD) 33.2 (2.1) 31.2 (1.3) 0.046
APTTr, mean (SD) 1.2 (0.1) 1.1 (0.0) 0.037
Urea (mmol/l), mean (SD) 4.30 (0.83) 4.33 (1.00) 0.959
Sodium (mmol/l), median (range) 145.2 (144.2–145.4) 145.0 (142.8–145.6) 0.62
Potassium (mmol/l), mean (SD) 4.03 (0.14) 4.03 (0.11) 1
Creatinine (µmol/l), mean (SD) 54.9 (4.9) 57.9 (3.3) 0.205
Bilirubin (µmol/l), mean (SD) 8.22 (0.65) 8.34 (1.29) 0.832
ALT (U/l), median (range) 32.0 (29.3–41.5) 30.5 (29.0–44.8) 1
Alkaline phosphatase (U/l), mean (SD) 81.9 (21.1) 85.5 (20.1) 0.751
Calcium (mmol/l), mean (SD) 2.04 (0.04) 2.08 (0.08) 0.232
Albumin (g/l), median (range) 25.8 (25.5–27.4) 26.9 (26.5–28.5) 0.128
Phosphate (mmol/l), mean (SD) 1.10 (0.17) 1.04 (0.11) 0.444
Magnesium (mmol/l), mean (SD) 0.83 (0.02) 0.85 (0.03) 0.269
C-reactive protein (mg/l), mean (SD) 148.8 (31.9) 160.4 (31.9) 0.511
Bicarbonate (mmol/l), mean (SD) 23.0 (0.7) 23.6 (0.5) 0.101
Lactate (mmol/l), mean (SD) 1.20 (0.10) 1.06 (0.11) 0.027
APTT, activated partial thromboplastin time; APTTr, activated partial thramboplastic time ratio.
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p = 0.018]. Average daily lactate concentrations were significantly greater in the TH group than in the
control group [mean 1.2 (SD 0.1) mmol/l in the TH group vs. mean 1.1 (SD 0.1) mmol/l in the control
group; p = 0.027], although serum bicarbonate concentrations were similar in both groups [mean 23.0
(SD 0.7) mmol/l in the TH group vs. mean 23.6 (SD 0.5) mmol/l in the control group; p = 0.10].
Organ dysfunction
Organ dysfunction was quantified using a modified abbreviated SOFA score. All analyses were made
comparing minimal (SOFA score of ≤ 1) with significant (SOFA score of > 1) organ dysfunction. There was
no significant difference in the distribution of SOFA scores between the TH group and the control group;
47 participants (32.9%) in the TH group and 55 participants (38.5%) in the control group had a SOFA
score of ≤ 1, and 96 participants (67.1%) in the TH group and 88 participants (61.5%) in the control group
had a SOFA score of > 1 (p = 0.388) (Table 21). In the TH group, there were significantly more participants
TABLE 21 Complications and organ dysfunction after randomisation and organ dysfunction quantified using a
modified abbreviated SOFA score
Complications
Treatment group
p-valueHypothermia Control
Haemofiltration, n (%)
Yes 7 (5.5) 3 (2.4) 0.333
No 120 (94.5) 124 (97.6)
Rhabdomyolysis, n (%)
Yes 11 (9.1) 11 (8.9) 0.87
No 110 (90.9) 113 (91.1)
Metabolic acidosis, n (%)
Yes 45 (36.9) 27 (22.1) 0.017
No 77 (63.1) 95 (77.9)
Bicarbonate infusion, n (%)
Yes 17 (13.7) 5 (4.2) 0.018
No 107 (86.3) 114 (95.8)
Troponin and/or CK elevation, n (%)
Yes 37 (33.9) 30 (28.6) 0.484
No 72 (66.1) 75 (71.4)
CK (units/l) n = 35/29, mean (range) 769 (505–1478) 1004 (606–1554) –
Troponin (ng/l) n= 9/3, mean (range) 41.0 (10.0–133.0) 15.0 (0.0–46.0) –
SOFA of ≤ 1, n (%) 47 (32.9) 55 (38.5) 0.388
SOFA of > 1, n (%) 96 (67.1) 88 (61.5)
SOFA score and survival – hypothermia
Died Survived
SOFA of ≤ 1, n (%) 7 (15.2) 40 (41.2) 0.004
SOFA of > 1, n (%) 39 (84.8) 57 (58.8)
SOFA score and survival – control group
Died Survived
SOFA of ≤ 1, n (%) 11 (34.4) 44 (40.0) 0.712
SOFA of > 1, n (%) 21 (65.6) 66 (60.0)
CK, creatine kinase.
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who died with a SOFA score of > 1 [39 (84.8%) died vs. 57 (58.8%) survived] than with a SOFA score
of ≤ 1 [7 (15.2%) died vs. 40 (41.2%) survived] (p = 0.004). This was not seen in the control group:
21 participants (65.6%) died compared with 66 participants (60.0%) survived with a SOFA score of > 1,
and 11 participants (34.4%) died compared with 44 participants (40.0%) survived with a SOFA score of
≤ 1 (p = 0.712). The distribution of SOFA scores was not significantly different for the dichotomised GOSE
in either the TH group [73 (71.6%) unfavourable vs. 23 (59.0%) favourable with a SOFA score of > 1, and
29 (28.4%) poor vs. 16 (41.0%) good outcome with a SOFA score of ≤ 1; p = 0.218] or the control group
[53 (60.2%) poor vs. 33 (62.3%) good outcome with a SOFA score of > 1 and 35 (39.8%) poor vs. 20
(37.7%) good outcome with a SOFA score of ≤ 1; p = 0.951].
Immunity and infection
Therapeutic hypothermia was associated with a significantly lower average daily leucocyte count [mean 9.9
(SD 0.9) × 109/l in the TH group vs. 11.0 (SD 0.7) × 109/l in the control group; p = 0.031]. Similarly, the
neutrophil count was also reduced [mean 7.8 (SD 0.6) x109/l in the TH group vs. mean 9.0 (SD 0.7) ×109/l
in the control group; p= 0.005]. However, there was no statistically significant difference between the
two groups for average daily C-reactive protein [mean 148.8 (SD 31.9) mg/l in the TH group vs. mean 160.4
(SD 31.9) mg/l in the control group; p= 0.511].
The number of participants suspected of having infection was similar over days 1–7 of data collection
[111 (81.6%) in the TH group vs. 106 (78.5%) in the control group; p = 0.627]. Confirmed infections
were also similar [98 (79.0%) in the TH group vs. 94 (77.0%) in the control group; p = 0.825] (Table 22).
Pneumonia was the most common infection in both groups, although there was no significant difference
in the number of episodes between the two groups [84 (58.7%) episodes in the TH group vs. 78 (54.5%)
in the control group; p = 0.551]. Endotracheal aspiration was the technique most frequently used to
confirm a respiratory infection [35 participants (44.3%) in the TH group vs. 29 participants (40.8%) in the
control group; p = 0.754]. There was no significant difference between the two groups in the number of
participants who received antibiotics [116 (89.2%) in the TH group vs. 113 (87.6%) in the control group;
p = 0.828].
Coenrolment
The number of participants coenrolled in other trials was similar in the two groups: 16 out of 143 participants
(11.4%) in the TH group and 12 out of 143 participants (8.6%) in the control group (p= 0.55). The distribution
of trials to which participants were coenrolled was not different. Coenrolment was not more frequent in non-
survivors than in survivors in either the TH group [5 (11.1%) non-survivors vs. 11 (11.6%) survivors; p= 0.839]
or the control group [3 (9.7%) non-survivors vs. 8 (7.4%) survivors; p= 0.972]. Similarly, coenrolment was not
more common in those participants with an unfavourable outcome by GOSE in the TH group [11 (11.2%)
unfavourable outcome vs. 3 (7.9%) good outcome; p= 0.796] or the control group [7 (8.2%) poor outcome
vs. 4 (7.7%) good outcome; p= 0.833].
Method of cooling
The majority of participants were cooled with an automated device and surface cooling; Blanketrol®
(Patient Temperature Management Solutions, Cincinnati, OH, USA) and ARCTIC SUN® 5000 Temperature
Management System (Bard Medical Division, Covington, GA, USA) were the most commonly used devices
(58.2% of the TH group sample), although a small percentage of participants were cooled with an
intravascular device (ZOLL®; ZOLL, Pitsburgh, PA, USA) (23.9% of the TH group sample).
Unfavourable outcome at 6 months by GOSE was not associated with the type of cooling device
used (p = 0.441).
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TABLE 22 Infection and antibiotic usage after randomisation
Intervention
Treatment group, n (%)
p-valueHypothermia Control
Suspected infection
Yes 111 (81.6) 106 (78.5) 0.627
No 25 (18.4) 29 (21.5)
Confirmed infection
Yes 98 (79.0) 94 (77.0) 0.825
No 26 (21.0) 28 (23.0)
Respiratory infection
Yes 84 (58.7) 78 (54.5) 0.551
No 59 (41.3) 65 (45.5)
Respiratory sample type
Formal bronchoalveolar lavage 19 (24.1) 16 (22.5) 0.754
Mini bronchoalveolar lavage 5 (6.3) 8 (11.3)
Endotracheal aspiration 35 (44.3) 29 (40.8)
Sputum 20 (25.3) 18 (25.4)
Infections
Respiratory infection
Yes 84 (58.7) 78 (54.5) 0.551
No 59 (41.3) 65 (45.5)
Urinary infection
Yes 4 (2.8) 9 (6.3) 0.256
No 139 (97.2) 134 (93.7)
Catheter-related bloodstream infection
Yes 4 (2.8) 5 (3.5) 0.756
No 139 (97.2) 138 (96.5)
Sepsis of uncertain origin
Yes 2 (1.4) 1 (0.7) 1
No 141 (98.6) 142 (99.3)
Other infection
Yes 8 (5.6) 7 (4.9) 1
No 135 (94.4) 136 (95.1)
Antibiotics
Antibiotics prescribed
Yes 116 (89.2) 13 (87.6) 0.828
No 14 (10.8) 16 (12.4)
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Discussion
This exploratory analysis collected additional information not considered in the original Eurotherm3235
Trial in order to explore possible reasons for the original trial results. Consistent with the ITT population,
analysis of this additional data sample also showed that there was a statistically significant increase in the
mortality within 6 months of randomisation in the hypothermia group. Treatment allocation, demographics
and outcomes were similar to the ITT population.
The main observation that stands out from these results is that hypothermia was associated with an excess
number of deaths as a consequence of sepsis/ARDS/MOF. In the case of non-surviving participants, study
centres were asked to give a likely cause of death. Hypothermia was associated with an excess number of
deaths as a consequence of sepsis/ARDS/MOF. In the TH group, significantly more participants who died
had increased organ dysfunction scores, but this study cannot prove causality. With an absence of any
difference in comorbidities or cointerventions between groups, the differences in the cause of death and
the incidence of non-neurological organ dysfunction among those who died point to profound systemic
consequences of hypothermia in this population of participants.
The harmful systemic effects of inflammation, linking sepsis, lung injury and MOF as a pathogenic consequence
of TH, might explain the greater requirement for cardiovascular support, the evidence of tissue hypoperfusion
and greater incidence of organ dysfunction associated with TH deaths.
One trigger for inflammation and organ dysfunction with TH may stem from a reduction in oxygen
availability at a cellular level. Hypothermia causes a decrease in the tension/partial pressure of dissolved
gases in the blood because of their increased solubility. This is accompanied by an increase in blood pH.
A reduction in PaCO2, pH and temperature causes a leftward shift in the oxyhaemoglobin dissociation
curve (OHDC),132 making less oxygen available in tissues.133
The alpha-stat blood gas management is a simple and reliable method used by the 33 centres that
participated in the Eurotherm3235 Trial and also in other hypothermia trials, such as the NABISH II and
TTM trials.108,134 It may be beneficial for participants with cerebrovascular disease or derangements of
cerebral autoregulation. Murkin et al.135 compared pH-stat and alpha-stat strategies and found that
flow–metabolism coupling was preserved using alpha-stat. Conversely, Kiziltan et al.136 found that the
pH-stat management might suppress the cerebral metabolic rate of oxygen more than the alpha-stat. In
addition, under pH-stat conditions, there is a decrease in haemoglobin affinity for oxygen compared with
alpha-stat, which could provide more dissolved oxygen for tissues. Similarly, Sakamoto et al.137 showed
that the pH-stat management increases cerebral oxygenation through improved oxygen delivery compared
with alpha-stat. Higher oxyhaemoglobin and lower deoxyhaemoglobin levels were identified on cerebral
near-infrared spectroscopy. The optimal strategy for blood gas management in TH remains uncertain and
was not addressed in the majority of laboratory studies we reviewed prior to studying this intervention.
In order to maintain cerebral autoregulation, the alpha-stat acid–base management for arterial blood gases
analysis was used in this trial and will have exacerbated tissue oxygen delivery. For example, a cooled
participant with an alpha-stat PaCO2 of 40 mmHg (measured at 37 °C) will have a substantially lower
PaCO2 at actual tissue temperature (32–35 °C) and a higher pH. A reduction in tissue oxygen delivery will
be compounded by the reduction in cerebral blood flow (due to autoregulation) as PaCO2 decreases. The
net result of this is a failure in oxygen delivery, tissue acidosis and a pro-inflammatory state. This relative
tissue hypoxia will affect not only the brain, but every organ system. Hypothermia creates a new and
heterogeneous blood flow distribution, with areas of hypoxia and lactic acid generation. Such systematic
effects might explain the greater use of vasopressors and inotropes in the TH group and the increased use
of steroids. This would also be in keeping with the small but significant increase in the average daily
lactate concentration and the greater prevalence of metabolic acidosis in the TH group.
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During rewarming, there is a rightward shift of the OHDC, which facilitates oxygen dissociation. Morray
et al.138 documented an increase in VO2 during rewarming and found that oxygen delivery failed to keep
pace with this VO2. Prolonged hypothermia may reduce blood flow through arterioles because of local
factors such as a decrease in oxygen requirement, vasoconstriction and a reduction in plasma volume.
Heterogeneous areas of blood flow distribution, tissue oxygen debt, an increment in lactate concentration
and a metabolic acidosis will result. During rewarming, lactate re-enters normal oxidative pathways,
consuming oxygen during this process. With a return to normothermia, free radical oxidation resumes,
leading to non-respiratory utilisation of oxygen and an increase in VO2.
To detect and prevent brain hypoxia, the use of brain tissue oxygen tension (PbtO2) monitoring as part of
a multimodality array of advanced cerebral monitoring is becoming increasingly common. Frequent and
long duration of cerebral hypoxaemic episodes in trauma patients have been repeatedly found to be
significantly associated with poor outcome.139 By manipulating CPP and ICP, and optimising PaO2, PaCO2
and blood haemoglobin concentration, it is possible to improve PbtO2.112
In a small, single-centre, retrospective analysis of the first 17 participants enrolled in the Eurotherm3235 Trial,
Flynn et al.140 found that there was a significant decline in mean PbtO2 from 30.2 mmHg to 22.4 mmHg in
the TH group, from induction to stable hypothermia. In five out of the nine TH participants, PbtO2 fell below
the target value of 20 mmHg but was unaffected by cooling in the remainder of the TH group. This raises the
possibility that the response to cooling could be heterogeneous. For some patients, TH might reduce oxygen
delivery to the brain to a greater degree than the reduction in metabolic oxygen consumption that occurs
with cooling. However, this effect is not universal. A greater understanding of why cooling might be better
tolerated in some patients, how to mitigate the effects of cooling on oxygen supply and of the use of cooling
to a target PbtO2 might improve the results of TH in this group of patients.
Although anaemia has also been associated with a decrease in PbtO2 following TBI, this exploratory analysis
found no statistically significant difference in the average daily mean of haemoglobin and haematocrit levels
in the two groups.141
We found no evidence of a significant imbalance in propofol use or infusion rate between the treatment
allocations.142 Similarly, there was no significant difference in propofol dose after adjustment for age,
post resuscitation GCS motor component, time from injury and pupil reactivity. Furthermore, there were
no statistically significant differences between the two groups in the number of participants receiving
potentially toxic (> 5 mg/kg/hour) rates of propofol in the first 48 hours.143,144
These comparisons, however, do not consider the effect of cooling on the metabolism of propofol, which,
by slowing clearance, could potentially promote toxicity. Leslie et al.145 demonstrated an approximate
28% increase in the serum concentration of propofol in six patients cooled to 34 °C. Moreover, the study
showed a decrease in the hepatic blood flow by 10% with cooling. Bjelland et al.146 showed that propofol
clearance was significantly lower during hypothermia than normothermia (median 2046 vs. 2665ml/minute;
p< 0.035) in 14 patients treated with TH following cardiac arrest.
That said, the average daily liver and kidney function tests did not differ between the groups and there
were no differences in the need for RRT, evidence of rhabdomyolysis or cardiac damage by treatment
allocation. These findings would argue against the effect of propofol-related infusion syndrome (PRIS) in
the TH group. The greater use of vasopressors and inotropes in the TH group may reflect a response to
cardiovascular compromise because of an inflammatory state rather than the cardiotoxic effects of PRIS.
Hypothermia can also affect the clearance of other drugs, including neuromuscular blocking agents.147
In this analysis, we found that atracurium was used more often in the TH group, possibly in an effort to
manage shivering, than in the control group. However, the median hourly infusion rate was significantly
lower with TH than with standard treatment; this could be explained by the reduction in the clearance of
atracurium, which is temperature dependent by Hofmann degradation.
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Decompressive craniectomy is performed in many neurotrauma centres worldwide. Over the course of our
study, two important trials148,149 were either published or nearing completion. These trials found that
decompressive craniectomy was associated with either a worse GOSE score at 6 months or greater survival
but no improvement in the proportion of patients with good recovery. In our study, the number of
participants undergoing decompressive craniectomy before and after randomisation was similar in the two
groups. The use of hemicraniectomy and bifrontal craniectomy did not vary by CT appearance in either the
TH group or the control group, nor was there a difference in Marshall scores by treatment allocation for
either decompressive technique.
The literature at the time of the Eurotherm3235 Trial did not recommend the use of steroids to improve
outcomes or reduce ICP.86 The large, multicentre CRASH trial150 found worse outcomes at 6 months and a
higher mortality within 2 weeks in patients treated with methylprednisolone (Consilient Health Ltd, Surrey, UK).
The mechanism and cause of the increase in death rate were not clear. The data from the exploratory analysis
in this report revealed that the number of participants receiving steroids was significantly greater in the TH
group than in the control group. However, when used, the steroids were of a relatively low dose compared
with those used in the CRASH trial, and more in keeping with an adrenocortical replacement dose, such as
what might be used in severe sepsis.
The Eurotherm3235 Trial was stopped early because of futility and safety concerns. The main trial was
designed to be pragmatic, namely focused on functional outcome rather than on detailed mechanistic
pathways. The fact that the study was stopped earlier than intended may introduce the risk of bias,
reducing the validity of the results.151 For this exploratory analysis, the Eurotherm3235 Trial team successfully
collected data on 74% of the ITT population, and received 286 anonymised CRFs out of 387 by post or
e-mail to the Eurotherm3235 Trial office by the deadline of 31 July 2016. The main reasons that we received
a smaller number of data than initially hoped for were that, among the 33 centres that took part in the main
trial, three sites were closed, three did not have the capacity for collecting data and eight were inactive.
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Chapter 7 Conclusions
Hypothermia with alpha-stat blood gas management is associated with important systemic effects,manifested as an inflammatory condition similar to sepsis/ARDS/MOF. This condition is associated with
increased mortality and poorer outcomes after TBI.
Impact of patient and public involvement, challenges of patient and
public involvement and lessons learnt
The Eurothern3235 Trial recruited patient populations that were very challenging for two main reasons:
1. Patients were incapacitated because they were sedated and connected to a ventilator at the time of
recruitment to the trial.
2. There is a high probability of a poor outcome following TBI; therefore, patients who have survived
their injury generally have many problems, either cognitively or physically, that impair their ability to
contribute to the design of a research trial.
This made patient involvement in the design and structure of the trial very difficult. For these reasons, it
was not possible to have a patient representative as part of the protocol design group; however, we did
involve a group of patients who had suffered a TBI and their relatives in the design and writing of the
patient and relative documentation. The patients and relatives involved were suggested to us by the
Edinburgh Headway Group, and time since suffering the TBI ranged from 2 to 25 years.
The trial manager (H Louise Sinclair) visited the Edinburgh Headway Group on a day, arranged by the group,
when the suggested patients and relatives would attend. The patients were given the draft patient consent
forms and patient information sheets to read, and the relatives were given the draft patient and relative
consent forms and information sheets to comment on. The patients were interviewed individually by
H Louise Sinclair and any comments were documented. The main comment from patients was that the
forms were too complicated; they struggled to understand some of the wording and could not read the
forms because of the font (Times New Roman) and the small font size that was used.
The relatives were also interviewed individually and their comments were documented. The main
concerns were:
l The length of the information sheets for both patients and relatives.
l The formal layout of the information sheets – A4 size double-sided documents.
l The complexity of the wording used for patients – we needed to use much more basic language
(approximately at the level of an 8-year-old).
l The complexity of the wording used for relatives. The concerns were that, at the time of reading the
documents and consent forms, relatives would be in a state of shock so would be unable to process a
lot of information.
The consent documents were then amended, taking into account all of the comments and concerns
raised. We could not reword the consent forms because they were written in accordance with the NRES
guidelines for wording consent forms and information sheets;152 however, we were able to change the
layout of these documents. In doing so, we changed the font used and increased the font size of the
consent forms, and changed the layout of the information sheets to an A5-sized booklet using basic
language, an informal, larger font and the use of colour text boxes. H Louise Sinclair then met with the
same cohort and the forms were approved by the group.
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We also appointed a patient’s relative as a lay member of the Trial Steering Committee. She was recommended
by Edinburgh Headway Group and attended the steering committee meetings in person. She did, however,
find being a member of the committee difficult at times because she is her husband’s main carer and could not
leave him at home alone for the duration of the meeting. She therefore had to arrange for carers to be with
him while she attended the meetings. She also found the role upsetting at times because she described how
it brought back memories of her husband’s brain injury, his stay in intensive care and subsequent difficult
recovery with the adaptations she has had to make to their lives.
Conclusions
In patients with TBI, TH plus standard care successfully reduced ICP. This intervention, however, did not
improve functional recovery as compared with standard care alone.
CONCLUSIONS
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Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support. Using
patient data is vital to improve health and care for everyone. There is huge potential to make better use of
information from people’s patient records, to understand more about disease, develop new treatments,
monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone’s
privacy, and it’s important that there are safeguards to make sure that it is stored and used responsibly.
Everyone should be able to find out about how patient data are used. #datasaveslives You can find out
more about the background to this citation here: https://understandingpatientdata.org.uk/data-citation.
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Appendix 1 Induction and maintenance of
therapeutic hypothermia
BOX 1 Induction and maintenance of hypothermia guideline
Patient randomised to hypothermia
Continue stage 1 and 2 therapy as indicated throughout the hypothermia/rewarming interventions.
Prior to induction of hypothermia
l Opiate and propofol (suggested dosage of 10 µg/kg/minute) or midazolam infusions.
l Paracetamol (1 g/6 hours oral/rectal/intravenously).
l Ensure that extremities are covered.
l Ensure that the maintenance method of hypothermia is in place and ready for use.
l Core temperature monitoring in place – bladder, oesophageal, pulmonary artery catheter or rectum.
l Assess baseline laboratory values as appropriate.
Induction of hypothermia
l Infuse 20–30 ml/kg of refrigerated 0.9% saline intravenously within 30 minutes.
l Closely monitor all vital signs during the induction phase of hypothermia.
l Observe continuously for obvious signs of shivering.
l Assess for signs of shivering using the shivering assessment tool every 30 minutes during the first 2 hours
and hourly thereafter, and if there is any indication of shivering between these times.
Maintenance of hypothermia
l Maintain hypothermia for > 48 hours.
l Maintain ICP of ≤ 20 mmHg by adjusting temperature (32–35 °C) (i.e. higher ICP may require a
lower temperature).
l Assess laboratory values as appropriate during hypothermia therapy.
l Observe continuously for obvious signs of shivering.
l Assess for signs of shivering using the shivering assessment tool every 30 minutes during the first 2 hours
and hourly thereafter, and if there is any indication of shivering between these times.
l Please note that all participants should be closely monitored and their care assessed to avoid any side
effects of induced hypothermia therapy:
¢ hypovolaemia
¢ respiratory and metabolic acidosis
¢ hypokalaemia
¢ relative drug overdose
¢ hypotension
¢ coagulopathy.
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BOX 2 Rewarming guideline
Rewarming phase
There is no maximum duration of hypothermia; however, rewarming should first be considered 48 hours from
induction of hypothermia only if ICP is ≤ 20 mmHg.
Rewarming rate: 1 °C/4 hours (0.25 °C per hour) until core temperature is ≥ 36 °C.
Assess laboratory values as appropriate.
All patients should be closely monitored and their care assessed to avoid any side effects:
l hypotension
l hypovolaemia
l hyperkalaemia
l arrhythmias.
Pause rewarming if ICP is > 20 mmHg and if necessary recool to maintain ICP of ≤ 20 mmHg.
Consider stage 3 options if necessary:
l barbiturate infusion
l decompressive craniectomy.
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Appendix 2 Detection and treatment of shivering
BOX 4 Shivering detection guideline: shivering assessment tool
Observe ECG and/or BIS trace continuously for artefact.
Formal assessment.
Observe patient for 2 minutes, during which time visually inspect and palpate jaw, neck, chest, arms and legs.
Score shivering as follows:
l 0 = no shivering
l 1 =mild: shivering localised to jaw, neck and/or chest only
l 2 =moderate: shivering involves gross movement of arms or legs, in addition to neck, chest and
two extremities
l 3 = severe: shivering involves gross movements of the trunk and arms and legs.
If the patient scores ≥ 1 using this scale, please refer to the Prevention of Shivering Guideline overleaf.
BIS, Bispectral Index; ECG, electrocardiogram.
Based on recommendations in Badjatia et al.95
BOX 3 Shivering detection guideline
Prior to induction of hypothermia
l Opiate and propofol or midazolam infusions.
l Paracetamol (1 g/6 hours enterally/intravenously).
l Ensure that extremities are covered.
Induction of hypothermia (cold salinewith/without cooling method or device)
l Observe continuously for obvious signs of shivering.
l Assess for signs of shivering using the shivering assessment tool every 15 minutes until target
temperature achieved.
Maintenance of hypothermia (cooling method or device)
l Observe continuously for obvious signs of shivering.
l Assess for signs of shivering using the shivering assessment tool every 30 minutes during the first 2 hours
and hourly thereafter, and if there is any indication of shivering between these times.
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Is shivering detected?
Yes No
Is seizure activity suspected/confirmed?
No Yes
Is the patient deeply sedateda and/or Bispectral Index is 40 – 60?
Yes No
Active skin
counterwarming
using forced air
convection blanket
at 40 – 43°C (if available)
Is shivering detected?
Yes No
Add midazolam (if not being given)
Add pethidine (if opiate not being given)
Add clonidine infusion only if heart rate is > 45 b.p.m.
Is shivering detected?
Yes No
Consider muscle relaxant
Continue monitoring for
detection of shivering
Continue monitoring for
detection of shivering
Continue monitoring for
detection of shivering
Administer anticonvulsant
therapy 
Increase sedationb to achieve
deeply sedated state
FIGURE 18 Shivering treatment guideline. a, Definition of ‘deeply sedated’ – no response to voice, but movement
or eye opening to physical stimulation. b, Increase in propofol dose every 10 minutes until deeply sedated state is
achieved and/or Bispectral Index. b.p.m., beats per minute.
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Appendix 3 Data Safety Monitoring
Committee charter
DATA MONITORING COMMITTEE (DMC) CHARTER FOR THE EUROTHER3235 TRIAL 
VERSION 1.0 27/04/2009 
 
EUROPEAN SOCIETY OF INTENSIVE CARE MEDICINE STUDY OF THERAPEUTIC 
HYPOTHERMIA (32-35°C) AFTER TRAUMATIC BRAIN INJURY 
 
VERSION 1.1 25.05.2009 
 
1. INTRODUCTION 
The trial is funded by the European Society of Intensive Care Medicine. REC approval has been 
gained in Scotland and England. CAS reference 09/MRE00/34 (Scotland AWI Study) and 
09/H1302/44 (England and Wales ALC study). 
 
The trial is registered on the European registry of trials (www.controlledtrials.com, ISRCTN 
ISRCTN34555414) 
 
1.1. Trial Objectives 
The EUROTHERM3235Trial is an international trial in neurological intensive care that will 
confirm or refute the research question, does therapeutic hypothermia (32-35°C) reduce morbidity 
and mortality rates at 6 months after TBI assessed by the extended Glasgow Outcome Scale 
questionnaire? 
 
Other questions that will be answered include: 
 
Does therapeutic hypothermia (32-35°C) reduce intra cranial hypertension? And is therapeutic 
 
hypothermia a cost effective treatment to improve outcome after TBI? 
 
1.2. Scope 
 
The purpose of this document is to describe the roles and responsibilities of the independent DMC 
for EUROTHERM, including the timing of meetings, methods of providing information to and 
from the DMC, frequency and format of meetings, statistical issues and relationships with other 
committees 
 
2. ROLES AND RESPONSIBILITIES 
2.1.Aims 
 
To protect and serve EUROTHERM participants, in particular with regard to safety and to 
assist and advise Principal Investigators so as to protect the validity and credibility of the 
trial. To safeguard the interests of trial participants, assess the safety and efficacy of the 
interventions during the trial, and monitor the overall conduct of the clinical trial. 
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The DMC should receive and review the progress and accruing data of the EUROTHERM 
trial and provide advice on the conduct of the trial to the Trial Steering Committee. The 
DMC should inform the Chair of the steering committee if, in their view the results are 
likely to convince a broad range of clinicians, including those supporting the trial and the 
general clinical community, that on balance one trial arm is clearly indicated or 
contraindicated for all participants or a particular category of participants, and there was a 
reasonable expectation that this new evidence would materially influence patient 
management. 
 
2.3.Specific roles of DMC 
 
Interim review of the trial’s progress including updated figures on recruitment, data 
quality, and main outcomes and safety data. This review would include, but not be 
restricted to, the following: 
· assess data quality, including completeness (and by so doing encourage collection 
of high quality data) 
· monitor recruitment figures and losses to follow-up 
· monitor compliance with the protocol by participants and investigators 
· monitor evidence for treatment differences in the main efficacy outcome measures 
· monitor evidence for treatment harm (e.g. toxicity data, SAEs, deaths) 
· decide whether to recommend that the trial continues to recruit participants or 
whether recruitment should be terminated either for everyone or for some 
treatment groups and/or some participant subgroups 
· suggest additional data analyses 
· monitor planned sample size assumptions 
· monitor continuing appropriateness of patient information 
· monitor compliance with previous DMC recommendations 
· consider the ethical implications of any recommendations made by the DMC 
· assess the impact and relevance of external evidence 
 
3. BEFORE OR EARLY IN THE TRIAL 
 
3.1.DMC input into the protocol 
 
All potential DMC members should have sight of the protocol before agreeing to join the 
committee. Before recruitment began the trial had undergone review by the ESICM and a 
REC. Therefore, if a potential DMC member has major reservations about the trial (e.g. the 
protocol or the logistics) they should report these to the Chief Investigator and may decide 
not to accept the invitation to join. DMC members should be independent and 
constructively critical of the ongoing trial, but also supportive of aims and methods of the trial. 
 
  
 
3.2.Timing of 1st DMC meeting 
The 1st meeting of the DMC has been scheduled for early in the course of the trial, to 
discuss the protocol, the trial, any analysis plan, future meetings, and to have the 
2.2.Terms of reference 
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opportunity to clarify any aspects with the principal investigators, and to discuss the 
format of reports to the DMC from the Trial Office (in the Edinburgh Clinical Trials Unit, 
University of Edinburgh). Subsequent meetings of the DMC will, where possible, be timed 
to precede a trial Steering Committee meeting by a few weeks. 
 
3.3.DMC member’s contracts 
Members of a DMC will have indemnity cover from the Sponsor for their work on the DMC. 
 
4. COMPOSITION 
 
4.1.DMC Membership 
 
The DMC members are independent of the trial (that is, they are not involved with the 
EUROTHERM trial in any other way or have some competing interest that could impact on 
the EUROTHERM trial). Any competing interests, both real and potential, should be 
declared. A short competing interest form should be completed and returned by the DMC 
members to the Chief Investigator, Peter Andrews, at Western General Infirmary 
Edinburgh. The members of the DMC for the EUROTHERM trial are: 
· Professor Peter M. Suter, Président ASSM/SAMW, Centre Médical Universitaire, 
Université de Genève, Rue Michel-Servet 1, CH-1211 Genève, Switzerland 
· Professor Ian Ford, Professor of Statistics, Robertson Centre for Biostatistics, Glasgow 
· Professor Peter Sandercock, University of Edinburgh, Edinburgh 
 
4.2.The responsibilities of the DMC statistician 
 
Professor Ian Ford will act as the DMC statistician, guiding the DMC on the statistical 
interpretation of the reports they receive. Professor Ford will liaise with the trial statistician 
on the specification of the statistical analyses and reports, which will be produced for him. 
 
4.3.The responsibilities of the trial statistician 
The independent statistician (located in ECTU Office) in conjunction with ECTU Senior Trial 
Coordinator (Bridget Colam) will oversee production of reports to the DMC and if 
appropriate the independent statistician will participate in DMC meetings, guiding the DMC 
through the report, participating in DMC discussions and, on some occasions, taking notes. 
 
4.4.The responsibilities of the Trial Office 
 
The Trial Office team comprises: 
· Clinical Coordinator [Jonathan Rhodes] 
· Trial Manager [Louise Sinclair] 
· Data Manager [TBA] 
· Senior Trial Manager [Bridget Colam] 
· Experienced Trialist [Stuart Ralston] 
· Trial Statistician [Gordon Murray] 
· Independent Statistician [TBA] 
With the exception of the independent statistician, these Trial Office staff will usually only 
contribute to the production of the non-confidential sections of DMC reports. 
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4.5.The responsibilities of the Chief Investigator and other members of the 
EUROTHERM Trial Steering Committee 
 
The Chief Investigator (Peter Andrews), may be asked, and should be available, to attend 
open sessions of the DMC meeting. Other EUROTHERM Steering Committee members will 
not usually be expected to attend but can attend open sessions when necessary. 
 
5. RELATIONSHIPS 
 
5.1.Relationships between study teams 
The study is guided by a Trial Steering Committee that meets approximately annually. The 
TSC has an independent chair, additional independent members, the grant holders and 
principal investigators, and members of the Trials Office. The day to day running of the 
trial is overseen by the Project Management Group, who meet weekly at the Trial Office 
and are joined by the Chief Investigator. The Trial Management Team in addition meet face 
to face approximately every 6-8 weeks. 
 
5.2.Advisory role of DMC 
 
As is customary, the EUROTHERM DMC will not make decisions about the trial, but rather 
make recommendations to the EUROTHERM Steering Committee from the DMC Chair to 
the Chief Investigator. 
 
5.3.DMC payments 
 
EUROTHERM DMC members will be reimbursed for travel and accommodation. No other 
payments or rewards are anticipated. 
 
5.4.DMC members competing interests 
 
Competing interests should be disclosed. These are not restricted to financial matters – 
involvement in other trials or intellectual investment could be relevant. Although members 
may well be able to act objectively despite such connections, complete disclosure enhances 
credibility. (See Annex 1) 
 
DMC members should not use interim results to inform trading in pharmaceutical shares, 
and careful consideration should be given to trading in stock of companies with competing 
products. 
 
 
 
6. ORGANISATION OF DMC MEETINGS 
 
6.1.Frequency of DMC meetings 
It is recommended that the DMC meet at least yearly. If possible the DMC meetings should 
be arranged to take place just prior to planned meeting of the Trial Steering Committee, so 
that the DMC report can be considered by the Trial Steering Committee in a timely fashion.   
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6.2.DMC meetings location and style 
It is expected that all the meetings will be face-to-face with teleconferencing if required. 
 
6.3.DMC meetings format 
· Open session: Introduction and any “open” parts of the report 
· Closed session: DMC discussion of “closed” parts of the report 
And, if necessary; 
· Further open session: Discussion with other attendees on any matters arising from the 
previous session(s). 
· Further closed session: extra closed session 
 
7. TRIAL DOCUMENTATION AND PROCEDURES TO ENSURE CONFIDENTIALITY AND 
PROPER COMMUNICATION 
 
7.1.Intended content for open sessions 
Accumulating information relating to recruitment and data quality (e.g. data return rates, 
treatment compliance) will be presented. SAE details based on pooled data will be 
presented and total numbers of events for the primary outcome measure and other 
outcome measures may be presented, at the discretion of the DMC. 
 
7.2.Intended content for closed sessions 
In addition to all the material available in the open session, the closed session material will 
include efficacy and safety data by treatment group. 
 
7.3.DMC blinding 
DMC will not be blind to treatment allocation. However the randomised groups will be 
labelled A and B. The identity of A and B will be supplied under separate cover, not in the 
report. 
 
7.4.Access to accumulating data and interim analysis 
No study personnel, with the exception of the independent statistician and his delegates 
(for example, a junior statistician to perform the analyses under the independent 
statistician’s supervision, or a clerical assistant to format the reports) will be unblinded to 
any study results during the conduct of the study. DMC members do not have the right to 
share confidential information with anyone outside the DMC, including the Chief 
Investigator. 
 
7.5.Responsibility for identifying and circulating external evidence 
The Chief Investigator (Peter Andrews) takes responsibility for the identification and 
circulation of external evidence (e.g. from other trials/ systematic reviews). 
 
7.6.DMC communications 
The DMC will report its recommendations in writing to the Trial Steering Committee. This 
will be copied to the trial statistician and if possible should be sent via the study data 
centre in time for consideration at a meeting of the Trial Steering Committee (See Annex 2)
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7.7.Prior availability of DMC reports 
The DMC will receive the independent statistician’s report at least 1 week before a DMC 
meeting. 
 
7.8.Destruction of confidential papers 
The DMC members should destroy their reports after each meeting. If requested, fresh 
copies of previous reports will be circulated with the newest report before each meeting. 
The Trial Office will take responsibility for keeping all DMC study reports and minutes for 
inspection at study termination and for subsequent archiving. 
 
8. DECISION MAKING 
 
8.1.Possible DMC decisions/recommendations 
Possible recommendations could include:- 
· No action needed, trial continues as planned 
· Early stopping due, for example, to clear benefit or harm of a treatment, futility, or 
external evidence 
· Stopping recruitment within a subgroup 
· Stopping the trial on the basis of futility of recruitment 
· Extending recruitment (based on actual control arm response rates being different to 
predicted rather than on emerging differences) or extending follow-up 
· Sanctioning and/or proposing protocol changes 
 
8.2.Statistical guidelines for termination 
The DMEC has the responsibility for deciding whether, while randomisation is in progress, 
the unblinded results (or the unblinded results for a particular subgroup), should be 
revealed to the TSC. The DMEC terms of reference state that they will do this if, and only 
if, two conditions are satisfied: (1) the blinded results provide proof beyond reasonable 
doubt that treatment is on balance either definitely harmful or definitely favourable for all, 
or for a particular category of patients, in terms of the major outcome; (2) the blinded 
results would, if revealed, be expected to substantially change the prescribing patterns of 
doctors who are already familiar with any other trial results that exist. Exact criteria for 
“proof beyond reasonable doubt” are not, and cannot be, specified by a purely 
mathematical stopping rule, but they are strongly influenced by such rules. DMEC 
members have expressed sympathy with the stopping rule proposed in Part I of the 1976 
report to the MRC Leukaemia Committee, whereby an interim analysis of major endpoint 
would generally need to involve a difference between treatment and control of at least 
three standard errors to justify premature disclosure. An interim subgroup analysis would, 
of course, have to be even more extreme to justify disclosure. This rule has the advantage 
that the exact number and timing of interim analyses need not be pre-specified. In 
summary, the stopping rules as specified in the CRASH trial protocol (as successfully 
applied in other trials including the MRC International Stroke Trial, which randomised 
19,436 acute stroke patients) require extreme differences to justify premature disclosure 
and involve and appropriate combination of mathematical stopping rules and scientific 
judgement. 
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8.3.DMC decision making methods 
It is recommended that every effort should be made for the DMC to reach a unanimous 
decision. If the DMC cannot achieve this, a vote may be taken, although details of the vote 
should not be routinely included in the report to the TSC as these may inappropriately 
convey information about the state of the trial data. It is important that the implications 
(e.g. ethical, statistical, practical, and financial) for the trial be considered before any 
recommendation is made. The role of the Chair is to summarise discussions and encourage 
consensus; it may be best for the Chair to give their own opinion last. 
 
8.4.DMC quorum for decision-making 
Effort should be made for all members to attend. The trial coordinating office will ensure 
that a date is chosen to enable this. With only 3 members comprising the DMC, all 
members will need to be taking part (in person or by teleconference) for any major 
decision to be taken. 
 
8.5.Non participation 
If a member does not attend a meeting, it should be ensured that the member is available 
for the next meeting. If a member does not attend a second meeting, they should be 
asked if they wish to remain part of the DMC. If a member does not attend a third 
meeting, they should be replaced. 
 
9. REPORTING 
 
9.1.Communication of DMC recommendation 
By letter to the Chief Investigator (Peter Andrews), within 3 weeks of the DMC meeting, 
with a copy of the letter to the Trial Office (ECTU, Edinburgh). 
 
9.2.DMC Minutes 
The DMC will keep an accurate minute of their discussions. Separate sections will be 
required for the open and closed sessions. The DMC Chair will sign off any minutes or 
notes. A sealed copy will be sent to the independent statistician at the Trial Office (ECTU, 
Edinburgh). 
 
9.3.DMC and Steering Committee conflict resolution 
If the DMC has serious problems or concerns with any Trial Steering Committee decisions a 
meeting of these groups should be held. The information to be shown would depend upon 
the action proposed and the DMC’s concerns. Depending on the reason for the 
disagreement confidential data may have to be revealed to all those attending such a 
meeting. The meeting should be chaired by a senior member of the Trials Office or an 
external expert who is not directly involved with the trial 
 
10.AFTER THE TRIAL 
10.1. Publication of results 
At the end of the trial there will be a meeting to allow the DMC to discuss the final data 
with the Chief Investigator and give advice about data interpretation. The Trial Steering 
Committee members are committed to publishing the results in a correct and timely manner, 
irrespective of the findings.   
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10.2. DMC information to be published 
DMC members will be named and their affiliations listed in the main report, unless they 
explicitly request otherwise. A brief summary of the timings and conclusions of DMC 
meetings will be included in the body of this paper. 
 
10.3. DMC role in publications 
The DMC will be given the opportunity to read and comment on major publications before 
submission. 
 
10.4. DMC confidentiality post study closedown 
The DMC members may discuss details of their involvement after permission is agreed with 
the Trial Steering Committee. 
 
Annex 1: Suggested EUROTHERM competing interests form 
Potential competing interests of Data Monitoring Committee 
members for EUROTHERM 
 
The avoidance of any perception that members of a DMC may be biased in 
some fashion is important for the credibility of the decisions made by the 
DMC and for the integrity of the trial. 
 
Possible competing interest should be disclosed via the trials office. In 
many cases simple disclosure up front should be sufficient. Otherwise, the 
DMC member should remove the conflict or stop participating in the DMC. 
Table 1 lists potential competing interests. 
Table 1: Potential competing interests 
· Stock ownership in any commercial companies involved 
· Stock transaction in any commercial company involved (if previously 
holding stock) 
· Consulting arrangements with the Sponsor 
· Frequent speaking engagements on behalf of the intervention 
· Career tied up in a product or technique assessed by trial 
· Hands-on participation in the trial 
· Involvement in the running of the trial 
· Emotional involvement in the trial 
· Intellectual conflict e.g. strong prior belief in the trial’s experimental arm 
· Involvement in regulatory issues relevant to the trial procedures 
· Investment (financial or intellectual) in competing products 
· Involvement in the publication 
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Signed: __________________________ Date:
 
DATA MONITORING COMMITTEE (DMC) CHARTER FOR THE EUROTHER3235 TRIAL 
VERSION 1.0 27/04/2009 
DATA MONITORING COMMITTEE (DMC) CHARTER FOR THE EUROTHERM3235 
TRIAL 9  
Annex 2: Illustrative report from EUROTHERM DMC to 
STEERING Committee where recommendation is to continue the 
trial according to the protocol 
[Insert date] 
To: Chair of Trial Steering Committee 
Dear [Chair of Trial Steering Committee] 
The Data Monitoring Committee (DMC) for the EUROTHERM trial met on [meeting 
date] to review its progress and interim accumulating data. [List members] 
attended the meeting and reviewed the report. 
The trial question remains important and, on the basis of the data reviewed at this 
stage, we recommend continuation of the trial according to the current version of 
the protocol [specify protocol version number and date] with no changes. 
We shall next review the progress and data [provide approximate timing] 
Yours sincerely, 
[Name of meeting Chair] 
Chair of Data Monitoring Committee 
On behalf of the DMC (all members listed below) 
DMC members: 
(1) [Insert name and role] 
(2) [Insert name and role] 
(3) [Insert name and role] 
______________
Please complete the following section and return to the trials office. 
No, I have no competing interests to declare 
Yes, I have competing interests to declare (please detail below) 
Please provide details of 
any competing interests: 
Name: ___________________________ 
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Appendix 4 Systematic review protocol:
PROSPERO international prospective register of
systematic reviews
An update: systematic review for the treatment of traumatic brain injury using 
therapeutic hypothermia 
Hannah Watson, Andrew Shepherd, Jonathan Rhodes, Peter Andrews, Margaret MacDougall 
Citation 
Hannah Watson, Andrew Shepherd, Jonathan Rhodes, Peter Andrews, Margaret MacDougall. An 
update: systematic review for the treatment of traumatic brain injury using therapeutic 
hypothermia.   PROSPERO 
2016:CRD42016036137 Available from 
http://www.crd.york.ac.uk/PROSPERO_REBRANDING/display_record.asp?ID=CRD420160361
37 
Review question(s) 
The purpose of this review is to update the evidence base for the use of therapeutic hypothermia in 
adult patients with traumatic brain injury following the recent publication of two randomised 
controlled trials. 
Searches 
The following electronic resources will be searched: 
- Cochrane Central Register of Controlled Trials (CENTRAL) 
- EMBASE 
- MEDLINE 
- PubMed 
Other notes: 
- Only foreign articles published in the English language will be included. 
- The electronic search will span from January 2011 to March 2016 and so will be complementary 
to the current evidence base 
(http://www.ncbi.nlm.nih.gov/pubmed/?term=crossley+andrews+traumatic+brain+injury). 
Types of study to be included 
This review will only include randomised clinical trials. 
Condition or domain being studied 
The condition being studied is adult traumatic brain injury sustained following acute closed head 
trauma. Therapeutic hypothermia is the intervention of interest. 
For the purpose of this review therapeutic hypothermia is defined as any intervention with the 
intention of reducing core body temperature to below the physiological norm (36 degrees Celsius). 
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Patient outcomes at follow-up will be assessed according to mortality and morbidity data. There 
will be a particular emphasis on outcomes recorded on a scale, fo r example, the Glasgow Outcome 
Scale or Ranchos Los Amigos Scale. 
Participants/ population 
Inclusion Criteria: 
- Randomisation. 
- Control group. 
- Use of therapeutic hypothermia 
- Adult patients, taken as the legal age of consent in the country of trial origin. 
- Closed head injury. 
Exclusion Criteria: 
- No control group. 
- Neonatal or paediatric patients. 
- Open head injuries, including gunshot wounds. 
Only articles meeting all inclusion criteria and no exclusion criteria will be included. 
Intervention(s), exposure(s) 
The intervention of interest is therapeutic hypothermia. 
Inclusion: 
- Any method of temperature reduction. 
Exclusion: 
- No article will be excluded on the basis of their cooling technique. 
For all articles the method of cooling will be detailed during data extraction. Other intervention 
factors that the authors may feel relevant, e.g. use of barbiturates, will also be noted during data 
extraction. 
Comparator(s)/ control 
This review will only include studies that detail a normothermic or no temperature reduction 
control group. 
Context 
Adult patients with moderate (Glasgow Coma Scale (GCS) 9-12) and severe (GCS <=8) acute 
traumatic brain injury and admitted to an intensive care unit. 
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The primary outcomes that will be assessed are mortality and morbidity, including, new 
pneumonia. Morbidity will 
be assessed using the Glasgow Outcome Scale Extended or Glasgow Outcome Scale at six 
months. 
Death or discharge Modified Oxford handicap scale will be used at 28 days. 
Secondary outcomes 
The following will be investigated as secondary hypotheses: 
a) Duration of cooling over 48 hours confers improved outcomes compared to less than 48 hours 
duration. 
b) The re-warming of patients at a rate of greater than 1 degree Celsius every four hours increases 
the risk of poor outcome. 
c) Those patients cooled to below 35 degrees Celsius will have a better outcome at follow-up 
compared to more 
moderate cooling of 35-36 degrees Celsius. 
d) An increasing time between injury onset and temperature reduction is associated with a poorer 
outcome. 
e) Hypothermia intervention is not more effective when the control group is managed to 
normothermia. 
Poor outcome at six months with the GOSE dichotomised 1-5 and 6-8. 
Data extraction, (selection and coding) 
The PRISMA statement will be followed at all stages. 
There are four co-authors that will be involved with abstract screening, full-text review and data 
extraction. 
A minimum of two independent reviewers will assess each title/abstract found by the searches 
against the defined inclusion and exclusion criteria. Any discrepancies will be resolved by one of 
the senior co-authors. Reasons for exclusion will be noted. 
All included abstracts will then undergo full-text review and data extraction by two of the co-
authors. As before, any discrepancies will be resolved by one of the senior co-authors. 
Outcome(s) 
Primary outcomes 
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iii. Unclear - No information on randomisation methodology. 
B) Blinding 
Blinding of investigators: Yes/No/Not stated 
Blinding of participants: Yes/No/Not stated 
Blinding of outcome assessor: Yes/No/Not stated 
Blinding of data analysis: Yes/No/Not stated 
C) Intention-to-Treat Analysis (Yes/No/Not stated) 
Yes - 1. Specifically reported by the authors that intention-to-treat analysis was undertaken and 
this was confirmed on study assessment; 2. Not stated, but confirmed on study assessment. 
No - 1. Not reported and lack of intention-to-treat analysis confirmed on study assessment*; 2. 
Stated but not confirmed upon study assessment. 
*(For example, patients who were randomised but not included in the analysis because they did 
not receive the study intervention, they withdrew from the study, or were not included because of 
protocol violation). 
D) Completeness of follow-up will be documented as the percentage of patients excluded or lost 
to follow-up. 
The quality of individual studies may be assessed using the Downs and Black Quality Checklist 
(1998). 
Strategy for data synthesis 
The data used will be aggregate with both quantitative and qualitative analysis. 
With respect to temperature data the difference in means will be calculated with 95% confidence 
intervals. If the quality of trials allows then a meta-analysis of weighted mean difference will be 
calculated. A statistical significance level of 0.05 will be used for all hypothesis testing Statistical 
heterogeneity will be tested for by means of the Q test and I-squared index. Depending on the 
outcomes forthcoming from applying these procedures, relative risk and 95% confidence intervals 
for all-cause mortality an improved neurological outcome will be calculated using a random-
effects model or fixed effect model. Subsequent models may be applied should the data be suitable 
for meta-analysis. When appropriate, sensitivity analyses as based on study quality (risk of bias) 
will be conducted. 
The following proforma will be used to asses the risk of bias: 
A) Allocation Concealment 
The randomisation methodology will be defined as adequate, inadequate or unclear. Definitions: 
i. Adequate - Neither the investigator nor participant knows or could influence the intervention 
group prior to participant enrollment. 
ii. Inadequate - Any indication that there was influence over the intervention group or use of a 
poor randomization technique employed, for example, unsealed envelopes etc. 
Risk of bias (quality) assessment 
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Peer review publication; local, national and possibly international presentation; uploading to 
Eurotherm3235Trial 
website; inclusion in HTA monograph on HTA project 11/01/30 Eurotherm3235. 
Contact details for further information 
Hannah Watson 
Peter JD Andrews 
 
 
Organisational affiliation of the review 
NHS Lothian and the University of Edinburgh 
http://www.nhslothian.scot.nhs.uk/Pages/default.aspx 
Review team 
 Dr Hannah Watson, ACCS Anaesthetics, NHS Lothian. 
Dr Andrew Shepherd, ACCS Anaesthetics, NHS Lothian. 
Dr Jonathan Rhodes, Consultant Anaesthetist & Intensivist, NHS Lothian. Honorary Clinical 
Senior Lecturer, University of Edinburgh. 
Professor Peter Andrews, Professor, Centre for Clinical Brain Sciences, University of Edinburgh. 
Dr Margaret MacDougall, Medical Statistician, University of Edinburgh. 
Details of any existing review of the same topic by the same authors 
Crossley S, Reid J, McLatchie R, Hayton J, Clark C, MacDougall M, Andrews PJ. A systematic  
review of therapeutic hypothermia for adult patients following traumatic brain injury. Crit Care. 
2014 Apr 17;18(2):R75. doi: 10.1186/cc13835. 
Analysis of subgroups or subsets 
 Specific subgroups that may be analysed are: 
- Earlier versus more recent trial data to determine whether there is a change of effect over time. 
- Controlled normothermia or no temperature control. 
- Trials that used propofol sedation. 
Dissemination plans 
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Search strategies: 
Thank you to Ms Shiela Fisken of the University of Edinburgh Library for her help in both 
developing our search strategies and in accessing the databases that were used.  
The search terms that have been used are complimentary to those from Crossley 2014. 
A full alphabetical list of our search terms may be found below our individual strategies. 
 
Pubmed search strategy: 
((((((randomized controlled trial[Publication Type] OR controlled clinical trial[Publication Type] 
OR randomised[Title/Abstract] OR randomized[Title/Abstract] OR randomly[Title/Abstract] OR 
random order[Title/Abstract] OR random sequence[Title/Abstract] OR random 
allocation[Title/Abstract] OR randomly allocated[Title/Abstract] OR at random[Title/Abstract])) 
OR randomized controlled trial[MeSH Terms]) NOT ((models, animal[MeSH Terms] OR 
animals[MeSH Terms] OR animal experimentation[MeSH Terms] OR disease models, 
animal[MeSH Terms] OR animals, laboratory[MeSH Terms]) NOT (humans[MeSH Terms]))))) 
AND Humans[Mesh] AND ((((((hypoterm*[Title/Abstract] OR normotherm*[Title/Abstract] OR 
cool*[Title/Abstract] OR cold*[Title/Abstract] OR temperature*[Title/Abstract] OR 
cryother*[Title/Abstract] OR cryogen*[Title/Abstract] OR cryotreat*[Title/Abstract])))) OR 
(((((((refrigeration*[Title/Abstract] OR cryo*[Title/Abstract]) AND anaesthes*[Title/Abstract])) 
OR ((cool*[Title/Abstract] OR cold*[Title/Abstract]) AND (therap*[Title/Abstract] OR 
device*[Title/Abstract] OR equipment*[Title/Abstract]))) OR (temperature[Title/Abstract] AND 
(reduc*[Title/Abstract] OR low*[Title/Abstract]))) OR ((cool*[Title/Abstract] OR 
cold*[Title/Abstract]) AND (blanket*[Title/Abstract] OR neck collar*[Title/Abstract] OR 
helmet*[Title/Abstract] OR hood*[Title/Abstract]))) OR (intravenous[Title/Abstract] AND 
(cold*[Title/Abstract] OR cool*[Title/Abstract]) AND (fluid*[Title/Abstract] OR 
catheter*[Title/Abstract])))) OR (((induced hypothermia[MeSH Terms]) OR cryotherapy[MeSH 
Terms]) OR hypothermia[MeSH Terms])) AND ((((((((((((Craniocerebral Trauma[MeSH Terms]) 
OR Brain Edema[MeSH Terms]) OR Glasgow Coma Scale[MeSH Terms]) OR glasgow outcome 
scale[MeSH Terms]) OR Unconsciousness[MeSH Terms]) OR Cerebrovascular Trauma[MeSH 
Terms]) OR intracranial hypertension[MeSH Terms])) OR ((((head[Title/Abstract] OR 
cranial[Title/Abstract] OR cerebral[Title/Abstract] OR capitis[Title/Abstract] OR 
brain[Title/Abstract] OR forebrain*[Title/Abstract] OR skull*[Title/Abstract] OR 
Hemispher*[Title/Abstract] OR intra-cran*[Title/Abstract] OR inter-cran*[Title/Abstract]) AND 
(injur*[Title/Abstract] OR trauma[Title/Abstract] OR damag*[Title/Abstract] OR 
wound*[Title/Abstract] OR fracture*[Title/Abstract] OR contusion*[Title/Abstract] OR 
concuss*[Title/Abstract] OR pressure*[Title/Abstract])))) OR (((head[Title/Abstract] OR 
cranial[Title/Abstract] OR cerebral[Title/Abstract] OR capitis[Title/Abstract] OR 
brain[Title/Abstract] OR forebrain*[Title/Abstract] OR skull*[Title/Abstract] OR 
hemispher*[Title/Abstract] OR intra-cran*[Title/Abstract] OR inter-cran*[Title/Abstract] OR 
tentori*[Title/Abstract]) AND (haematoma*[Title/Abstract] OR hematoma*[Title/Abstract] OR 
haemorhag*[Title/Abstract] OR hemorrhag*[Title/Abstract] OR Bleed*[Title/Abstract] OR 
hernia*[Title/Abstract] OR oedema*[Title/Abstract] OR edema*[Title/Abstract] OR 
swell*[Title/Abstract])))) OR ((glasgow[Title/Abstract] AND (scale[Title/Abstract] OR 
score[Title/Abstract]) AND (outcome[Title/Abstract] OR coma[Title/Abstract]))) OR ranchos Los 
amigos[Title/Abstract]) OR diffuse axonal injur*[Title/Abstract]) OR 
((unconscious[Title/Abstract] OR coma*[Title/Abstract] OR concuss*[Title/Abstract] OR 
persistent vegetative state[Title/Abstract]) AND (injur*[Title/Abstract] OR trauma[Title/Abstract] 
OR damag*[Title/Abstract] OR wound*[Title/Abstract] OR fracture*[Title/Abstract]))) 
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2. Brain Edema/  
3. glasgow coma scale/ or glasgow outcome scale/  
4. exp Unconsciousness/  
5. exp Cerebrovascular Trauma/  
6. exp Intracranial Hypertension/  
7. ((head or crani* or cerebr* or capitis or brain* or forebrain* or hemispher* or intrac-cran* or 
inter-cran*) adj3 (injur* or trauma* or damag* or wound* or fracture* or contusion* or concuss* 
or pressure*)).ti,ab.  
8. ((head or cran* or cerebr* or capitis or tentori* or brain* or forebrain* or hemispher* or intra-
cran* or inter-cran*) adj3 (haematoma* or hematoma* or hemorrhag* or haemorrhag* or bleed* or 
hernia* or oedema* or edema* or swell*)).ti,ab.  
9. (Glasgow adj3 (coma or outcome*) adj3 (scale* or score*)).ti,ab.  
10. "Rancho Los Amigos".ti,ab.  
11. "diffuse axonal injur*".ti,ab.  
12. ((unconscious* or coma* or concuss* or 'persistent vegetative state*') adj3 (injur* or trauma* 
or damag* or wound* or fracture*)).ti,ab.  
13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12  
14. exp hypothermia, Induced/  
15. exp Cryotherapy/  
16. exp Profound Induced Hypothermia/  
17. (hypotherm* or normother* or cool* or cold* or temperature* or cryother* or cryogen* or 
cryotreat*).ab,ti.  
18. ((refrigeration* or cryo*) adj3 anaesthes*).ab,ti.  
19. ((cool* or cold*) adj3 (therap* or device* or equipment*)).ab,ti.  
20. (temperature adj3 (reduc* or low*)).ab,ti.  
21. (intravenous adj3 (cold* or cool*) adj3 (fluid* or catheter*)).ab,ti.  
22. ((cool* or cold*) adj3 (blanket* or neck collar* or helmet* or hood*)).ab,ti.  
23. exp Hypothermia/  
24. or/14-23  
25. (randomised or randomized or randomly or random order or random sequence or random 
allocation or randomly allocated or at random or controlled clinical trial*).tw,hw.  
26. clinical trial.pt.  
27. randomized controlled trial.pt.  
28. or/25-27  
29. exp models, animal/  
30. exp animals/  
31. exp animal experimentation/  
32. exp animals, laboratory/  
33. or/29-32  
34. Humans/  
35. 33 not 34  
36. 28 not 35  
37. 13 and 24 and 36 
Ovid Embase and Medline search strategy: 
 
1. exp Craniocerebral Trauma/ 
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6. MeSH descriptor: [Cerebrovascular Trauma] explode all trees 
7. MeSH descriptor: [Intracranial Hypertension] explode all trees 
8. (head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-
cran* or inter-cran*) near/3 (injur* or trauma* or damag* or wound* or fracture* or contusion* 
or concuss* or pressure*) 
9. (head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-
cran* or inter-cran* or tentori*) near/3 (haematoma* or hematoma* or haemorrhag* or 
hemorrhag* or bleed* or hernia* or oedema* or edema* or swell*) 
10. (glasgow near/3 (coma or outcome) near/3 (scale or score)) 
11. "rancho los amigos scale" 
12. (diffuse near/3 axonal near/3 injur*) 
13. (unconscious* or coma* or concuss* or "persistent vegetative state") near/3 (injur* or trauma* 
or damag* or wound* or fracture*) 
14. (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13) 
15. MeSH descriptor: [Hypothermia, Induced] explode all trees 
16. MeSH descriptor: [Cryotherapy] explode all trees 
17. MeSH descriptor: 67 explode all trees 
18. (hypotherm* or normotherm* or cool* or temperature* or cryother* or cryogen* or cryotreat*) 
19. (refrigeration* or cryo*) near/3 anaesthes* 
20. (cool* or cold*) near/3 (therap* or device* or equipment*) 
21. temperature near/3 (reduc* or low*) 
22. Intravenous near/3 (cold* or cool*) near/3 (fluid* or catheter*) 
23. (cool* or cold*) near/3 (blanket* or neck collar* or helmet* or hood*) 
24. (#15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23) 
25. (#14 and #24) 
26. (#25) 
Cochrane Central Register of Controlled Trials (Central) search strategy: 
1. MeSH descriptor: [Craniocerebral Trauma] explode all trees 
2. MeSH descriptor: [Brain Edema] explode all trees 
3. MeSH descriptor: [Glasgow Coma Scale] explode all trees 
4. MeSH descriptor: [Unconsciousness] explode all trees 
5. MeSH descriptor: [Glasgow Outcome Scale] explode all trees 
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Search Terms 
The following are a list of the individual search terms used in each strategy to ensure sensitivity 
and specificity of each search for patient treatment and control group, as well as therapeutic 
management and trial design. Terms were re-evaluated for this review in May 2016 with Dr 
Jonathan Rhodes and Ms Shiela Fisken. 
allocated
allocation 
anaesthes* 
axonal 
blanket* 
bleed* 
brain edema 
brain* 
capitis 
catheter* 
cerebr* 
cerebrovascular trauma 
clinical 
clinical trial 
cold* 
collar* 
coma
coma* 
concuss* 
controlled 
contusion* 
cool* 
cran* 
crani* 
craniocerebral trauma 
cryo* 
cryogen* 
cryother* 
cryotherapy
cryotreat*  
 damag* 
device* 
diffuse 
edema*
equipment* 
fluid* 
forebrain* 
fracture* 
glasgow 
glasgow coma scale 
glasgow outcome scale 
haematoma* 
haemorrhag* 
head 
helmet* 
hematoma* 
hemispher* 
hemorrhag* 
hernia* 
hood* 
hypotherm*
hypothermia 
hypothermia, induced 
injur* 
inter-cran* 
intra-cran* 
intrac-cran*
intracranial hypertension
intravenous
low*      
neck 
normother* 
oedema* 
order 
outcome*
'persistent vegetative state*’ 
pressure* 
profound induced hypothermia 
rancho los amigos* 
random 
randomised 
randomized 
randomized controlled trial 
randomly 
reduc* 
refrigeration*
scale* 
score* 
sequence 
swell* 
temperature 
temperature* 
tentori* 
therap* 
trauma* 
trial* 
unconscious* 
unconsciousness 
wound*    
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Appendix 5 Characteristics of included
randomised controlled trials
The table below shows the characteristics of the included RCTs.
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Study: first author and
year of publication Method of intervention
Target or lowest
body temperature
achieved (°C) Duration of TH
Maximum time
between TBI and TH
Temperature
management of
control group (°C)
Lowest GCS score
on admission
(GCS score of 3–15)
Rate of
rewarming
Andrews 20151 i.v. cooling and individual
centre techniques
32–35 48 hours 72 hours to 10 days No temperature
control
3 0.25 °C/
hour
Clifton 199373 Cooling blankets 32–33 48 hours 6 hours CN to 37 4 0.25 °C/
hour
Clifton 200176 Application of ice and
gastric lavage
33.2± 1.0 47.2 ± 3.0 hours 6 hours CN to 37 3 0.25 °C/
hour
Clifton 2011121 i.v. cooling, surface cooling
and gastric lavage
33 48 hours 2.5 hours CN to 37 3 0.25 °C/
hour
Gal 200264 Forced air cooling and
circulating-water mattress
cooling
34 72 hours 15 hours CN 36.5–37.5 3 –
Guo 2004119 Cooling blankets 32–34 24–48 hours extra
following ‘normal’ ICP
24 hours No temperature
control
TH: 5.3± 1.5 –
Control: 5.2± 1.4
Hashigushi 2003120 Water blankets 33.5 48 hours – CN 3 1 °C/
24 hours
Hirayama 1994115 Cooling blankets 32–33 48 hours 6 hours Normothermia
37–38, no further
detail
GCS score of ≤ 8 0.25 °C/
hour
Jiang 200069 Cooling blankets 33 3–14 days – CN 37–38 3 –
Lee 2010122 Surface cooling and ice
pillows
33 – – Unclear 4 –
Liu 200660 Cooling blankets and ice
bags
33–35 0–6 hours (average
4.5 hours) on
3 consecutive days
2 hours No temperature
control
3 –
Maekawa 2015107 Cooling blankets 32–34 Ideally > 72 hours 92 hours CN 35.5–37 4 –
Marion 199375 Cooling blankets and
gastric lavage
32–33 24 hours 10 hours CN 37–38 3 –
Marion 199771 Cooling blankets and
nasogastric lavage
32–33 24 hours 6 hours CN 3 1 °C/hour
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Study: first author and
year of publication Method of intervention
Target or lowest
body temperature
achieved (°C) Duration of TH
Maximum time
between TBI and TH
Temperature
management of
control group (°C)
Lowest GCS score
on admission
(GCS score of 3–15)
Rate of
rewarming
Qiu 200577 Cooling blanket and/or
cooling cap and/or ice bags
Brain 33–35,
rectal 34.5–36
Natural rewarming
after 3–5 days
(average 4.3 days)
‘Immediately’ or
3–5 days (average
4.3 days) after
craniotomy
Controlled to 38 3 –
Qiu 200759 Cooling blanket and/or
cooling cap and/or ice bags
Brain 33–35, rectal
34.5–36
4 days Started immediately
after unilateral
craniotomy
CN to 37.5 < 6 –
Shiozaki 199374 Surface cooling Core 34, bladder
33.5–34.5
48 hours 2 hours Unclear – –
Shiozaki 1999117 Surface cooling 33.5–34.5 48 hours – CN 36.5–37.5 4 1 °C/
24 hours
Smrcka 2005117 Surface cooling 34 72 hours 15 hours Unclear – –
Zhao 2011118 Cooling blankets 32.5–33 72 hours 6 hours Unclear 3 –
Zhi 200363 Cooling blankets 32 1–7 days (average
62.4 hours ±
27.6 hours)
20 hours Unclear – 0.25 °C/
hour
CN, controlled normothermia; i.v., intravenous.
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Appendix 6 Comparison of included trials from
previous systematic reviews and meta-analyses
Study: first author and
year of publication
Study: first author and year of publication
Sydenham 2009153
(Cochrane review) Crossley 2014110 Zhu 2016111 Watson 2018154
Adelson 2005 (HYPO1)56 Y N N N
Adelson 2005 (HYPO2)56 Y N N N
Aibiki 200068 Y N N N
Andrews 20151 - - Y Y
Biswas 200257 Y N N N
Clifton 1992 Y N N N
Clifton 199373 Y Y Y Y
Clifton 200176 Y Y Y Y
Clifton 2011121 - Y N Y
Gal 200264 Y Y Y Y
Guo 2004119 Y Y N Y
Harris 2009155 Y N N N
Hashigushi 2003120 Y Y Y Y
Hirayama 1994115 Y Y N Y
Hutchison 2008156 Y N N N
Ishikura 1998157 Y N N N
Jiang 200069 Y Y Y Y
Lee 2010122 – Y Y Y
Liu 200660 N Y N Y
Maekawa 2009158 N Y N (Maekawa 2015107) N (Maekawa 2015107)
Maekawa 2015107 – – Y Y
Marion 199375 N Y N Y
Marion 199771 Y Y Y Y
Qiu 200577 N Y Y Y
Qiu 200658 N N Y N
Qiu 200759 Y Y Y Y
Shiozaki 199374 Y Y Y Y
Shiozaki 1999117 Y Y Y Y
Shiozaki 200149 Y N Y N
Smrcka 2005117 Y Y Y Y
Yan 200167 Y N N N
Zhang 200070 Y N N N
Zhao 2011118 – Y Y Y
Zhi 200363 N Y Y Y
Total studies (n) 23 20 18 21
N, no; Y, yes.
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Appendix 7 Quality assessment with
academic bias
Academic bias for all 21 included RCTs is shown below. The first table outlines the quality assessment ofthe two new RCTs added to update the systematic review. The second table shows the characteristics
of the other 19 previously included RCTs. Those scoring 14–18 were considered studies having a low risk
of bias and those scoring ≤ 13 were considered having a high risk of bias.
Quality assessment
Study: first author and year of publication
Andrews 20151 Maekawa 2015107
Has the control group been managed to normothermia? Yes Yes
Yes = 1; no/NS= 0 1 1
Was the control group actively warmed on admission if
hypothermic?
NS NS
Yes = 0; NS= 1; no = 2 1 1
Has the treatment arm received barbiturates in addition to TH? No No
Yes = 0; NS= 1; no = 2 2 2
Are there significant differences between the treatment and
control sample populations?
No No
Yes = 0; no = 1; NS= 0 1 1
Has the standard treatment that the control group received
been clearly outlined?
Yes Yes
Yes = 1; no = 0 1 1
Adequacy of randomisation technique? Adequate Adequate
Adequate = 1; inadequate/unclear = 0 1 1
Blinding of investigators No No
Yes = 1; no/NS= 0 0 0
Blinding of participants No No
Yes = 1; no/NS= 0 0 0
Blinding of outcome assessor Yes Yes
Yes = 1; no/NS= 0 1 1
Blinding of data analysis Yes Yes
Yes = 1; no/NS= 0 1 1
ITT analysis Yes Yes
Yes = 1; not stated but confirmed on study assessment = 1;
stated but not confirmed on study assessment = 0;
no/NS = 0
1 1
Completion of follow-up (at 6 months if possible) Yes, loss of 10 cases to follow-up Yes, 100%
100% = 2; > 95%= 1; < 95% = 0; no/NS = 0 1 2
Reasons given when patients were excluded from enrolment,
allocation follow-up or analysis?
Yes Yes
Yes = 1; no= 0 1 1
Has the first author published two or more RCTs that have
been included in this review?
No No
Yes = 0; no = 2 2 2
Total score 14 15
Maximum score 18 18
NS, not stated.
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Study; first author
and year of
publication
Has the first author published
at least two RCTs that have
been included in this review?
Yes= 0;
no= 2
Original score from
Crossley 2014110
Following assessment
of academic bias
(maximum score= 18)
Clifton 199373 Y 0 8 8
Clifton 200176 Y 0 11 11
Clifton 2011121 Y 0 6 6
Gal 200264 N 2 9 11
Guo 2004119 N 2 10 12
Hashigushi 2003120 N 2 8 10
Hirayama 1994115 N 2 5 7
Jiang 200069 N 2 8 10
Lee 2010122 N 2 8 10
Liu 200660 N 2 6 8
Marion 199375 Y 0 10 10
Marion 199771 Y 0 11 11
Qiu 200577 Y 0 7 7
Qiu 200759 Y 0 8 8
Shiozaki 199374 Y 0 7 7
Shiozaki 1999117 Y 0 8 8
Smrcka 2005117 N 2 8 10
Zhao 2011118 N 2 7 9
Zhi 200363 N 2 6 8
N, no; Y, yes.
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Appendix 8 Modified Jadad scores for included
randomised controlled trials
Study: first
author and year
of publication
Randomisation
(2, 1 or 0 points)
Blinding
(2, 1 or
0 points)
Accounting
for all
patients
(1 point)
Total modified
Jadad score
(maximum 3 points)
Low quality (0, 1 or
2 points) or high
quality (3 points)
Andrews 20151 2 0 1 3 High
Clifton 199373 2 0 1 3 High
Clifton 200176 0 0 0 0 Low
Clifton 2011121 2 0 1 3 High
Gal 200264 1 – inadequate 0 0 1 Low
Guo 2004119 0 0 1 1 Low
Hashigushi
2003120
1 – method not
stated
0 1 2 Low
Hirayama 1994115 0 0 0 0 Low
Jiang 200069 0 0 0 0 Low
Lee 2010116 0 0 0 0 Low
Liu 200660 2 0 0 2 Low
Maekawa 2015107 2 0 1 3 High
Marion 199375 2 0 1 3 High
Marion 199771 2 0 1 3 High
Qiu 200577 0 0 1 1 Low
Qiu 200759 1 – unclear if
adequate
0 1 2 Low
Shiozaki 199374 1 – inadequate 0 1 2 Low
Shiozaki 1999117 1 – inadequate 0 1 2 Low
Smrcka 2005117 0 0 1 1 Low
Zhao 2011118 0 0 0 0 Low
Zhi 200363 0 0 1 1 Low
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